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Abstract 
Type 1 Diabetes Mellitus is a metabolic disease requiring lifelong treatment with exogenous 
insulin which significantly affects patient’s lifestyle. Therefore, it is of paramount importance 
to develop novel drug delivery techniques that achieve therapeutic efficacy and ensure patient 
safety with a minimum impact on their quality of life. Motivated by the challenge to improve 
the living standard of a diabetic patient, the idea of an artificial pancreas that mimics the 
endocrine function of a healthy pancreas has been developed in the scientific society. 
Towards this direction, model predictive control has been established as a very promising 
control strategy for blood glucose regulation in a system that is dominated by high intra- and 
inter-patient variability, long time delays, and presence of unknown disturbances such as diet, 
physical activity and stress levels.  
This thesis presents a framework for blood glucose regulation with optimal insulin infusion 
which consists of the following steps: 1. Development of a novel physiologically based 
compartmental model analysed up to organ level that describes glucose-insulin interactions in 
type 1 diabetes, 2. Derivation of an approximate model suitable for control applications, 3. 
Design of an appropriate control strategy and 4. In-silico validation of the closed loop control 
performance. The developed model’s accuracy and prediction ability is evaluated with data 
obtained from the literature and the UVa/Padova Simulator model, the model parameters are 
individually estimated and their effect on the model’s measured output, the blood glucose 
concentration, is identified. The model is then linearised and reduced to derive low-order 
linear approximations of the underlying system suitable for control applications.  
The proposed control design aims towards an individualised optimal insulin delivery that 
consists of a patient-specific model predictive controller, a state estimator, a personalised 
scheduling level and an open loop optimisation problem subjected to patient specific process 
model and constraints. This control design is modifiable to address the case of limited patient 
data availability resulting in an “approximation” control strategy. Both designs are validated 
in-silico in the presence of predefined, measured and unknown meal disturbances using both 
the proposed model and the UVa/Padova Simulator model as a virtual patient. The robustness 
of the control performance is evaluated in several conditions such as skipped meals, 
variability in the meal content, time and metabolic uncertainty.   
The simulation results of the closed loop validation studies indicate that the proposed control 
strategies can achieve promising glycaemic control as demonstrated by the study data. 
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However, further prospective validation of the closed loop control strategy with real patient 
data is required.   
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1. Introduction & Motivation 
 
1.1 Introduction 
Diabetes type 1 is one of the most prevalent severe chronic diseases of childhood. According 
to Diabetes UK, it is estimated that in the UK 2.6 million people have been diagnosed with 
diabetes in 2009, 15% of which have type 1 diabetes mellitus (T1DM) and according to 
(Patterson et al., 2009) the incidence of T1DM is increasing worldwide reaching epidemic 
proportion (yearly incidence 15 cases per 100.000 people younger than 18 years old, in the 
United States). T1DM is a metabolic disorder that is characterised by insufficient or absent 
insulin circulation, elevated levels of glucose in the plasma and beta cells inability to respond 
to metabolic stimulus. It results from autoimmune destruction of beta cells in the pancreas 
which is responsible for secretion of insulin, the hormone that contributes to glucose 
distribution in the human cells. T1DM can cause serious complications in the major organs of 
the body such as heart, kidneys, eyes and nerves which develop gradually over the years.  
Hence, it is important to define effective management strategies of treating T1DM. Patients 
with T1DM rely on exogenous insulin administration to maintain their blood glucose 
concentration within a normal range (80-140mg/dl). Insulin is administered either with daily 
subcutaneous insulin injections or with an insulin pump. Due to the nature of the treatment 
the controlled T1DM is reformulated from preventing hyperglycaemia to preventing 
hypoglycaemia. Hypoglycaemia is a life threatening condition that results from inadequate 
supply of glucose to the brain and causes 4-5% of deaths in T1DM.  In order to overcome 
these complications improved glycaemic control is required. This can only be achieved when 
the patient continuously adjusts their insulin dose according to their blood glucose 
measurements. However, this manual control method is subject to several limitations, such as 
the requirement for patient’s appropriate education and adherence to a specific lifestyle and 
increased risk of poor glycaemic control leading to hyper or hypoglycaemia. Inevitably 
patient lifestyle and quality of life are significantly affected by the treatment. Motivated by 
the challenge to improve the living conditions of a diabetic patient and actually to adapt the 
insulin treatment to patient’s life rather than the opposite, the idea of an artificial pancreas 
that would mimic the endocrine function of a healthy pancreas has been well established in 
the scientific society.  
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1.2 The Artificial Pancreas 
Currently the most advanced insulin therapy for diabetic patients is the use of an insulin 
pump. The insulin pump delivers a basal dose of rapid acting insulin and several bolus doses 
according to the meal plan of the patient. Good glycaemic control requires 4-6 measurements 
of blood glucose per day. These measurements, taken either by standalone fingersticks meters 
or by continuous glucose monitoring systems (CGMs), are entered into the pump usually by 
the user or by wireless connection. These measurements are an indicator whether insulin 
administration needs adjustment. A wireless connection of the pump data with a personal 
computer offers a good programming of the pump settings (Medronic, 2008). 
The appropriate basal dose for a specific patient is set by the physician and can be modified to 
several profiles (week days, weekends). The bolus doses are set by the patient themselves, 
depending on the meal content, and indicated by the blood glucose levels.  
The automation of this therapy constitutes the concept of the artificial pancreas. Essentially, 
the artificial pancreas is a device composed of a continuous glucose sensor, which reports 
blood glucose concentration approximately every 5 minutes; a controller implemented on  
smartphone,  tablet or pc, which computes the appropriate insulin delivery rate according to 
the provided data from the sensor and signals the insulin pump to carry out the appropriate 
delivery of insulin. The insulin pump, the controller and the CGMs are wirelessly connected. 
This representation of an artificial pancreas is presented in Figure 1.1. 
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Figure 1.1: Schematic representation of an Artificial Pancreas  
Many research groups worldwide have believed in this idea and the research society has 
directed their focus on the development of the key components for the production of the 
artificial pancreas. Pump and CGMs manufactures, as well as FDA (Food and Drug 
Administration) and several organisations for Diabetes, such as JDRF (Juvenile Diabetes 
Research Foundation) are involved in projects, by encouraging collaborations and solving 
practical issues in order to accelerate the design of the artificial pancreas. The challenges lie 
in the improvement of the control algorithms, the development of reliable platforms that 
incorporate the three features (controller, pump, CGMs) and resolving issues related mainly 
to the sensor technology.  
1.2 Project deliverables 
Towards the development of an artificial pancreas, this thesis focuses on two levels. The first 
level is the development of a detailed mathematical model that describes in depth the 
complexity of the glucoregulatory system in T1DM, presents adaptability to patient 
variability and demonstrates adequate capture of the dynamic response of the patient to 
various clinical conditions (normoglycaemia, hyperglycaemia, hypoglycaemia). The second 
level is the development of reliable model-based controllers that ensure safe and tight glucose 
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regulation. The closed loop insulin delivery system is formulated as a model predictive 
control problem, aiming to reach the desired target of blood glucose concentration subject to 
safety and operational constraints. 
The general framework used for the control design to regulate the blood glucose 
concentration is presented in Figure 1.2 as modified by (Pistikopoulos, 2012) It involves the 
development of a high fidelity model that predicts the glucose-insulin dynamics in T1DM, the 
simplification of the original model with linearisation and model order reduction techniques 
to derive a reliable approximation of the system dynamics and finally the design of the 
appropriate control strategy. The involved steps are described analytically in the chapters 
mentioned in Figure 1.2. 
 
Figure 1.2: Framework for MPC controllers design adapted from (Pistikopoulos 2012)   
Mathematical models are used to explain a system, analyse the effect of different components 
and predict future behaviours of the investigated system. In this context, an informative 
mathematical model of glucose-insulin interactions in T1DM is developed to understand the 
system physiology, investigate the effect of insulin and meal disturbances on glucose 
dynamics and use it as a predictive tool for optimisation and control studies. The proposed 
physiologically based model combines actual anatomical compartments to describe glucose 
metabolism and simple compartmental representation to describe insulin administration 
through the subcutaneous route. The reason why this approach was selected is to increase the 
level of understanding of the system’s physiology using individualised parameterisation 
obtained from fundamental biomedical properties without the need for complex experimental 
evidence. Simultaneously, the limitation of experimental data to describe the involved 
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mechanisms of insulin diffusion, dissociation and absorption induced the use of simpler 
models that produce the desired output. Global sensitivity analysis is performed to investigate 
the influence of the parameters on the prediction ability of the model. The model parameters 
are estimated using data obtained from the UVa/Padova Simulator (B. P. Kovatchev, M. 
Breton, et al., 2009) which are treated as real patient data. The UVa/Padova T1DMS has been 
accepted by the FDA for preclinical closed-loop control experiments by substituting animal 
trials as well as for clinical trials of closed-loop control based entirely on silico tests. Both the 
proposed model and the UVa/Padova model are simulated and programmed in gPROMS 
(PSE, 2011b). Issues of model identifiability are analysed and the parameter correlations are 
quantified in order to evaluate the robustness and validity of the proposed model. This 
process provides an indication whether the proposed equations require reformulation or re-
parameterisation. The model describing individual dynamic responses can be used as a virtual 
patient for closed loop control validation studies. 
Optimisation of insulin dosing minimises the risk of possible hypoglycaemia (over-dosing) 
and avoids hyperglycaemia (under-dosing). Rigorous optimisation studies are performed in 
gPROMS (PSE, 2011a) for 10 patients with T1DM on an insulin pump, using both the 
proposed model as well as the T1DMS model as the process model. The insulin bolus, given 
to compensate for food consumption, is optimised in terms of time to maximum effect. These 
results are compared with conventional insulin dosing and finally the insulin regimen that 
normalises the glucose curve more effectively – maintain blood glucose concentration within 
the normal range – is determined. Additionally, an alternative to bolus insulin dosing is 
evaluated and the two dosing types are compared in terms of their effect on glucose 
concentration. This study intends to identify the most effective dosing strategy to be further 
used as a background guideline in closed loop studies.  
The original proposed model has 16 states. The model is simplified to a linear state-space 
model suitable for MPC and the control design is developed and evaluated in closed loop 
validation studies for different scenarios against firstly the original model and secondly the 
UVa/Padova T1DMS. Model based control design is a suitable control method for the studied 
system since it can handle constraints, which is the most crucial aspect of glucose regulation 
and it is able to control time delayed systems and disturbances. Therefore, there has been a 
wide use of MPC  in the context of glucose regulation and many MPC strategies have been 
clinically evaluated (Hovorka et al., 2014), (B. P. Kovatchev et al., 2013), (Russell et al., 
2012), (Breton et al., 2012), (Dassau et al., 2013). The promising results indicate that MPC 
can be a potential strategy towards the artificial pancreas, and therefore the research on this 
Chapter 1: Introduction & Motivation 
 
26 
 
field has been intensified. The inherent complications of the system such as the occurrence of 
disturbances that have a major impact on the system’s dynamics, the large time delays and the 
patient variability make the use of a simple controller insufficient for the optimal solution of 
the closed loop. Therefore, advanced control techniques are required to safely regulate the 
system. A generalised control framework is proposed which involves four parts, an MPC a 
state estimator, an optimiser/or a second MPC and a scheduler. Depending on the nature of 
the imposed disturbances different parts are activated. Two approaches are investigated i) a 
systematic approach which aims towards an individualised closed loop insulin delivery and ii) 
an “approximation” approach which aims towards a generalised applicability of the closed 
loop system. 
1.3 Structure of the thesis 
The rest of the thesis is organised as follows: Chapter 2 presents an introduction to the 
physiology of glucose regulation, the pathophysiology of T1DM and the current treatment 
approaches. An introduction to modelling of a biomedical system is presented, providing the 
theoretical background of pharmacokinetic and pharmacodynamic modelling. Finally, a 
literature review of the specific system of glucose-insulin interactions is presented. Chapter 3 
involves the mathematical development of the proposed model for glucose metabolism and 
four alternative models of insulin kinetics. In Chapter 4 the most suitable model of insulin 
kinetics is selected by performing a series of model analysis tests. Additionally, a global 
sensitivity analysis of the entire model is performed to investigate the influence of the model 
parameters on the uncertainty of the model’s prediction ability. The model parameters are 
estimated using data obtained from the UVa/Padova Simulator and the analytical results for 
all patients are presented in Appendix B1. Moreover, Chapter 4 presents open loop 
optimisation studies that on one hand deepen the understanding of the involved time delays of 
the system and on the other hand can be deemed as an alternative to model validation studies. 
Chapter 5 describes the available control methods evaluated in the literature as well as a brief 
introduction to MPC and Kalman Filter. Details about MPC can be found in Appendix B2. 
The derivation of the approximate model is presented in Chapter 5. Chapter 6 describes the 
proposed control strategies and the evaluation of the closed loop control performance. The 
conclusions of this thesis are presented in Chapter 7. Appendix A presents the model of 
UVa/Padova simulator and the control framework and studies performed using exclusively 
this model. Appendix B presents tabulations of the model parameters values for the studied 
patients.  Finally, Appendix C describes an example of mpMPC in the context of closed loop 
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insulin delivery and Appendix D presents the MPC control specifications used in the 
proposed control strategies. 
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2. Modelling the T1DM System - An Overview 
 
2.1 Introduction to Diabetes Mellitus 
Diabetes Mellitus is a group of metabolic diseases characterised by elevated blood glucose 
levels. The pathogenesis of diabetes involves a defect in insulin secretion, action or both.  
Insulin is a hormone which is released from the pancreas and is responsible for glucose 
transportation in the body cells.  Diabetes is a chronic medical condition, meaning that 
although it can be controlled, it lasts for a lifetime.   
 
Classification 
There are two main types of diabetes. Type 1, or previously known as Insulin-dependent 
diabetes mellitus (IDDM), and type 2 or as formally called non-insulin-dependent diabetes 
mellitus (NIDDM). The terms IDDM and NIDDM are no longer used because, according to 
the revised classification of the World Health Organization
 
(World Health Organization, 
1999) and the ADA (American Diabetes Association, 2008), these terms have been confusing 
since they categorised the patients based on the treatment rather than the pathogenesis. Hence, 
according to the revised classification T1DM, which results from autoimmune mediated 
destruction of the beta cells of the pancreas, is called Type 1A. It is usually diagnosed in 
children and young adults, which is why it was previously known as juvenile diabetes. The 
rate of beta cell destruction is quite variable. In children and adolescents it is very rapid, 
while there is a form of slow deterioration of metabolic control that may occur later in life 
called latent autoimmune diabetes in adults (LADA).  Additionally, there are some forms of 
T1DM that have no known aetiology. Clinical conditions such as permanent insulinopenia 
and proneness to ketoacidosis may appear, but no evidence of autoimmunity is observed, 
especially among individuals of African and Asian origin. This form is called either Type 1B 
diabetes or idiopathic type 1 Diabetes.  
Type 2 diabetes is the most common form of diabetes. Its key pathognomonic feature is 
relative (rather than absolute) deficiency of insulin. It is more prevalent in people aged over 
40, but nowadays it is becoming more common in children and young people of all 
ethnicities. The aetiology of type 2 diabetes is still not fully understood but several 
predisposing factors have been identified, such as obesity, sedentary lifestyle etc.  This type 
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of diabetes frequently remains undiagnosed for many years, because its symptoms are not 
severe enough to provoke noticeable evidence of the disease.   
Another common type of diabetes is gestational diabetes, which can occur transiently during 
pregnancy. This type of diabetes includes cases in which glucose intolerance is first 
recognised during pregnancy and also cases that glucose intolerance may precede pregnancy 
but has not been previously recognised. In most cases, gestational diabetes resolves after 
delivery but these patients are high risk for developing diabetes type 2 later in life.  
Other specific types of diabetes have also been recognised and attributed to different causes 
such as genetic, exocrine pancreatic, endocrine and drug- or chemically- induced. 
 
Prevalence and incidence of T1DM 
Prevalence of a disease in a statistical population is the proportion of people in the population 
who have the disease at a given time. It is a factor that represents how common a condition is 
within a population. According to American Diabetes Association, 1 in 400-600 children and 
adolescents in the USA have T1DM. Internationally, Scandinavia has the highest prevalence 
rates for T1DM (20% of the total number of people with DM), while China and Japan have 
the lowest prevalence rates, with less than 1% of all people with diabetes (Khardori, 2014). 
Incidence is the rate at which new cases of the disease appear in a population (usually 
100.000 persons) within a specified time period (i.e. per annual). According to (Onkamo et 
al., 1999) and (Patterson et al., 2009) the incidence is increasing worldwide and not only in 
the populations with high incidence such as Finland (2010: 50/100000 a year) but also in low 
incidence populations (30/100000 a year).    
The incidence of T1DM is dependent on the geographic location, ethnicity, gender and age 
(Steck and Rewers, 2004). The incidence presents wide variability in geographic location, 
with higher incidence in the Northern hemisphere exceeding 15/100000. There is also an 
additional within-country variability, for example in the US, non-Hispanic Whites are 1.5 
times as likely to develop T1DM as African Americans or Hispanics
 
(Steck and Rewers, 
2004) which indicates that T1DM is related to racial composition of the population. But a 
study showing that migrants presented adaptability to the incidence of the country in which 
they are living reflects an impact of environmental factors on the disease aetiology.  
According to “The Diamond Group Project” (The DIAMOND Project Group, 2006) there is 
no significant difference in the risk of developing T1DM among males and females, but there 
is a difference in incidence rate between age groups, with a peak occurring at puberty.  
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The following figure shows the incidence of T1DM worldwide, for the years 1990-1999, data 
were obtained from (The DIAMOND Project Group, 2006) 
 
Figure 2.1: Incidence of T1DM worldwide, data from (Onkamo et al., 1999) 
 
2.1.1 Physiology  
The body cells require continuous supply of glucose to perform their normal metabolic 
activities, since glucose is the major source of cellular energy. Blood glucose concentration 
should be maintained within a very narrow range in order to meet the metabolic requirements 
of vital organs such as the brain. The regulation of blood glucose is achieved with the 
contribution of many hormones, with the most crucial being insulin and glucagon. The 
following section focuses on: (i) glucose sources and role, (ii) pancreas contribution to 
glucose regulation with insulin and glucagon secretion and finally (iii) the hepatic function in 
metabolism. 
 
2.1.1.a Glucose 
Carbohydrates are an essential nutrient as the major source of glucose for the human body. 
Glucose C6H12O6 is a monosaccharide which plays a very important role in human biology. It 
constitutes the major source of accessible energy for the body cells, in addition to amino acids 
portions of proteins and fatty acids. Energy in biology is translated in ATP (Adenosine 
triphosphate) which is often called as the "molecular unit of currency" of intracellular energy 
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transfer. The overall reaction that takes place is the oxidation of fuel substrates to carbon 
dioxide and water in the presence of oxygen: 
 
Glucose + Oxygen →Energy + Carbon dioxide + Water 
 
Table 2.1: The mechanisms of energy production through glucose 
Metabolic Mechanism Location Description 
1.Glycolysis 
 
Glucose is converted to 
pyruvate through a series of 
10 enzymatic reactions.  7 of 
these reactions are reversible 
(gluconeogenic direction). In 
organs where gluconeogenesis 
can take place (liver, kidney) 
there are enzymes which 
activate the reverse direction 
of the irreversible glycolytic 
reaction. 
Cytoplasm 
 
 
 
2.Pyruvate decarboxylation 
 
Pyruvate enters the 
mitochondria and through an 
enzymatic reaction activated 
by pyruvate dehydrogenase 
complex it is converted to 
acetyl-CoA.  
Mitochondrion Matrix 
 
 
                     
     
3.Krebs Cycle 
 
During the chain of the 
enzymatic reactions that 
constitute the tricarboxylic 
acid cycle (TCA) the 
metabolic  fuel is oxidised. 
Generally  fatty acids and 
amino acids can also be 
oxidised through the TCA 
cycle.(DeFronzo, 2004) The 
TCA cycle activates electrons 
transportation (following 
mechanism) 
Mitochondrion Matrix 
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4. Oxidative 
phosphoryliation 
 
Process during which ATP is 
produced, by using the energy 
released in the electron 
transport chain (Smeitink, 
2004) 
 
Inner Mitochondrion 
Membrane 
 
 
 
 
Table 2.1 presents a brief description of aerobic respiration. In cases of insufficient oxygen, 
for example during intense exercise, muscle cells can perform anaerobic respiration, which 
incorporates all the metabolic paths described previously, but instead of O2 as an electron 
receptor, other electronegative substances are used. 
 
2.1.1.b Pancreas: insulin, glucagon 
One of the most important organs that are responsible for glucose regulation is the pancreas. 
A small region (2% approximately) of the pancreas mass, called the Islets of Langerhans, is 
responsible for the production of the endocrine hormones. It contains 3 types of cells, a-cell 
where glucagon is synthesised, b-cell for insulin and amylin synthesis and d-cells for 
somatostatin synthesis and the PP cells which secrete pancreatic polypeptide. The remaining 
98% of the pancreas mass is responsible for exocrine secretions.  
 
 
Figure 2.2: Islets of Langerhans adapted from (Parlerm, 2003) 
ADP 
H2O O2 
ATP 
e- 
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The insulin molecule 
Synthesised in b-cells of the pancreas, insulin is a dipeptide consisting of A and B amino 
chains. Initially a precursor molecule, preproinsulin, is synthesised (Ferrannini and DeFronzo, 
2004) which is translated to proinsulin. In this form the A and B chains are linked to a 
polypeptide, known as a connecting peptide or C-peptide. C peptide is released and insulin is 
produced. Because both insulin and C-peptide are secreted from b-cells, C-peptide can be 
used as an indicator of the levels of endogenous insulin production when exogenous insulin is 
administrated.    
 
Insulin action 
Insulin is an anabolic hormone which plays a vital role in human metabolism. The main 
anabolic actions which insulin performs are: 
 
1. enabling glucose uptake by muscle cells and adipose tissue  
 
Insulin acts as a key that opens up the cell so as to accept glucose. Insulin binds to insulin 
receptors located on the cellular membrane and a complex series of protein reactions is 
activated, leading to the translocation of GLUT-4, a glucose receptor, from the intracellular 
area to the cell membrane and finally the influx of glucose into the cell, where glucose is 
metabolised and supplies the cell with energy (Nussey and Whitehead, 2002). 
 
2. glycogenesis (glycogen synthesis) 
 
Insulin has several effects which stimulate glycogen synthesis in the liver and in the muscles, 
such as activation of glucose phosphorylase (required enzyme for the synthesis) and 
inhibition of the reverse action. Glucose uptake from the liver is not dependent on insulin 
because the responsible glucose receptor of the hepatocytes is GLUT2, which is not activated 
by insulin, contrary to glucose uptake from the muscles (Nussey and Whitehead, 2002).  
 
3. glycolysis 
 
Insulin regulates glycolysis, because it provides the metabolic path with available substrate 
(glucose) and it affects the rate of transcription of the enzymes which catalyse some steps of 
glycolysis (Meisler and Howard, 1989), (Iynedjian, Gjinovci and Renold, 1988). 
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4. lipogenesis (adipocytes) 
 
Insulin stimulates the convertion of acetyl CoA to fatty acids and then to triglycerides, by the 
activation of glycolytic enzymes (Kersten, 2001). Lipogenesis is also amplified because 
insulin enhances glucose uptake from adipocytes.  
 
5. protein synthesis 
 
Insulin determines protein synthesis by increasing the content of ribosomes with amino acids 
and by restricting protein breakdown.  
 
6. amino acids transport into cells 
 
The transport rate of amino acids into the cells is increased due to insulin.  
 
Apart from anabolic effects insulin contributes to preventing catabolic actions. In particular, 
in the liver insulin inhibits glyconeogenesis, glycogenolysis and ketogenesis; in the muscles 
the breakdown of proteins and in the adipose tissue the breakdown of lipids.  
Generally, the body detects that blood glucose levels rise and normally the pancreas secrete 
insulin to account for that alteration in glucose concentration, as a response to several 
stimulators. Initially an increase in blood glucose concentration provokes an immediate 
release of insulin that has already been synthesised and stored in the b-cells. This response is 
the distinct first phase of the biphasic insulin secretion. Then the newly synthesised insulin is 
released for as long as the glucose levels are elevated. There are other factors that function as 
b-cells stimulators, such as certain amino acids, fatty acids, several gastrointestinal hormones 
and activity of the parasympathetic nervous system. While insulin is being released, glucose 
can enter the body cells, can be stored as glycogen in the liver until the concentration is 
between the normal range and insulin release can be stopped.  
 
Glucagon  
Another important hormone controlling glucose metabolism is glucagon known as counter-
regulatory hormone, because it acts in opposition to insulin, being the major hormone 
regulating the fuel mobilisation and catabolism. Glucagon’s action is located specifically in 
the liver and is responsible for stimulating the breakdown of glycogen to glucose and for the 
production of glucose from lactate, glycerol and mainly amino acids. These pathways are the 
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mechanisms of hepatic glucose production (Griffin and Ojeda, 2004). These mechanisms are 
better understood than that of insulin (Storey, 2005). Furthermore glucagon is responsible for 
regulating the rate of oxidation of free fatty acids that enter the liver, and the consequent 
production of ketones which enter the bloodstream.    
Glucagon release is regulated by both insulin and glucose. In case of low blood glucose 
levels, hypoglycaemia, due to fasting or exercise, the a-cells of the pancreas produce and 
release glucagon that activates the conversion of glycogen to glucose. Normally, the release 
of glucagon occurs when blood glucose concentration is 50mg/dl. When blood glucose levels 
rise above 150 mg/dl glucose production is minimised, with a mechanism which is not fully 
understood (Storey, 2005). 
Other counter regulatory hormones which have catabolic action, similar to glucagon can be 
seen in Figure 2.3. 
 
Figure 2.3: Impact of insulin and other counter regulatory hormones on glucose levels 
2.1.1.c The Liver 
The liver is the main regulator of glucose metabolism. It can store glucose as glycogen when 
glucose levels are high and release glucose when it is required. Hepatic glucose production is 
the second source of glucose in the blood apart from exogenous glucose influx, derived from 
carbohydrates breakdown. In healthy people, hepatic glucose production is high during the 
fasting state. This rate decreases in response to the rise of blood glucose and the consequent 
insulin secretion from beta cells. Net hepatic glucose production is defined as the difference 
between the pathways which stimulate glucose formation (gluconeogenesis, glycogenolysis) 
and those that contribute to glucose consumption or storage (glycogen synthesis, glycolysis, 
pentose monophosphate shunt). As it has already been mentioned, the hormones controlling 
these actions are insulin and glucagon, insulin contributes to glucose disposal and glucagon to 
glucose production.  
In Figure 2.4 the overall flow of fuels and the actions of insulin and glucagon in the liver, 
muscles and adipose tissue are illustrated: 
GLUCOSE 
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Cortisol 
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Figure 2.4: The overall flow of fuels and the actions of insulin in the liver, muscles and adipose 
tissue, adapted from (Pocock, Richards and Richard, 2006) 
 
2.1.2 Pathophysiology and T1DM 
T1DM is a catabolic disorder characterised by insufficient or absent insulin circulation, 
elevated levels of glucagon in the plasma and b-cells inability to respond to metabolic 
stimulus. It results from autoimmune destruction of b-cells originates from genetic or 
environmental factors.  
It is suggested (Knip et al., 2005) that there is a genetic susceptibility to the disease 
development, and the exposure to environmental agents triggers the onset of diabetes type 1. 
A preclinical period up to 13 years has also been identified. This is characterised by 
hyperglycaemia for a few years progressing to clinical diabetes when the complications begin 
to appear (Steck and Rewers, 2004), (Khardori, 2014). 
 
2.1.2.a Complications of T1DM 
T1DM can cause serious complications in the major organs of the body. Problems in the 
heart, kidney, eyes and nerves can potentially develop gradually over years. The risk of the 
complications can be decreased only by optimal glycaemic control. In detail, the long-terms 
complications encompass: 
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Macro vascular complications (disease of any large (macro) blood vessels) 
An environment of high glucose conditions stimulates the adhesion of monocytes to arterial 
endothelial cells. The monocytes, in turn, take up lipids and their accumulation in the artery 
walls lead to increased levels of atherosclerosis (Chait and Bornfeldt, 2009). 
 Depending on the location of the affected artery, the following diseases can occur:   
- Coronary artery disease (coronary arteries-ischemic heart disease) 
- Cerebral vascular disease (carotid artery-stroke, Transient ischemic attack) 
- Intermittent claudication (iliofemoral and smaller arteries of the lower legs-gangrene) 
 
Micro vascular complications 
Caused by wall thickening of small arterioles and capillaries and include: 
- Diabetic retinopathy (can lead to glaucoma, cataracts or even blindness) 
- Diabetic nephropathy (can lead to chronic renal failure) 
- Diabetic neuropathy  (leads to ulceration-diabetic foot) 
 
Other complications may include skin infections, hearing complications, increased risk 
fordeveloping osteoporosis and complications during pregnancy. 
 
2.1.2.b Symptoms of T1DM 
Diabetes type 1 onset can be very sudden and usually the symptoms and signs are very 
obvious and can develop over a few weeks. The most common symptoms are polyuria, 
polydipsia, polyphagia with weight loss, tiredness, muscle cramps and blurred vision. 
 
Main Symptoms 
Polyuria: due to osmotic diuresis (increase in the osmotic pressure within the kidney tubules, 
caused by the presence of glucose, that leads to a reduced reabsorption of water and to an 
increased urine output) leading to nocturnal enuresis especially in young children. 
 
Polydipsia: usually as a result of osmotic diuresis (with the amount of water leaving the body 
being greater than the amount being taken in) leading to dehydration. 
 
Polyphagia with weight loss: weight loss in the presence of normal or increased appetite is 
due to stored fat breakdown as an alternative supply of energy to the body cells.  
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Tiredness:  caused by muscle wasting, hypovolemia (decrease in volume of blood plasma due 
to dehydration), hypokalaemia (urinary loss). 
 
Other Symptoms 
 
Muscle cramps: due to muscle fatigue and electrolyte imbalance (hypokalaemia) 
 
Blurred vision: caused by the lens of the eyes becoming very dry   
 
Itchiness around the vagina or penis: caused by glucose excess in the urine 
 
Gastrointestinal symptoms: Nausea, abdominal discomfort or pain, constipation, usually 
accompany other causes such as neuropathy, pancreatitis, DKA 
Younger children ( <7years old) present more severe symptoms because they lose 
approximately the 80% of the islets compared to 60% in children 7-14 years old and 40% in 
children older than 14 years old.  
 
2.1.2.c Diagnostic Tests for T1DM 
Diagnosis of T1DM 
- Blood Glucose Test 
Fasting Plasma glucose: 2 samples greater than 125mg/dl (i.e. 6.99 mmol/L) according to 
ADA 
Random plasma glucose (for symptomatic patients): 200mg/dl 
-  Urinalysis for glucose, ketones and protein 
-  Physical examination 
On-going monitoring of diabetes control 
- Glycosylated haemoglobin (Hb) or Hb A1c: Glucose molecules react with 
haemoglobin, forming glycated haemoglobin. Once a haemoglobin molecule is 
glycated, it remains that way. The HbA1c level is proportional to average blood 
glucose concentration over the previous four weeks to three months, a period which 
reflects the life span of a red blood cell. (HbA1c>6.5% indicates DM) 
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- Fructosamine blood test: Glucose molecules react with the amino group of proteins, 
forming fructosamines which reflect glucose control in the previous 1-3 weeks  
 
- Oral glucose tolerance test with insulin levels 
 
- C-peptide/ insulin level test 
 
- Islet cell antibodies 
 
- Self-managed blood glucose testing  
 
- Fingerpick blood drop blood glucose tests 
 
- Urine glucose home testing  
 
- Urine ketone home testing 
2.1.2. d Treatment 
Diabetes type 1 requires administration of exogenous insulin, which replaces the body’s own 
insulin in order to maintain the blood glucose within a normal range. In general, for patients 
with T1DM, intensive insulin treatment is recommended. Conventional (standard) insulin 
therapy is suggested only in special cases. In order to achieve tight blood sugar control, 
intensive insulin therapy requires frequent insulin injections or the use of an insulin pump, to 
check blood glucose concentration at least 4 times a day and to follow specific eating and 
exercise plans.  
Occasionally, there is a period following the diagnosis of diabetes that the patient doesn’t 
present any symptoms of the previously mentioned and the blood sugar levels improve to 
normal or near-normal, levels. This so- called "Honeymoon period" is due to remaining islets 
of Langerhans which begin to recover their ability to produce endogenous insulin. This period 
may last for several weeks or months.  
Insulin schedules 
Insulin schedules consist of multiple subcutaneous insulin injections which are administrated 
throughout the day with regard to blood glucose control (avoid hyperglycaemia or 
hypoglycaemia). Usually a background or long acting insulin is taken at bedtime, and rapid 
acting insulin is taken before meals. The schedule is individualised depending on the patient’s 
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characteristics and needs (meal plan, activities). It should also be flexible to adjust to 
changing daily routines (holidays, fasting). 
CSII 
Continuous subcutaneous insulin infusion (CSII) therapy or insulin pump is a small, battery- 
operated pump that is worn on the body and infuses continuously rapid-acting insulin 
(Medronic, 2008) through a cannula inserted under the skin. The pump can provide the 
patient with a continuous basal rate of insulin and manually the patient can administrate bolus 
doses before each meal, according to the current blood glucose level and the content of 
carbohydrates in the meal.  
It can be stated that successful treatment of diabetes type 1 requires the contribution of a 
physician, nurse, dietician and the patient’s and family’s appropriate education and 
motivation. Particularly important is the patient’s diet that should be configured according to 
the patient’s nutrition habits, but should consist of a specific caloric plan and specific daily 
intake of carbohydrates, proteins and fat subjected to timing, size and composition 
management of each meal. Furthermore daily activity is highly recommended to patients and 
adjustment of insulin therapy and nutrition should be taken into account.  
2.1.2.e Types of insulin  
There are three kinds of insulin, according to its origin: a. animal insulin, b. recombinant 
insulin or "Human" insulin and c. insulin analogues (Mohan, 2002). Animal insulin is 
extracted from the pancreas of healthy animals (such as beef, pork and salmon) and then is 
highly purified. Although this product is very cheap (Mohan, 2002) it is used less frequently 
in the developed countries due to fear of immunogenic reactions caused by contaminated 
preparations and due to the rapid increase of the demand during the 70s, that could not be 
covered by the existing supplies.  Consequently biosynthetic methods of synthesizing insulin 
were developed to ensure that there would always be available supplies. The production of 
"Human" insulin is based on either recombinant DNA technology by using E. coli and yeast 
cells, or on alteration of the structure of animal insulin. Ultimately, insulin analogues are 
genetically produced starting from "Human" insulin with further alteration in the amino 
chains that finally are different from any occurring in nature. These modifications can 
produce two types of insulin, the rapid acting insulin which is monomeric and hence it is 
easily absorbed and biologically active; and the long acting insulin, preparations which 
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contain a high proportion of hexamers and its slow diffusion is appropriate to cover the daily 
basal rate.   
Insulin, regardless of the preparation method, can be classified according to the following 
three characteristics: the onset (length of time before insulin reaches the bloodstream and 
begins lowering blood glucose), the peak time (time during which insulin is at maximum 
strength in terms of lowering blood glucose), and duration (how long insulin continues to 
lower blood glucose). In Table 2.2 the characteristics of the typical types of insulin can be 
observed.  
 
Table 2.2: Characteristics of Insulin(American Diabetes Association) 
  Rapid acting Regular Intermediate-acting Long-acting 
Onset 5min 30min 2-4hr 6-10hr 
Peak time  1hr 2-3hr 4-12hr Peakless profile 
Duration 2-4hr 3-6hr 3-6hr 20-24hr 
 
The following table shows in detail the commercially available types of insulin and their 
mixtures. 
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Table 2.3: Commercially available types of insulin and their mixtures 
Generic name  
(U-100 except where noted) 
Brand name Form Manufacturer Cloudy or 
Clear 
Rapid acting  
Insulin glulisine Adidra* analog Sanofi-Aventis Clear 
Insulin lispro Humalog* analog Eli Lilly Clear 
Insulin aspart Novolog* analog Novo Nordisk Clear 
Regular 
Regular Humulin R ** human Eli Lilly Clear 
Regular Novolin R*, 
ReliOn (Wal-
Mart) 
human Novo Nordisk Clear 
Intermediate-acting 
NPH Humulin N* human Eli Lilly Cloudy 
NPH Novolin N*, 
ReliOn(Wal-Mart) 
human Novo Nordisk Cloudy 
Long-acting 
Insulin detemir Levemir* analog Novo Nordisk Clear 
Insulin glargine Lantus* analog Sonofi-Aventis Clear 
Mixtures 
70%NPH/30%regular Humulin 70/30* human Eli Lilly Cloudy 
70%NPH/30%regular Novolin 70/30*#, 
ReliOn(Wal-Mart) 
analog Novo Nordisk Cloudy 
50%lispro 
protamine/50%insulin lispro 
Humalog Mix 
50/50* 
analog Eli Lilly Cloudy 
75%lispro 
protamine(NPL)/25%lispro 
Humalog Mix 
75/25* 
analog Eli Lilly Cloudy 
70%aspart 
protamine/30%aspart 
NovoLog Mix 
70/30*# 
analog Novo Nordisk Cloudy 
Less commonly used insulin 
Regular Humalin R U-
500**$ 
human Eli Lilly Clear 
50%NPH/50%regular  human Eli Lilly Cloudy 
* Available in prefilled, disposable pens or cartridges for reusable pens 
** Note difference between Humulin R and Humulin R U-500 
#Note difference between Novolin 70/30 (70% NPH/30% regular) and NovoLog Mix 70/30 (70% aspart protamine/30% 
aspart) 
$U-500 and U-100 are different concentrations of insulin. U-500 is typically used in very insulin-resistant people 
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2.2 Literature Review 
 
2.2.1 Modelling the drug delivery system 
From the moment a therapeutic agent is administered in the human body until the desired 
therapeutic effect becomes apparent, there are numerous mechanisms and factors involved 
that play a substantial role to the drug’s therapeutic efficacy. In an effort to maximise the 
drug’s efficacy and increase the patient’s safety, modelling the entire drug delivery process 
has become a very useful tool for understanding, simulating, optimising and predicting 
patient’s response to the drug. This is achieved through pharmacokinetic and 
pharmacodynamic studies. The pharmacokinetics describe mechanisms such as drug 
metabolism, transport, absorption, distribution, diffusion and elimination, (the effect of the 
body on the drug). The pharmacodynamics, on the other hand, describe the effect of the drug 
on the body and is usually expressed mathematically by dose-response relations. A brief 
description of the established ways to model the pharmacokinetics and pharmacodynamics is 
presented below.   
2.2.1.a Pharmacokinetic Modelling 
Compartmental Models 
One of the most common modelling approaches to describe the pharmacokinetic process is 
the compartmental modelling. This approach assumes that the drug molecules act inside the 
considered compartments, and explicit mathematical expressions of the drug concentration in 
each compartment are determined (Hladky, 1990). The simplest case is to represent the 
human body as a single compartment in which the drug is administered and   eliminated, as 
shown on the left hand side of Figure 2.5. The basic assumption in compartmental modelling 
is that the concentration of the drug inside the compartment is constant, in other words, there 
is instant homogeneous distribution of materials within a compartment. A single compartment 
can be considered only when there is a very rapid distribution of the drug from the central 
compartment (the plasma) to the peripheral compartment (the equilibrating tissues). Usually, 
this approach describes intravenously injected well-diffused drugs whose elimination follows 
first-order kinetics. If that is not the case, usually because of slow diffusion of the drug to the 
peripheral tissues, additional compartments should be considered (right hand side of Figure 
2.5). There are several drawbacks of the compartmental analysis, such as the correlation of 
the model parameters (e.g. transfer coefficients) to physiological parameters, as well as 
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difficulties related to the determination of the appropriate number of compartments that 
should be used to represent the pharmacokinetics of the entire population.   
 
 
Figure 2.5: Single Compartment (left hand side), two compartmental approach (right hand side) 
 
Physiological Models 
To overcome the difficulty of relating the model parameters (compartment’s volume, transfer 
rate between compartments) to physiological features in compartmental modelling, 
physiological models have been developed. The physiological models take advantage of a 
priori knowledge of the mechanisms involved in the drug action and the mathematical 
representation reflects the administration, diffusion and elimination of a drug in every organ 
of the body. This approach requires deeper understanding of the physiology but provides 
detailed and explicit representation of the drug delivery system. The advantages of 
physiologically based models over compartmental/empirical models include the ability to be 
extrapolated between different species and different drug dosages (Saltzman, 2001), 
(Cashman et al., 1996). The main drawback of physiologically based models is that 
sometimes certain parameters cannot be measured and their values are difficult to be 
accurately predicted.  
Figure 2.6 illustrates a schematic of a physiological pharmacokinetic model. The grey arrows 
represent the routes of a drug administration: inhaled, intravenous, oral, intramuscular. The 
black arrows show the elimination from several compartments depending on the route of 
administration.   
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Figure 2.6: physiological modelling, adapted from 
(http://aiche.confex.com/aiche/2008/webprogram/Paper138436.html) 
Simplifications in the previous schemes can be made depending on the exact system which is 
studied. In Figure 2.6, organs which do not contain important amounts of the drug agent can 
be neglected (Saltzman, 2001). Every organ can be described with more than one 
compartment when a more detailed representation is required. Accordingly, the scheme of 
Figure 2.7 can be changed in cases where wall permeability of either the capillary or cell 
membrane or both is high, and the corresponding transport through the membranes is rapid. 
In such cases, the respective compartments can be lumped in two or just one (Sorensen, 
1978). 
 
Figure 2.7: Organ compartmental analysis 
Vascular (Blood)
Interstitial
Intracellular
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2.2.1.b Pharmacodynamic Modelling 
Modelling the pharmacodynamics of a system (i.e. the effect of a drug on the human body) is 
essentially connected to pharmacokinetic modelling because the profile of drug concentration 
(pharmacokinetic model) is required to estimate the parameters that describe the consequent 
effect. Usually, precise measurements of the drug effect cannot be easily obtained, so in 
practice the pharmacodynamic model is determined by testing potential models and 
estimating the parameters when a reference pharmacokinetic model is used.  
Pharmacodynamic models assume that the concentration of the drug is in equilibrium with the 
effect site, which could only  hold at steady state, and therefore the pharmacodynamic 
expression cannot be complete without the combined usage of a pharmacokinetic model.  
Table 2.4 briefly presents types of empirical pharmacodynamic models proposed in the 
literature: 
Table 2.4: The most common types of empirical pharmacodynamics models (adapted from (Holford 
and Sheiner, 1982) 
Model Model Equations Description 
Fixed Effect 
Model 
Effect: Present (1) or Absent (0), or degree of effect
 
Linear Model oECSE   
E=drug effect, C=drug concentration, S=slope 
parameter, Eo= initial drug effect  
Log-linear 
Model 
ICSE  log  
E=drug effect, C=drug concentration, S=slope 
parameter, I=constant  
EmaxModel 
CEC
CE
EE o



50
max
 
E= drug effect, C=drug concentration, Emax= 
maximum drug effect, Eo= initial drug effect 
from previous application, EC50=concentration 
producing half of the maximum drug effect 
Sigmoid 
Emaxmodel nn
n
CEC
CE
E



50
max
 
E= drug effect, C=drug concentration, Emax= 
maximum drug effect, Eo= initial drug effect 
from previous application, EC50=concentration 
producing half of the maximum drug effect,n= 
constant affecting the shape of the drug effect-
concentration curve 
 
2.2.1.c Applications 
A model of a biomedical process is an analogue of the studied system. The reason why a 
process is modelled determines the complexity of a proposed model. Two of the most 
common applications of modelling of biomedical systems are the development of virtual 
patients or patient simulators and the development of reliable predictive tools for control 
studies. A patient simulator is used for educational purposes such as AIDA developed by 
(Lehmann & Deutsch, 1992) or it can substitute clinical trials to determine optimal drug doses 
that produce effective and safe responses, such as the UVa/Padova Simulator (B. P. 
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Kovatchev, M. D. Breton, et al., 2009) These models have a strong relevance to physiology. 
The models derived for control purposes are usually simpler and can also be empirical. The 
aim of these software tools is to provide the doctor with a decision advice, acting as a 
therapeutic advisory system in a model based control context.     
2.2.2 Modelling the glucose-insulin system in T1DM 
In the last 35 years a large number of models describing the glucose-insulin interaction 
system have been developed. Usually, the system is divided in insulin pharmacokinetics and 
glucose metabolism, which describes mathematically the mechanisms of glucose absorption, 
distribution and production in the relevant organs. Glucose appears in the blood either as a 
result of carbohydrates consumption or by being released by the liver. Insulin is administered 
externally in the subcutaneous tissue. Insulin contributes to glucose metabolism in the liver, 
where it suppresses the endogenous glucose production and in the adipose tissue and muscle 
cells where insulin-dependent glucose uptake is taking place. Consequently, the main 
components that contribute to the entire description of the process are: glucose absorption 
from the blood through the gastrointestinal tract, insulin absorption from the blood through 
the subcutaneous tissue, endogenous glucose production, glucose excretion and glucose 
uptake. The models encountered in the literature describe these processes with several 
approaches. A selection of models can be seen in Table 2.5. Detailed description of the 
available models of glucose-insulin interactions is presented below: 
 
Models based on Minimal Model 
Modelling the glucose-insulin system for normal and diabetic subjects started in 1970s, when 
Dr. R. Bergman and co-workers introduced the Minimal model (Bergman, Phillips and 
Cobelli, 1981), which essentially is a method to estimate pancreatic effectiveness and insulin 
sensitivity. The model describes the dynamics during an intravenous glucose tolerance test 
(IVGTT) or an oral glucose tolerance test (OGTT). It consists of two subsystems describing 
insulin and glucose kinetics at a level of minimal complexity.  Glucose subsystem 
encompasses a plasma compartment and a remote compartment in which insulin is inserted to 
transfer glucose into the periphery and liver and to inhibit hepatic glucose production; the 
insulin minimal subsystem involves only a single plasma compartment. Although this model 
contributed fundamentally to later research work, it has several drawbacks regarding the 
modelling approach. For example, Caumo (1993) has indicated that the minimal model 
presents an abnormal behaviour of endogenous glucose production and limited validity in the 
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unsteady state. Furthermore Cobelli et al., (2009) state that the assumption of insulin 
secretion in proportion to glucose concentration cannot be experimentally verified. Generally, 
the model simplifies the complexity of the metabolic system and its validity is restricted to 
the description of insulin-glucose dynamics during an IVGTT or OGTT (Van Herpe et al., 
2007).  
In Fisher (1991) two more terms were introduced in the minimal model. One represents the 
effect of glucose intake from meal consumption; and the other represents exogenous insulin 
infusion. The limitations of this approach are derived from the limitations of the minimal 
model approach, such as fixed values of the model parameters. Furthermore this approach has 
not been validated clinically, but the results are consistent with the literature. 
Fabietti et al. (2006) modified the minimal model to focus on patients with T1DM. The 
glucose kinetics model consists of two compartments, insulin kinetics is described by two 
compartments, one representing the exogenous, subcutaneous administration of insulin and 
the other a remote one.  External inputs such as meals and glucose boluses are assumed 
together with liver glucose uptake. A drawback as mentioned by (Wilinska and Hovorka, 
2008) is that  the model is not capable of representing personalised results, following real 
time changes of the patient’s physiological responses. However, it is able to represent within 
patient variability, by considering circadian insulin sensitivity variation.  
Several models have been introduced which retained the core of the minimal model but 
altered specific parts to account for certain aspects, such as descriptive representation of the 
glucose kinetics according to experimental data (Caumo and Cobelli, 1993). Van Herpe et al. 
(2007) have evolved the MM so as to take into consideration the critical ill patients 
(intravenous glucose and insulin administration).   
 
Further compartmental approaches 
Berger and Rodbard (1991) have developed a simulation and optimisation program 
(GLUCOJECT) for insulin therapy in patients with T1DM. The model used in this program is 
consistent of two subsystems describing insulin and glucose kinetics at a level of minimal 
complexity.  The insulin subsystem describes the pharmacokinetics of insulin within 3 
compartments: subcutaneous insulin depot, plasma insulin compartment and a remote 
compartment. Glucose kinetics is described by a single compartment of plasma glucose. This 
program stores glucose values and insulin doses and can reproduce an average 24h glucose 
and insulin profile. There are no published data referring to its clinical evaluation. The 
pharmacokinetic model of insulin action of this model was used by (E D Lehmann and 
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Deutsch, 1992) in combination with a model describing glucose pharmacodynamics, which is 
based on experimental data from the literature and presented by (Guyton et al., 1978) to 
describe glucose-insulin interaction of T1DM. This model was used by AIDA, an online 
educational tool. The authors of AIDA model suggested a generic subcutaneous absorption of 
insulin  (Lehmann et al., 2007). This model is suggested initially from Tarín et al. (2005) and 
it is incorporated alongside the existing model of insulin kinetics and disposal from Berger 
and Rodbard. In this way, novel insulin analogues can be simulated and the current insulin 
dose can exceed the limit of 40 IU per injection, which was assumed in the previous model. 
This tool, as mentioned by the authors, should be used only for patients’ education and not as 
a treatment tool. Currently, further developments are considered to account for the existing 
limitations.  
Two of the most commonly used physiologically-based compartmental models are those 
developed by the groups of Hovorka and Cobelli.  
The model of the glucoregulatory system developed by Hovorka et al. (2002) and  Hovorka et 
al. (2004) considers the glucose subsystem using 2 compartments representing the accessible 
and non-accessible pool; the insulin subsystem with a chain of three compartments to 
describe the rapid acting insulin infusion and distribution (Willinska et al., 2010) and finally a 
subsystem of insulin action on glucose transport, disposal, and production.  Additionally the 
glucose absorption from the gut as well as the interstitial glucose kinetics have been 
modelled. This model so far has been validated in the sense that it can reproduce the results 
obtained from a clinical study of a closed loop insulin delivery in patients with T1DM. The 
model and its parameters represent a virtual patient.  The simulation environment is currently 
fully validated in order to be used for the development of closed loop insulin delivery 
systems. 
Another simulation environment has been developed from the Universities of Padova and 
Virginia (Dalla Man et al., 2007), (B. P. Kovatchev, M. Breton, et al., 2009). This model 
describes accurately the glucose and insulin dynamics during a meal. It consists of a glucose 
and an insulin subsystem. Glucose subsystem encompasses two compartments while the 
insulin dynamics are also represented by two compartments. The modelling of glucose rate of 
appearance coming from the food consumption as well as the endogenous glucose production 
and glucose utilisation are addressed. One issue that should be taken into account is the 
diurnal variability of the parameters. This simulator has been accepted by FDA for preclinical 
closed-loop control experiments by substituting animal trials as well as for clinical trials of 
closed-loop control based entirely on silico tests.  
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Models in the form of delay differential equations 
There are two kinds of time delays in the physiology of glucose-insulin system. The first 
delay is related to insulin production triggered by increased glucose levels as well as the time 
required for insulin to become accessible for utilisation. The other one is the delay between 
the appearance of insulin in the plasma and its inhibitory effect on the hepatic glucose 
production. Regarding the pathophysiology of T1DM, there is another delay concerning the 
exogenous insulin infusion; it represents the required time of subcutaneous infused insulin to 
be absorbed. These delays can be represented implicitly or explicitly. In other words, they can 
be expressed by either separating insulin/glucose in two compartments, by using auxiliary 
variables, or by introducing time delay terms in the functions describing insulin production 
and endogenous glucose production.  
Models assuming physiological delays in the system of insulin – glucose have been 
developed. In these models circadian insulin secretion oscillations are analysed in the form of 
differential equations. The initial model suggesting that behaviour has been developed by 
(Sturis et al., 1991). The delays are modelled by assuming insulin action in two separate 
compartments and by assuming auxiliary variables representing insulin effects on endogenous 
glucose production. The model equations were modified by (Tolić, Mosekilde and Sturis, 
2000) and insulin secretion was represented as a sigmoid function of glucose concentration.  
In order to examine whether oscillatory insulin supply is more efficient, as it mimics the 
pulsatile secretion of hormones in the endocrine system, Tolić et al. (2000) have suggested 
that insulin infusion should be sinusoidal. Actually, it was proved that only when hepatic 
glucose release is near the upper limit oscillatory, will insulin supply be more efficient; 
otherwise oscillatory and constant insulin infusion produce similar effects.  
Bennett and Gourley (2004) instead of the three auxiliary linear equations, proposed in the 
previous model, introduced a time delay of insulin effect on hepatic glucose production, 
explicitly in the model. The two-compartment approach for insulin production/utilization 
delay was maintained. Engelborghs et al. (2001) assumed only the delay related to insulin 
effect on hepatic glucose production, which was represented explicitly in the model. Because 
this model is not physiologically complete, it is not further considered. Li et al. (2006) 
suggested a two time delay model that introduces two explicit time delays in the system. 
Finally, Chen et al. (2010) have developed a model for diabetic patients in which the time 
delays for hepatic glucose production and insulin release from beta cells are maintained, but 
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exogenous inputs of meal and insulin are described, as well as the effects of hyperglycaemia. 
Further modifications have been proposed by (Chen and Tsai, 2010). 
 
Physiological Models 
One of the most important models developed is the physiological model of Sorensen (1978). 
It contributed in the understanding of the physiology of the glucoregulatory system and it has 
been a reference point for subsequent research studies on modelling of the system.  It is based 
on the work of Guyton et al. (1978) and was modified by Parker et al. (1999). Although it 
describes the complexity of the metabolism it cannot represent the intra-patient variability.  
 
Empirical Models-Hybrid Models 
Several research groups have worked on data driven models, in an attempt to overcome the 
assumptions and simplifications that physiological and physiologically based compartmental 
models are by default subject to. An approach of using Volterra Models to describe the 
glucoregulatory system has been proposed by Mitsis et al. (2009). For the particular study the 
data are obtained from simulation results of the Minimal Model. Eren-Oruklu et al. (2009) 
have used an ARMA (autoregressive moving-average) model to describe the glucose-insulin 
dynamics in order to capture the between patients variability. Additionally Ghosh and Maka 
(2009) has described the system by a NARX model by using data obtained from IVGTT. 
Finally Mougiakakou et al. (2005) have proposed the combination of compartmental models 
and artificial Neural Networks as an individualised representation of the glucose metabolism. 
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Table 2.5: Mathematical models of glucose-insulin system 
Mathematical Models 
Compartmental Models 
Number of compartments 
Glucose 
Kinetics 
Insulin 
Kinetics 
Validation Comments Reference 
1 2 IVGTT data 
Minimal complexity 
Healthy subjects 
(Bergman, Phillips and 
Cobelli, 1981) 
1 2 Literature data 
Minimal model for 
T1DM 
(Fisher, 1991) 
2 2 IVGTT data Healthy subjects (Caumo and Cobelli, 1993) 
1 3 Literature data 
No published data for 
clinical evaluation 
(Berger and Rodbard, 1991) 
1 2 Literature data 
AIDA: educational 
tool 
(E D Lehmann and Deutsch, 
1992) 
1 1 Literature data 
experimental data on 
critical ill patients 
(Hann et al., 2005) 
2 2 Literature data 
average patient 
Circadian SI 
variation 
(Fabietti et al., 2006) 
2 3 Literature data critical ill patients (Van Herpe et al., 2007) 
2 
3 
3 effect of 
insulin action 
Clinical study of closed 
loop insulin delivery in 
young people with T1DM 
Validated simulation 
environment 
(Willinska et al., 2010) 
2 2 Experiments FDA approval 
(Dalla Man, Rizza and 
Cobelli, 2007), (Dalla Man et 
al., 2007) 
Physiological Models 
6 6 Literature data average 70kg man (Sorensen, 1978) 
6 6 
Literature data 
 
average 70kg man 
Includes a meal 
submodel 
(Parker, Doyle and Peppas, 
1999) 
Models in the form of delayed differential equation 
1 
2 
3 delayed 
insulin effect 
Literature data 
Healthy subjects 
Implicit delays 
(Tolić, Mosekilde and Sturis, 
2000) 
1 2 Literature data 
Healthy subjects 
explicit delays 
(Bennett and Gourley, 2004) 
1 2 Literature data 
Healthy subject 
explicit delay 
(Engelborghs et al., 2001) 
1 2 Literature data 
Healthy subjects 
Explicit/implicit 
(Li, Kuang and Mason, 2006) 
1 
 
2 Literature data T1DM 
explicit delay 
(Chen, Tsai and Wong, 2010) 
 
Empirical Models 
Volterra Model Literature data (Mitsis, Markakis and Marmarelis, 2009) 
ARMA model Literature data (Eren-Oruklu et al., 2009) 
NARX model Literature data (Ghosh and Maka, 2009) 
Compartmental-Neural 
Networks 
Literature data (Mougiakakou, Prountzou and Nikita, 2005) 
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3. Mathematical Model Development 
 
3.1 Introduction 
An essential step for the design of model predictive control is the development of a reliable 
mathematical model. The model presented in this section is describing glucose metabolism 
and insulin kinetics for a patient with T1DM in a detailed compartmental approach. The 
system is analysed at organ-level aiming to provide thoughtful insight and understanding of 
the physiology. Additionally, in an effort to reduce the intra-patient variability and describe 
the individualised glucose metabolism, patient-specific variables that are functions of the 
patient’s individual characteristics such as gender, age, weight, height and hematocrit are 
introduced. However, the pharmacodynamic variables that are related to the effect of insulin 
on glucose remain uncertain and present inter and intra- patient variability. In the next 
chapter, the uncertainty in the predictability of blood glucose is investigated by using model 
analysis techniques to prioritise the variables that need to be identified first to successfully 
predict the patient’s current state.  
3.2 Physiologically based Compartmental Model of Glucose Metabolism 
The proposed model describes glucose distribution in the involved body compartments, as 
presented in Figure 3.1, and the effect of insulin on glucose uptake and suppression of 
endogenous glucose production. The structure of the proposed model is inspired by the 
Sorensen’s model (Sorensen, 1978) that describes the glucose metabolism with actual 
anatomical compartments. The body is considered to be divided in six compartments, brain, 
heart, liver, gut, periphery and kidney, where glucose is distributed via blood circulation. The 
periphery compartment that lumps the muscles and adipose tissue is described by two sub 
compartments, the interstitial fluid and the tissue, in order to highlight the dependence of 
glucose diffusion on the prevailing blood flow and capillary permeability as well as the 
dependence of glucose tissue uptake on insulin concentration. At steady state, an 
approximation of constant physiological conditions, the blood glucose concentration reflects 
the net balance of endogenous glucose release in the circulation and glucose uptake. When 
food is consumed, the contained carbohydrates break down into glucose in the gastrointestinal 
tract which is absorbed through the small intestine into the bloodstream. Physiologically, an 
increase in blood glucose triggers pancreatic insulin release, which activates glucose 
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transporters to mediate glucose translocation into the insulin-sensitive cells (adipose tissue, 
skeletal and cardiac muscles) and additionally suppresses the endogenous glucose production. 
In T1DM the pancreatic insulin secretion is replaced by optimal administration of exogenous 
insulin that mimics the pancreatic response. Glucose appearance in the gut after meal 
consumption, endogenous glucose production in the liver and glucose excretion from the 
kidney are described with additional sub models that are well-established in the literature and 
are embedded into the structure of the model to entirely describe glucose metabolism.  
 
Figure 3.1: Structure of the physiologically based compartmental model of glucose metabolism in 
T1DM 
For the highly perfused organs (brain, liver, gut, kidney) glucose concentration is considered 
to be in equilibrium with the tissue glucose concentration. The periphery compartment lumps 
the adipose tissue and muscle cells. Glucose transfer from the blood capillaries to the 
interstitial fluid and glucose uptake in the periphery is described with two compartments. 
Homogeneity and instant mixing is assumed for every compartment, imposing all the exiting 
fluxes to be in equilibrium with the compartment. For the insulin insensitive organs glucose 
uptake is assumed to be a constant ratio of the available glucose. The core of the model is 
described with (3.1)-(3.6) and the definition of the involved variables is presented in detail in 
the notation section at the beginning of this thesis.  
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The driving force for glucose transport into the compartments is the blood-tissue 
concentration difference. The concentration in every organ is given by mass balances in every 
compartment. 
 
Brain (B)  
, ( )
B
g B B H B B
dC
V Q C C u
dt
    (3.1) 
Kidney (K)  
, ( )
k
g K K H K K
dC
V Q C C u excretion
dt
     (3.2) 
Liver (L)  
, ( )
L
g L L H G G L G L L
dC
V Q C Q C Q Q C u BW EGP
dt
           
(3.3) 
Gut (G)  
g, ( )
G
G G H G G a
dC
V Q C C u BW R
dt
      (3.4) 
Heart (H)  
,
H
g H B B L L P P K K CO H H
dC
V Q C Q C Q C Q C Q C u
dt
          
 
  (3.5) 
 
Periphery (P) 
 
,
, ,
( ) ( )
( )
( )
P
g Pc P H P P Pt
Pt
g P ISF P Pt P
P o Pt
dC
V Q C C p C C
dt
dC
V p C C u
dt
u C
   
  
 
 
(3.6.1) 
(3.6.2) 
(3.6.3) 
where the Ci is the glucose concentration (mg/dl) in i compartment, Vg,i  the accessible 
glucose volume (dL) of i compartment, Qi the blood flow (dL/min) in i compartment, ui the 
glucose uptake (mg/min), EGP the endogenous glucose production (mg/kg/min), Ra the rate 
of glucose appearance in the blood (mg/kg/dL) through the interstitial wall and λο the rate of 
glucose uptake (dL/min).  
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For (3.1)-(3.6) the blood flow in every organ i is described by (3.7). The ratio of cardiac 
output perfusing every organ is presented in Table 3.1.  
,i CO i COQ r Q                                                          (3.7)  
 
Table 3.1: Ratio of cardiac output at rest (Ferrannini and DeFronzo, 2004) 
 
 
 
Similarly the glucose uptake in every organ is described with (3.8) and the ratio of glucose 
uptake 𝑟𝑢,𝑖 is presented in  Table 3.2.  
 
, _i u iu r Total uptake                                  (3.8) 
Table 3.2: Ratio of glucose uptake (Ferrannini and DeFronzo, 2004) 
Tissue (ru,i) 
Brain 0.45 
Liver 0.13 
Kidneys 0.02 
Gut 0.07 
Periphery 0.30 
Heart 0.03 
In the following section the sub models of glucose metabolism functions are described in 
more detail.                  
Endogenous Glucose Production (EGP) 
Glucose is produced endogenously in the liver with a percentage of approximately 80% 
through gluconeogenesis and glycogenolysis, and in the cortex of kidney with a percentage of 
20% (Cano, 2002)
.
 mainly through glyconeogenesis (Gerich, 2010), (Gerich et al., 2001). In 
this study it is assumed that glucose is entirely produced in the liver, due to limited data 
availability. Generally, in diabetes, the insufficiency of insulin causes liver to function as 
being in fasting condition, where the rate of glucose production is high. In particular, when 
glucose is consumed, there is no indicator to suppress hepatic glucose production (Newgard, 
2004). In T1DM, the rate of EGP depends on adequate control of the disease (Roden and 
Bernroider, 2003). When referring to intensive insulin therapy, it can be assumed that EGP is 
approximately the same as in normal humans (Roden and Bernroider, 2003), (Davis, Fowler 
Tissue (rco,i) 
Brain 0.11 
Liver 0.20 
Kidneys 0.13 
Gut 0.15 
Periphery 0.40 
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and Costa, 2000). The model describing the endogenous glucose production in T1DM and 
used in (3.3) is adapted from (Dalla Man, Rizza and Cobelli, 2007).  
1 2 3( )p p L p dEGP k k M k I                                                   (3.9) 
1
1( )i p
dI
k I I
dt
  
                               
(3.10) 
1( )
d
i d
dI
k I I
dt
  
                                                       
             (3.11) 
 
ML (mg/kg) denotes the liver glucose mass and Id (pmol/l) denotes the delayed insulin signal 
described by a chain of two compartments (I1, Id). The model parameters are estimated using 
available literature data (Boden, Cheung and Homko, 2003). 
Rate of glucose appearance (Ra) 
The model describing the rate of glucose appearing in the circulation when food is consumed 
is adopted from (Dalla Man, Camilleri and Cobelli, 2006). This model describes glucose 
transit from the stomach with two compartments representing the solid and liquid phase, to 
the upper small intestine which is described with one compartment.  
1 2sto sto stoq q q   (3.12) 
1
21 1
( )
( ) ( )sto sto
dq t
k q t D t
dt
    (3.13) 
2
2 1
( )
( ) ( )sto empt sto gri sto
dq t
k q t k q t
dt
    (3.14) 
2
( )
( ) ( )
gut
abs gut empt sto
dq t
k q t k q t
dt
    (3.15) 
max min
min
-
( ) {tanh[ ( - )]- tanh[ ( - )] 2}
2
empt sto sto
k k
k t k a q bD q cD    (3.16) 
( )
( )
abs gut
a
fk q t
R t
BW
  (3.17) 
5
2 (1 )
a
D b

    
(3.18) 
5
2 D c
 
 
 (3.19) 
 
with qsto1, qsto2 (mg) the glucose mass in solid and liquid phase, qsto (mg) the overall glucose 
mass in the stomach, qgut (mg) is the glucose mass in the small intestine, kempt (min
-1
) is the 
rate of gastric emptying, α and β are model parameters, kmax, kmin (min
-1
) are the max and min 
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gastric emptying, kabs (min
-1
) is the rate constant of intestinal absorption, kgri is the rate 
constant of grinding, f (dimensionless) is the fraction of intestinal absorption, b and d are 
percentages of the dose and D (mg)  is the amount of ingested meal. 
Glucose Renal excretion (excretion) 
In diabetes, the threshold of renal glucose reabsorption is exceeded when glucose 
concentration increases above 180mg/dl and glucose gets excreted by the kidney. It is 
assumed that renal glucose excretion (mg/min) increases proportionally to increasing blood 
glucose concentration (Willinska et al., 2010), (Rave et al., 2006). 
 
If  180 /KG mg dL   (3.20) 
If 180 /KG mg dL  (3.21) 
CLrenal (dl/min) is renal glucose clearance.  
Glucose diffusion in the periphery 
The structure presented in Figure 3.2 is considered to model glucose distribution and uptake 
in the periphery compartment: 
 
                                Figure 3.2. Detailed glucose uptake in the periphery 
 
It is assumed that glucose is extracted from the arterial flux with a rate factor given in the 
current literature (Crone, 1965), (Regittnig et al., 2003): 
(1 exp( / ))P Pp Q PS Q                                             (3.22) 
PS is the permeability across the capillary wall, a product of permeability of exchange surface 
to glucose P and exchange surface area S. This rate factor can increase in case of increased 
blood flow to the periphery or increased perfusion due to increased capillary exchange area 
during for example exercise. According to Gudbjornsdottir et al. (2003) PS was increased 
( 180)
( )
0
renal KCL G
E t

 

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significantly during a one-step hyperinsulinemic clamp. The following equation describes the 
effect of insulin on glucose permeability across the capillary wall. 
2, 1,PS PS p
dPS
k PS k I
dt
   
                            (3.23) 
When glucose enters the interstitial fluid it is absorbed by the tissues to provide them with 
energy, (3.6). The rate of uptake, λο (dL/min) is dependent on insulin concentration in the 
blood and insulin effect is described with (3.24).  
1
2 1
2
         (0)=o o p o basal pbasal
d k
k k I with I
dt k

                                         (3.24) 
1 2/IS k k      
                                      (3. 25) 
SI represents the patient’s sensitivity to insulin.  
Adaptation to the individual patient 
 
1) Total Blood Volume 
The total blood volume (TBV) (dL) is adapted to the patient’s height, weight and gender to 
account for the differences between obese and underweight patients and for males and 
females. The formula used for men is (Wennesland et al., 1959):  
0.285 0.316 2.820MTBV h m    
                               (3.26)
  
and for women
 
(Brown et al., 1962)   
0.1652 0.3846 1.369FTBV h m                                       
(3.27)  
where the height (h) is in centimeters and weight (m) in kilograms  
2) Cardiac Output 
The cardiac output (mL/min) can be efficiently approximated as a proportional relationship to 
the patient’s weight BW (kg) according to the equation (Ederle et al., 2000): 
3/4224COQ BW                  
            (3.28) 
3) Compartmental Volume 
Plasma proteins comprise approximately 8% of the plasma volume and the erythrocytes about 
38% of the total packed red blood cells volume or Haematocrit (Ferrannini and DeFronzo, 
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2004), (Hemat). This percentage of the total blood volume is inaccessible to glucose. 
Consequently the accessible glucose volume in every compartment is determined as: 
  , V, ,1 0.08 (1 ) 0.38 ( )g i i C iV Hemat Hemat V V                                (3.29) 
The blood volume of the every compartment i is defined as the sum of venous and capillary 
volume. The glucose venous volume equals 60% of total blood volume and the capillary the 
10% of total blood volume
 
(Gerich et al., 2001), (Enderle, 2011). The compartmental venous 
and capillary volumes are defined as: 
, , 0.6V i f iV r TBV                                                (3.30) 
, , 0.1C i c iV r TBV                                     (3.31) 
Where 
,f ir refers to the ratio of total venous volume in compartment i. The compartmental 
venous blood volume is calculated by distributing the total venous blood volume at the body 
organs at the basis of fractional blood flows (Sorensen, 1978) (3.32): 
, /f i i ir Q Q                                          (3.32) 
and ,c ir refers to the ratio of total capillary volume respectively (Sorensen, 1978) and is 
presented in Table 3.3.  
Table 3.3: Ratio of capillary volume 
Tissue (rc,i) 
Brain 0.071 
Liver 0.18 
Kidneys 0.08 
Gut 0.13 
Periphery 0.53 
 
4) Peripheral Interstitial Volume  
The total regional volume for the adipose tissue is defined as 
,P ,P ,PP Capillary Interstitial IntracellularV V V V          
                                     (3.33) 
According to Man and Uribarri (Man and Uribarri, 2006) the interstitial volume represents 
28% of the total body water while the intracellular volume 60%. Hence, 
0.47Interstitial IntracellularV V .  The adipose tissue mass is described by: 
 1.2 10.8 0.23 5.4 0.01ATm BMI sex age BW      
 
(Deurenberg, et al., 1991)                (3.34)  
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with /i i id m V                                              (3.35) 
The interstitial volume of the adipose tissue and the muscles is considered to be 10% of the 
total tissue volume according to (Eckel, 2003) and (Johnson, 2003) respectively. Muscle mass 
is considered to be approximately 40% of the total body weight (3.36), according to Ackland, 
Elliott and Bloomfield (2009). 
0.4musclesm BW  
                                                                  (3.36) 
The peripheral volume of the interstitial fluid is calculated via (3.37), using Table 3.4: 
, , , ,g P ISF Interstitial AT Interstitial muscV V V       
                                (3.37) 
Table 3.4: Density of muscles and adipose tissue 
Tissue Density (kg/L) Reference 
Adipose Tissue (dAT) 0.92 (Gallagher et al., 1998) 
Muscles (dmuscles) 1.04 (Gallagher et al., 1998) 
3.3 Insulin Kinetics 
When pump therapy is used, rapid/short acting insulin is continuously infused through the 
subcutaneous tissue. The amount of insulin delivered is programmed and administered at a 
basal rate which varies depending on the patient’s daily requirements, and additional bolus 
doses that compensate for blood glucose level increase when meal is consumed. The 
formulation of rapid acting insulin reduces the tendency of insulin monomers to dimerize and 
further associate into hexamers (Leslie, Taylor and Pozzilli, 1997). Hence, the diffusion in the 
blood is enhanced with onset of action within 10-20min and maximum serum concentration 
reached in 45min (Home, 2012). However, the absorption of insulin from the subcutaneous 
tissue is dependent on the blood flow in the tissue, which causes variable time of onset and 
maximum effect. Hence, insulin kinetics describe the mechanisms involved from the moment 
insulin is administered in the subcutaneous tissue until it is fully eliminated from the body. 
Several models have been proposed in the literature (Tarín et al., 2005), (Kraegen and 
Chisholm, 1984), (Kuang and Li, 2008), (Nucci and Cobelli, 2000), with compartmental 
modelling being the most common approach. In this study, the structure to describe insulin 
kinetics is investigated when an insulin pump is used. Four alternative compartmental models 
are presented in this section that describe experimental data of insulin kinetics and compared 
in terms of identifiability, parameter correlations and accuracy, as presented in the following 
chapter. The models of insulin kinetics are linked with the glucose metabolism model (3.1-
3.37) via equations 3.10 and 3.24 which represent, respectively, insulin action on endogenous 
glucose production and glucose absorption from the periphery.  
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Model 1 
This model considers two different channels for insulin transport for basal infusion and bolus 
dose,  Figure 3.3. 
1
_1 1sub
dS
bolus k S
dt
  
       
                        (3.38) 
2
_ 2 2sub
dS
basal k S
dt
  
       
                           (3.39)
 
_1 1 _ 2 2
lim
p sub sub
e p
dist
dI k S k S
k I
dt V
  
  
    
                        (3.40) 
Model 2 
This model describes insulin transport for the bolus dose as one compartment and the basal 
infusion is considered as a direct input to the plasma compartment as a proportion of the 
initial basal rate, assuming that rest of the dose is degraded in the subcutaneous tissue,  Figure 
3.4.  
 1 _ 2 1sub
dS
bolus k S
dt
  
       
                     (3.41)
 
1
lim
p sub
in e p
dist
dI k S
k basal k I
dt V

   
     
                      (3.42) 
The variable and parameter definitions for both models are shown in Table 3.5. 
 
Table 3.5: Variable and parameter definition of Model 1 and Model 2 
Symbol Definitions 
S1, S2 Insulin mass(mU) in the subcutaneous compartments 
ksub_1, ksub_2 intercompartmental transfer rate constants (min
-1
) 
kelim elimination rate constant (min
-1
) 
Vdist insulin distribution volume (L/kg) 
kin Proportion of the initial basal rate as direct input 
basal Continuous insulin infusion (U/min) 
bolus Pulse insulin infusion (U/min) 
 
 
 
 
Chapter 3: Mathematical Model Formulation 
 
63 
 
  
 Figure 3.3. Schematic representation of model 1  Figure 3.4. Schematic representation of model 2 
Model 3 
This model consists of three compartments in series, namely two compartments to describe 
insulin absorption through the subcutaneous tissue (S1, S2) and a single compartment for 
insulin in the plasma (I). This model of insulin kinetics has been widely used in the literature 
(Wilinska et al., 2005), (Willinska et al., 2010) 
1
1sub
dS
u k S
dt
 
 
 (3.43) 
2
1 2sub sub
dS
k S k S
dt
   (3.44) 
𝑑𝐼
𝑑𝑡
= 𝑘𝑠𝑢𝑏𝑆2 − 𝑘𝑒𝑙𝑖𝑚𝐼 (3.45) 
𝐼𝑝 =
𝐼
𝑉𝑑𝑖𝑠𝑡
 (3.46) 
The variables and parameter definitions are presented in Table 3.6 and the schematic 
representation in Figure 3.5 
Table 3.6: Variable and parameter definition of Model 3 
Symbol Definitions 
S1, S2 Insulin mass(mU) in the subcutaneous compartments 
I Insulin mass(mU) in the plasma compartment 
ksub Intercompartmental transfer rate constant (min
-1
) 
kelim Elimination rate constant (min
-1
) 
Vdist Insulin distribution volume (L/kg) 
u Continuous insulin infusion (U/min) 
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Figure 3.5: Schematic representation of model 3 
 
Wilinska Model (Wilinska et al., 2005) 
This model assumes a slow channel of insulin absorption Q1a,, Q2 and a fast absorption 
channel Q1b,.  
 
max, 11
1 1
, 1
LD aa
a a
M LD a
V QdQ
ku k Q
dt k Q
  

                     (3.47) 
max, 11
2 1
, 1
(1- ) - -
LD bb
a b
M LD b
V QdQ
k u k Q
dt k Q


                (3.48) 
2
1 1 1 2a a a
dQ
k Q k Q
dt
                     (3.49) 
3
1 2 2 1 3a a b e
dQ
k Q k Q k Q
dt
                    (3.50) 
3
dist
Q
I
V
                     (3.51) 
The variables and parameter definitions are presented in Table 3.7 and the schematic 
representation in Figure 3.6. 
Table 3.7: Variable and parameter definition of Wilinska Model 
Symbol Definitions 
Q1, Q2, Q3 Insulin mass(mU) in the accessible, non-accessible 
subcutaneous compartment, plasma 
Vmax,LD ,kM,LD Michaelis-Menten coefficients describing saturated 
degradation  
ka1, ka2, ke transfer rate constants (min
-1
) 
Vdist insulin distribution volume (L/kg) 
k proportion of insulin flux entering the slow channel 
u Continuous insulin infusion (U/min) 
a, b insulin mass administered as continuous infusion and bolus 
respectively 
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Figure 3.6: Schematic representation of Willinska model 
 
The most suitable model to describe the insulin kinetics through the subcutaneous tissue to 
the plasma is found in the following chapter.  
3.4 Concluding Remarks  
In this chapter a mathematical model describing glucose metabolism in T1DM is presented. 
The core of the model consists of six compartments representing the most important organs 
associated with glucose metabolism, as introduced in Sorensen (1978).  Glucose appearance 
in the gut after meal consumption, endogenous glucose production in the liver and the kidney 
as well as glucose excretion from the kidney are described with additional sub models that are 
well-established in the literature and are embedded into the structure of the model to entirely 
describe glucose metabolism. The compartmental accessible glucose volumes, the cardiac 
output and the total blood volume are expressed as functions of patient characteristics, 
leading towards an individualised representation of the system’s dynamics. Unlike Sorensen’s 
model, insulin administration and absorption through the subcutaneous route is considered as 
simple compartmental representation, due to limited availability of experimental data to 
describe the involved mechanisms of insulin diffusion, dissociation and absorption. In the 
next chapter, the most appropriate model to describe the insulin kinetics is selected and the 
entire model is analysed in terms of influential parameters and variables, parameters 
correlations and estimation.  
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4. Model Analysis and Dynamic Optimisation 
 
4.1 Introduction 
In this chapter, the most suitable model for insulin kinetics is selected by performing a series 
of analysis tests. Experimental data obtained in the literature are used to estimate the model 
parameters. Additionally, the suggested structure of the EGP sub model is evaluated in terms 
of reliability, using experimental data from the literature to estimate the model parameters 
and confirm the model’s accuracy. Subsequently, the previously presented entire 
mathematical model of glucose metabolism is analysed in order to identify the most 
influential parameters that contribute to the model’s uncertainty. This uncertainty originates 
to a large extent from the high intra- and inter-patient variability that dominates the system. 
Global sensitivity analysis, parameter estimation and correlation are performed to evaluate 
the model’s ability to represent the glucoregulatory system’s physiology.  Additionally, the 
model’s adaptability to the specific patient and predictive ability are evaluated with data 
available in the literature and data provided from the UVa/Padova T1DMS simulator. 
4.2 Insulin Kinetics: Model Selection 
4.2.1 Methods 
The experimental plasma insulin concentration profiles used to investigate the accuracy of the 
proposed insulin kinetic models were obtained by (Boden, Cheung and Homko, 2003).  Nine 
subjects with T1DM (Sex (M/F) 1/8, Age (years), 24±3, Weight (kg), 68.8± 3.1, Height (cm), 
169± 4 BMI (kg/m
2
), 24.2 ±1.2, duration of T1DM (years),  7.5± 1.5, HbA1c (%),7.6 ± 0.7, 
insulin dose (units/24 h), 33.3± 5.1) were hospitalised to perform the particular study, which 
involved an euglycaemic clamp to determine the effect of insulin excess on gluconeogenesis 
(GNG), glycogenolysis (GL), or both, by measuring GNG (with 
2
H
2
O) and GL (EGP-GNG) 
and during insulin deficiency that developed after approximately 5 to 8h of the subcutaneous 
insulin injection. Boden et al.(2003) report the mean plasma insulin concentration profiles 
averaged over all nine patients which were used to evaluate the suggested models.  
4.2.2. Parameter Estimation 
The values of the parameters of the four models of insulin kinetics listed in Table 4.5 are 
identified via parameter estimation, performed in gPROMS. The solution method used in 
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gPROMS to obtain the optimal parameter estimates is to minimise the maximum log 
likelihood objective function (PSE, 2011a) by solving an optimisation problem.  
The goodness of the fit of the proposed model to the experimental data is evaluated with a 
Pearson’s chi-squared test (𝑥2) (PSE, 2011a), the accuracy of the estimates of the parameters 
was evaluated with a t-test and the reliability of the estimated values with the confidence 
intervals. The structural identifiability of the models is investigated by analysing the 
correlation matrix of the model parameters. Finally, the most suitable model to represent the 
experimental data was selected by applying the principle of parsimony and the Akaike 
criterion (Akaike, 1974)  is tested.  
Figure 4.1 shows the plasma insulin concentration (Ip) profiles produced by the suggested 
models versus the experimental data. Generally, we can conclude that all models describe 
relatively well the experimental data. However, a more in-depth analysis reveals the strengths 
and the weaknesses of each model.  
 
Figure 4.1: Comparison of Model 1, 2, 3 and Wilinska model with experimental data 
 
Figure 4.2 shows the weighted residuals of the models which present more clearly the 
deviation of each model from the experimental level. The residuals for all models are small in 
magnitude and thus it is difficult to conclude whether a model is better than the other.  
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Figure 4.2: Weighted Residuals of the four models  
A Pearson’s chi-squared test (𝑥2) is performed and the result that all models describe 
relatively well the experimental data in Figure 4.1 is confirmed in Figure 4.2. For N-p degrees 
of freedom, where N is the number of experimental data and p the number of parameters, the 
𝑥2-value is obtained for a 95% confidence level. The calculated 𝑥2 are smaller than the 
reference 𝑥2-value, which indicates that the fit of the considered model is good.  
Table 4.1: Goodness of fit of proposed models and model selection 
 Model 1 Model 2 Wilinska Model Model 3 
Pearson’s chi-squared test(𝑥2) 23.404 9.1041 13.362 9.0727 
𝑥2-Value ( 95%, k) 27.587 27.587 23.685 28.869 
Akaike Criterion 11.28 13.19 15.56 5.13 
 
4.2.3 Model Selection 
The Akaike criterion (AIC) is applied in order to select the most appropriate model that 
represents the experimental data. The test is presented in (4.1). 
AIC = Nln(WRSS) + 2K                              (4.1) 
N denotes the number of data points, K the number of parameters and WRSS the weighted 
residuals sum of squares.  
The Akaike values shown in Table 4.1 indicate that Model 1, Wilinska model and Model 3 
are suitable to describe the available experimental data. Model 2 is excluded from the 
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selection since it has the maximum Akaike value for the same number of model parameters as 
Model 1 (p=4). In principle, Model 3 should be selected since the AIC value is the smaller, 
but this choice is verified by analyzing further the remaining three models in terms of 
structural identifiability. The correlation matrix of the remaining models is calculated.  The 
elements of the correlation matrix C are: 
ij
ij
ii jj
V
C
V V

     
                                     (4.2) 
with ijv the elements of the variance-covariance matrix. A value of cij of the elements off-the 
diagonal close to 1 indicates that there is high correlation between the parameters i and j, 
whereas a value equal to 0 indicates no correlation.  
 
Table 4.2: Correlation Matrix of the parameters of Model 1 
 ksub1 ksub2 kelim Vdist 
ksub1 1.00 -0.94 0.98 -0.98 
ksub2 -0.94 1.00 -0.99 0.99 
kelim 0.98 -0.99 1.00 -0.99 
Vdist -0.98 0.99 -0.99 1.00 
The correlation matrix of the parameters of model 1 indicates that there is a high correlation 
among all pairs of estimated parameters, and therefore each parameter cannot be estimated 
independently. This implies that there are concerns related to the structural identifiability of 
the model and hence, the structure of the model may be inappropriate to describe the 
experimental data.  
The correlation matrices of Wilinska Model and Model 3 are presented in Table 4.3 and 
Table 4.4. 
Table 4.3: Correlation Matrix of Wilinska Model  
 k ka1 ka2 kelim km Vdist VmaxLD 
k 1.00 -0.57 -0.60 0.14 0.99 -0.90 0.97 
ka1 -0.57 1.00 -0.10 0.65 -0.64 0.24 -0.69 
ka2 -0.60 -0.10 1.00 -0.78 -0.56 0.88 -0.48 
kelim 0.14 0.65 -0.78 1.00 0.06 -0.53 -0.05 
km 0.99 -0.64 -0.56 0.06 1.00 -0.86 0.99 
Vdist -0.90 0.24 0.88 -0.53 -0.86 1.00 -0.81 
VmaxLD 0.97 -0.69 -0.48 -0.05 0.99 -0.81 1.00 
 
The correlation matrix of Wilinska Model shows that there is high correlation between the 
parameters k and km, k and kmand VmaxLD and ka2. Whereas, the correlation matrix for Model 3 
shows that parameters Vdist and kelim cannot be estimated independently.  
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Table 4.4: Correlation Matrix of Model 3 
 k1 kelim Vdist 
k1 1.00 -0.67 0.70 
kelim -0.67 1.00 -0.90 
Vdist 0.70 -0.90 1.00 
 
In the Wilinska Model and Model 3 there are significant correlations between pairs of 
parameters. But the model structures can be considered acceptable since both pass the 
goodness of fit test and both describe adequately the complexity of the physiology (Wilinska 
et al., 2005). The mean of the parameter estimates for all models are presented in Table 4.5.  
Table 4.5: Optimal Mean Parameter Estimates and standard deviations reported in parenthesis. Initial 
guess and lower-upper bounds of the parameters used for estimation are reported in the 2nd column.  
Parameter Initial Guess 
[Lower-Upper] 
Model 1 Model 2 Wilinska Model Model 3 
ksub1 0.1 
[0.05-1.5] 
0.36 
(±0.28) 
- - - 
ksub2 0.05 
[0.001-0.1] 
0.016 
(±0.048) 
0.042 
(±0.012) 
- - 
kin 0.5 
[0-1] 
- 
0.59 
(±0.3) 
  
kelim 
[M1,M2] 
0.015 
[0.001-0.1] 
0.017 
(±0.0065) 
0.011 
(±0.004) 
  
Vdist 
[M1,M2] 
1.5 
[0.1-5] 
3.46 
(±1.57) 
2.76 
(±0.5) 
  
kelim 
[WM] 
0.037 
[0.011-0.1]** 
  
0.012  
(±0.023) 
- 
Vdist 
[WM] 
0.42 
[0.17-1.25]** 
  
1.12 
(±0.3) 
- 
k 0.67 
[0.45-0.82]** 
- - 
0.51* 
(±0.07) 
- 
ka1 0.011 
[0.004-0.029]* 
- - 
0.003 
(±0.001) 
- 
ka2 0.021 
[0.011-0.040]* 
- - 
0.03 
(±0.006) 
- 
km 62.6  
[62.6-62.6]* 
- - 
65.66 
(±28.87) 
- 
VmaxLD 3.4  
[0.06-7.5]** 
- - 
7.09* 
(±3.4) 
- 
kelim 
[M3] 
0.33 
[0.067-1.34]* 
   
0.418  
(±0.338) 
Vdist 
[M3] 
0.054 
[0.016-0.25]* 
   
0.087 
(±0.072) 
ksub 0.016 
[0.01-0.026]* 
   
0.025 
(±0.0017) 
*Obtained from (Wilinska et al., 2005) 
**Bounds relaxed  
°M1 refers to Model 1, M2 to Model , M3 to Model 3 and WM to Wilinska Model 
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The values of the estimated parameters for Wilinska model and Model 3 are in good 
accordance with the literature (Wilinska et al., 2005).  
 
Key Points 
 Good fit to experimental data for the four models as verified from the Pearson’s chi-
squared test  
 Model 3 is selected according to the Akaike Criterion 
 Estimated parameters of Model 3 in good accordance with the literature 
4.3 Endogenous Glucose Production: Parameter Estimation 
The experimental data used for parameter estimation for the EGP submodel (3.9-3.11) are 
obtained from (Boden, Cheung and Homko, 2003). The purpose of this experiment was to 
study the mechanisms of endogenous glucose production (3.9-3.11) during insulin excess and 
insulin deficiency, while maintaining blood glucose concentration constant. Therefore, the 
parameter related to the effect of glucose to the suppression of EGP, kp2, was kept constant 
and equal to the mean value obtained from the literature
 
(Dalla Man, Rizza and Cobelli, 
2007).  
 
Figure 4.3. Effect of subcutaneous insulin injection on endogenous glucose production 
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Figure 4.3 shows that the model fits well the experimental data and the values of the 
estimated model parameters can be seen in Table 4.6. A t-test was performed that indicates 
accurate estimates of the parameters since the t-value is larger than the reference t-value for 
95% confidence level. Additionally, the confidence interval shows the precision of the 
estimated values for the corresponding parameters and is calculated with (4.3) 
 
Confidence Interval=± 
𝑡𝑎
2
(𝑛 − 1)
𝑆𝐷
√𝑛
,                  (4.3) 
 
Considering a a=95% confidence level 
 
Table 4.6: Parameter estimation results 
Symbol 
Optimal Estimate 
(mean±SD) 
Confidence 
Interval* (95%)
 
95% 
t-value 
ki 0.024±0.0034 0.0085 2.82 
kp1 3.058±0.17 0.42 7.33 
kp3 0.014±0.0022 0.0053 2.7 
                   Reference t-value (95%):1.94 
                
4.4 Global Sensitivity Analysis 
The model’s reliability is evaluated with the performance of global sensitivity analysis. The 
uncertain factors that have a relative influence on the model’s measurable output are 
determined and provide information on the proposed model’s structure, in an effort to reduce 
the model’s uncertainty by examining the most influential parameters. The GSA has been 
performed with the GUI-HDMR software (Ziehn and Tomlin, 2009) which uses an expansion 
of high dimensional model representation (RS-HDMR) method. This software calculates the 
sensitivity index (SI) for the parameter of interest. The RS-HDMR method maps the input 
(parameters) and output relationship as a function of orthonormal polynomials, the 
metamodel, using random sampling. The metamodel contains up to second order interactions, 
expressed as components of the orthonormal basis function as derived with ANOVA 
decomposition. The sensitivity indices are determined from the coefficients of the polynomial 
approximation. Sobol’s sampling set is preferred because it provides evenly uniform 
distributed points of the input space. The samplings was performed by simulating the model 
in gPROMS via gO: MATLAB interface, developed by Krieger et al. (Krieger et al., 2014). 
The SI is scaled between 0 and 1, with a SI=0 indicating a non-influential parameter. The 
parameters values vary between their upper and lower bounds and for every GSA, a set of 
Chapter 4: Model Analysis & Dynamic Optimisation 
 
73 
 
20000 Sobol’s distributed points within the range were used to calculate the SI for specified 
time points. The sum of all the SI converges to 1.  
In this study, the effect of the parameters on blood glucose concentration (CH) was evaluated 
in two cases. In the first case the sensitivity indices were calculated for all the parameters to 
investigate their influence in a system with respect to intra- and inter-patient variability. In the 
second case only the parameters related to the intra-patient variability were included 
assuming that the weight, the organ volumes, the insulin distribution and the meal absorption 
can be considered constants for an individual patient and were fixed at their default values. 
The results are presented in Table 4.7. 
Individual Model Parameters 
The model parameters are shown in Table 4.7. The range of the parameters Qco and Vg,i is 
calculated from (3.29)-(3.33) when considering the body weight of 50-115 kg, height of 150-
190 cm and age of 18-80 years. The default values are set for a male patient of 170 cm height, 
50 years old and 94 kg. The range of the parameters related to the Ra and EGP is adapted 
from the Uva/Padova Simulator. The default values of the parameters for these subsystems 
were set at the mean value. The ratio of cardiac output and the ratio of glucose uptake were 
considered to vary ±5%, a value chosen when performing a series of stochastic simulation 
studies, while the default values were obtained from Table 3.1 and Table 3.2. The range and 
the default value of the parameters for insulin kinetics was obtained from (Wilinska et al., 
2005). A big variation of the default value in the parameters k1 and k2 was assumed to 
evaluate the predictability of the model. Finally a ±20% variation was assumed for k1,PS and 
k2,PS. The initial guess of the values of the parameters k1, k2, and k1,PS, k2,PS  was selected 
when performing a set of stochastic simulation studies in comparison with the simulation 
results provided by the simulator.  
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Table 4.7: Model parameters default values and range. SIs for of all parameters and for those related to intra-
patient variability calculated with GUI-HDMR toolbox 
Symbol Default Range Sensitivity Index Units 
   All parameters Intra-patient parameters  
   480min 720min 480min 720min  
ka1 1.66×10
-02
 (1.0-2.66 )×10
-2
 0 0 - - min
-1
 
Vdist 5.38×10
-02
 (1.16-25.08) ×10
-2
 1.12E-06 5.07E-07 - - L/Kg 
kelim 3.02×10
-01
 (6.79-134.55) ×10
-2
 0 0 - - min
-1
 
k1 3.00×10
-04
 (0.40-1.00)×10
-03
 0.263565 0.340726 0.791256 0.445745 
dL
2
 per 
pmol·min
2 
k2 2.00×10
-01
 (0.50-5.00)×10
-01
 0.096337 0.418659 0.154249 0.565001 min
-1
 
kp1 5.38×10
+00
 (3.56-7.20)×10
+00
 0 0 7.93E-06 3.21E-05 mg/kg/min 
kp2 5.23×10
-03
 (2.44-8.02)×10
-03
 0 0.000721 0 0 min
-1
 
kp3 1.43×10
-02
 (0.46-2.39)×10
-02
 0.301874 0.005473 0.11209 0.039743 
mg/kg/min 
per pmol/L 
ki 0.78×10
-02
 (0.29-1.62)×10
-02
 3.51E-06 4.19E-05 0 0.000163 min-
1
 
k2_PS 4.00×10
-03
 (3.20-4.80)×10
-03
 0.015557 0.004761 0 3.37E-05 min
-1
 
k1_PS 5.00×10
-04
 (4.00-6.00)×10
-04
 0.000932 0.000138 3.64E-05 2.27E-05 
dL
2
 per 
pmol·min
2
 
kmax 3.01×10
-01
 (0.21-5.82)×10
-01
 0 0 - - min
-1
 
kmin 4.00×10
-02
 (2.19-5.82)×10
-02
 0 0.000127 - - min
-1
 
kabs 8.84×10
-03
 (0.28-1.49)×10
-02
 0.160871 1.67E-05 - - min
-1
 
kgri 4.00×10
-02
 (2.19-5.82)×10
-02
 0 8.23E-05 - - min
-1
 
B 7.95×10
-01
 (6.27-9.62)×10
-01
 3.63E-05 0.001582 - - - 
D 2.15×10
-01
 (0.92-3.37)×10
-01
 0 0.001022 - - - 
CLrenal 5.00×10
-05
 (4.00-6.00)×10
-01
 1.33E-04 0 6.32 E-05 0 dL/min 
Qco 6.04×10
+03
 (3.76-7.02)×10
+03
 0.003759 0.003217 6.69E-05 2.64E-05 mL/min 
VK 3.90×10
+00
 (2.24-4.86)×10
+00
 0.000289 0.000225 - - dL 
VG 4.44×10
+00
 (2.55-5.54)×10
+00
 0.012974 0.008315 - - dL 
VP 1.09×10
+01
 (0.63-1.37)×10
+01
 0 0.000374 - - dL 
VB 3.06×10
+00
 (1.76-3.82)×10
+00
 6.78E-05 0.010876 - - dL 
VL 5.62×10
+00
 (3.23-7.02)×10
+00
 0 0.00272 - - dL 
VH 1.34×10
+01
 (1.27-1.35)×10
+01
 3.38E-05 0.000164 - - dL 
rco,K 1.78×10
-01
 (1.69-1.87)×10
-01
 1.33E-05 0.000539 1.16E-05 0.006560 - 
rco,G 1.95×10
-01
 (1.85-2.05)×10
-01
 0.067301 0.004797 0 3.68E-05 - 
rco,P 4.39×10
-01
 (4.17-4.61)×10
-01
 4.28E-05 0.00048 6.26E-05 0.003743 - 
rco,B 1.38×10
-01
 (1.31-1.45)×10
-01
 0.000107 0.003262 1.29E-05 2.34E-06 - 
rco,L 2.44×10
-01
 (2.32-2.56)×10
-01
 2.75E-05 0.018778 1.04E-05 0.000398 - 
ru,K 2.00×10
-02
 (1.90-2.10)×10
-02
 0 0.00064 0.000774 0.003097 - 
ru,G 7.00×10
-02
 (6.65-7.35)×10
-02
 0.02257 0.001398 0.008611 0.003169 - 
ru,L 1.30×10
-01
 (1.24-1.37)×10
-01
 0.052423 0.137398 0.027909 0.001827 - 
ru,H 1.80×10
-02
 (1.71-1.89)×10
-02
 0.000969 0.033467 0.000112 0.025256 - 
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A meal containing 50 g of carbohydrates and a 10 U bolus were given at 420min. The time 
points in Table 4.7 refer to 1 hour and 5 hours after meal consumption and were chosen to 
investigate the influence of the parameters when the sub models of meal absorption and bolus 
insulin kinetics are active and when all the external disturbances are absorbed and the system 
is relatively balanced. For the first case the most influential parameters are the k1, k2, kp3, kabs 
and ru,L at 480min and k1, k2, ru,L and ru,H at 720min. Hence, the parameters related to glucose 
absorption from the periphery k1, k2 as a function of insulin concentration (3.24) are the most 
critical since they are related to the patient’s sensitivity to insulin and therefore their ability to 
absorb glucose. For the second case the parameters k1, k2, ru,L and ru,H  are the most 
influential.  
The time varying parameters for the two cases defined in Table 4.7 are shown in Figure 4.4 
and Figure 4.5. Only the parameters with the highest sensitivities are included in the graphs. 
For both cases, the sensitivities of parameters k1 and k2 remain high throughout the 
performance analysis while both are increased after meal and bolus administration. The 
sensitivity of kp3, as expected, increases during bolus administration and decreases at the 
postprandial state when insulin concentration decreases after the bolus peak. Additionally for 
kabs, a parameter that indicates how fast the blood glucose is absorbed from the small 
intestine, the sensitivity increases with meal consumption and decreases when glucose has 
been absorbed. For the ratio of glucose absorption from the liver the sensitivity is high at the 
fasting state and decreases relatively at the postprandial state. While the ratio of glucose 
absorption from the heart increases after meal consumption, indicating that both of these 
parameters influence the glucose regulation in accordance with (3.3) and (3.5).  
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Figure 4.4: Time varying SIs when all parameters are considered 
 
Figure 4.5: Time varying SIs when intra-patient variability related parameters are considered 
 
As a conclusion, it can be stated that the parameters with the most influential role are those 
related to insulin effect on glucose. The parameters related to insulin distribution, absorption 
and elimination through the subcutaneous tissue, as well as the parameters related to glucose 
distribution in the various compartments can be considered as non-influential compared to the 
insulin-effect related parameters. 
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4.5 Parameter Estimation 
The performance of the proposed model is evaluated with detailed simulation studies 
performed in gPROMS
 
and its predictive ability is verified by comparison with results from 
the simulator UVa/Padova T1DMS. In order to obtain individual parameter estimates, an 
experiment is designed and the following information is required: duration of the experiment 
(24h), CGMs blood glucose concentration measurements and the time the measurements were 
taken, time varying control inputs (bolus, basal doses, meal amount,), their variation profiles 
(timing, meal duration) and plasma insulin concentration profile after a subcutaneous insulin 
injection. The insulin regimen is set for every patient using their total daily dose (TDD), and 
the standard clinical rules (5.4-5.8).  Although the blood glucose concentration measurements 
and the control input information can be collected and recorded easily, measurements of 
plasma insulin concentration require invasive experimental design. However, the GSA 
concluded that the parameters of insulin kinetics are not as influential and therefore a mean 
value of the parameters can be considered. In this work individual parameter estimation 
studies are performed using plasma insulin concentration measurements coming from the 
“virtual patient” in order to estimate precisely the range of all the parameters. Additionally, it 
is considered that the patient is not taking any exercise during the experiment.  
 
To demonstrate the prediction ability of the proposed model, a specific diet plan of 45g of 
carbohydrates for breakfast, 70 g for lunch and 70 g for dinner is set and the simulation 
results are shown for the ten patients. The same experimental conditions are applied in the 
simulator and the blood glucose and plasma insulin concentration profiles are used as 
“experimental” data to estimate the most influential model parameters. Hence, the individual 
parameters of model 3 for insulin kinetics and k1, k2, ru,L and kp3 and kabs of glucose 
metabolism are estimated as shown in Table 4.8. The rest of the parameters of the sub model 
Ra and EGP are estimated for each patient to obtain patient-specific glucose-insulin 
dynamics. Parameters Qco and Vi are calculated for every patient using (3.28-3.29), 
parameters ru,K, ru,G and ru,H are calculated according to the estimated value of ru,L to maintain 
the initial ratio as in  Table 3.2 and parameters k1,PS, k2_PS, rco,i are set to their default values as 
specified in Table 4.7. The estimated parameter values for all the patients are presented in 
detail in Appendix B.1. 
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Table 4.8: Optimal parameter estimates presented as mean value (lower-upper) value for the 10 
patients 
Symbol Value Units Symbol Value Units 
k1 
1.58×10
-04
 
(2.11-38.4) ×10
-05
 
dL
2 
per 
pmol·min 
ki 8.15×10
-03
 
(0.294-1.34) ×10
-02
 
min
-1
 
k2 
2.35×10
-02
 
(1.17-4.53) ×10
-02
 
min
-1
 
kp1 5.65 
(3.97-7.2) 
mg/kg/min 
ru,L 
1.7×10
-01
 
(0.6-1.9) ×10
-01
 
- 
kp2 4.73×10
-03
 
(2.44-7.72) ×10
-03
 
min
-1
 
kmax 3.53×10
-02
 
(2.19-5.82) ×10
-02
 
min
-1
 
kp3 1.49×10
-02
 
(0.0551-2.39) ×10
-02
 
mg/kg/min 
per pmol/L 
kmin 7.62×10
-03
 
(0.373-1.16) ×10
-02
 
min
-1 kelim 1.36 
(0.2996-2.1433) 
min
-1
 
kabs 1.14×10
-01
 
(0.214-5.82) ×10
-01
 
min
-1
 
ksub 1.86×10
-02
 
(1.21-2.46) ×10
-02
 
min
-1
 
b 8.27×10
-01
 
(7.36-9.29) ×10
-01
 
- Vdist 1.54×10
-02
 
(1.00-5.16) ×10
-02
 
L/Kg 
d 1.91×10
-02
 
(0.98-3.32) ×10
-01
 
-    
 
4.6 Simulation Results 
The glucose profiles of the proposed model compared to the simulator are shown in Figure 
4.6 for the ten patients. A meal plan of 45g, 70g and 70g of carbohydrates is considered at 
420min, 720min and 1080min. The right-hand side y-axis represents insulin amount (U). The 
amount of insulin bolus given to compensate for the glucose increase after each meal is 
shown with the insulin pulses colored in black. The left-hand side y-axis represents the blood 
glucose concentration (mg/dl). The glucose profiles as calculated by both models for the 
particular meal plan and insulin treatment are compared. The black curve shows the glucose 
profile calculated by the simulator and the grey curve the glucose profile calculated using the 
proposed model.  
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Figure 4.6: Comparison of blood glucose concentration (mg/dl) as predicted from the proposed model 
with the Simulator, for the 10 adults when a meal plan of 45g, 70g and 70g of carbohydrates are 
considered at 420min, 720min and 1080min respectively. The insulin infusion (U) is shown at the 
right axis for every patient. 
 
The simulation results indicate that the proposed model can predict accurately the daily blood 
glucose concentration profile. The good fit of the model to the UVa/Padova Simulator shows 
that the estimated values of the most influential parameters, as identified from the previous 
section are well adjusted for all cases.  
In Figure 4.7 the glucose concentration profile in all organs is presented for adult 5, in the 
presence of 45 g of meal and 6.5 U of insulin bolus. The concentration in the liver is higher as 
expected since liver can store and produce glucose and thus the capacity of glucose 
accumulation is higher. It is shown that the concentration in the gut increases rapidly when 
the meal is consumed before being absorbed into the blood.    
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Figure 4.7: Glucose concentration profiles in the organs for a 45 g of CHO meal and a 6.5 U insulin 
bolus 
In Figure 4.8 the rate of glucose uptake by the body organs is presented.  The rate of glucose 
uptake by the brain is considered constant since the brain’s glucose requirements remain 
continuously the same and account for approximately 46% of the total available glucose to be 
absorbed. Glucose absorption by the periphery account for 29% and the remaining percentage 
is absorbed by the rest of the organs.  
 
Figure 4.8: Rate of glucose absorption from the organs for a 45 g of CHO meal and a 6.5 U insulin 
bolus 
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Figure 4.9 and Figure 4.10 present the EGP profile and the Ra respectively, of 45 g of CHO 
and 6.5 U of insulin bolus for adult 5. Since the parameters were estimated using the glucose 
profiles as presented in section 4.5, and no exact EGP and Ra profiles were considered, the 
profiles of two sub models for adult 5 are compared with the area produced when performing 
a series of 50 simultaneous stochastic simulations at the UVa/Padova simulator with the 
corresponding parameters of each model varying 20% of their mean values. 
 
Figure 4.9: Grey area presents the EGP profiles of a stochastic simulation performed in UVa/Padova 
Simulator for 20% variation of the parameters from their mean value and the dashed line the EGP 
profile as obtained from the proposed model using the estimated parameter values.  
 
Figure 4.10: Grey area presents the Ra profiles of a stochastic simulation performed in UVa/Padova 
Simulator for 20% variation of the parameters from their mean value and the dashed line the Ra 
profile as obtained from the proposed model using the estimated parameter values.  
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Figure 4.9 and Figure 4.10 show that the model parameters of Ra and EGP sub models as 
estimated using only blood glucose concentration profiles are well adjusted and the prediction 
of Ra and EGP profiles is very adequate. Additionally, Figure 4.9 and Figure 4.10 
demonstrate that there is a high inter-patient variability. 
Key Points 
 The simulation results indicate that the proposed model can accurately represent 
individual glucose-insulin dynamics 
 The model states describe the involved physiology of glucose metabolism and insulin 
interactions at organ level 
 The model can be regarded as an educational and simulation tool that increases the 
level of understanding for the particular system  
 
4.7 Time Delays in the system 
Time delay in a system is the time that intervenes from the instant the input, the control or a 
force is applied until the instant the effect is observed. One of the great challenges of an 
automated system of insulin delivery is the delayed insulin absorption and action. That means 
that there is a time lag between the time insulin is given and the time to cause the maximum 
effect. This time lag is related to the type of insulin used, the route of administration, the 
detection of a glucose fluctuation and the patient’s sensitivity to insulin. The difference in the 
glycaemic response produced by the same dose of insulin in different individuals indicates 
that there is a high intra-patient variability involved in glucose-insulin interactions. When this 
variability is low then a more predictable glycaemic response can be determined, which is 
important for a closed loop system. In order to reduce the factors that cause variability and 
deteriorate the prediction of the glycaemic response, open loop simulation analysis is 
performed to gain deep knowledge of the particular system and use the conclusions as a 
guideline for the closed loop studies, studied in the next chapter. 
In this particular system the input is the insulin dose and the effect is the decrease in the blood 
glucose concentration. Figure 4.11 reveals the complexity of blood glucose regulation when 
subcutaneous rapid acting insulin is used. Rapid acting insulin is a human insulin analogue 
that, due to its chemical structure, reduces aggregation of insulin molecules and therefore 
accelerates the absorption process. Assuming that the sampling time Ts is 5min (available 
measurements of glucose concentration in the blood by the sensor), it can be noticed that 
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insulin requires up to 15min to initiate the decrease of blood glucose concentration, 
practically to observe a 1mg/dl change of the concentration. This time involves the absorption 
of rapid acting insulin through the subcutaneous tissue and insulin action can take up to 1-3 
hours for its maximum effect. 
 
 
Figure 4.11: Time delay in the system 
In Figure 4.12, 1U bolus of rapid acting insulin is given at 60min in four patients. It can be 
noticed that the time to observe a 10mg/dl decrease of blood glucose concentration is not 
equal for the four patients. This can be explained since every patient responds differently to 
insulin and has a different ability to increase the body’s glucose uptake by the various tissues. 
This can be quantified with insulin sensitivity index. The more sensitive to insulin the patient 
is, the less amount of insulin is required. Patients 4 and 7 with high insulin sensitivity index 
require less time for their blood glucose to be decreased than patients 3 and 6. 
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Figure 4.12: Patient dependent time delay 
  
In Figure 4.13 and Figure 4.14 for two patients, low and high insulin sensitive, 3 different 
bolus doses are given at 400min without considering meal consumption. It can be noticed that 
the time required for glucose to be decreased by 10mg/dl is dependent on the amount of bolus 
given. The delayed insulin effect decreases while the amount of insulin bolus increases. This 
implies that the time delay property cannot be considered constant for an individual patient.  
 
Figure 4.13 : Time delay dependence on patient and bolus (adult 3-low insulin sensitive) 
Time (min)
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Figure 4.14: Time delay dependence on patient and bolus (adult 4-high insulin sensitive) 
In conclusion, the dynamic system involves inherent time delays. These include the delayed 
insulin absorption and action and also the approximately 10 min delayed glucose appearance 
in the blood after food consumption due to interstitial glucose kinetics, meaning the route 
from the mouth to the small intestine and then to the blood. Apart from these delays, there are 
additional technical delays which involve the delayed detection of blood glucose 
concentration change because the continuous glucose monitoring devices calculate blood 
glucose concentration by measuring interstitial fluid (ISF) glucose concentration (Keenan et 
al., 2009). Hence the time lag of the displayed glucose value and the real blood glucose value 
consists of the time lag between ISF and blood glucose accounting for the processing 
requirements as well. This analysis has motivated the performance of patient-specific 
optimisation studies, to find the optimal timing of insulin dosing to maintain the patient’s 
glycaemic target. 
4.8 Dynamic optimisation of insulin delivery 
From the previous analysis, it has been evident that, in order for the patients to maintain their 
blood glucose close to their glycaemic target, the timing of the bolus insulin administration 
must be optimally decided to achieve safe glycaemic regulation. It has also been evident that 
each patient presents a unique response to insulin and therefore must be treated differently. 
Hence, patient-specific optimisation studies are performed to obtain the optimal insulin 
profile that minimizes the time over which glucose is outside of the normal range. The 
mathematical formulation of the optimisation problem has the following general form: 
Time (min)
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   (5.3) 
1 1 max0,              w w G G    (5.3.a) 
2 2 min0,          w w G G    (5.3.b) 
where tf is the time horizon, G is the blood glucose concentration described by the nonlinear 
process model presented in Chapter 3, Gmax (140 mg/dl), Gmin (70mg/dl) are the upper and 
lower glucose concentration bounds. (5.3.a) and (5.3.b) are the blood glucose constraints 
imposed to prevent severe health complications related to hyperglycaemia and hypoglycemia. 
A window of 4h before the meal was considered, which is long enough to cover the cases of 
patients with extremely low insulin sensitivity. This time span was discretised every 2min, 
which is the time the pump requires to deliver an insulin bolus, hence resulting in 120 control 
intervals. A time invariant, binary variable di was considered to be 1 if a bolus was given over 
time interval i, and 0 otherwise. The Mixed Integer Nonlinear Programming problem was 
implemented and solved in gPROMS.  
At t0=400 mins a breakfast meal of 50 g of carbohydrates is given to the 10 patients. The 
optimal amount of insulin that can compensate for the forthcoming glucose increase due to 
the meal intake is calculated using standard medical rules for optimal insulin dosing: 
Conventional Optimal Insulin Dosing:  
 
Basal Dose = 60% of the TDD (Walsh and Roberts, 2006)              (5.4) 
Bolus Dose = CHO/CR+CID (Walsh and Roberts, 2006)              (5.5) 
 
where CHO is the carbohydrate meal size in g, CR (g/U) is the carb factor (calculated with 
the 500 Rule as 500/TDD) which defines the amount of carbohydrates (in g) covered by 1U 
of insulin. The Correction Insulin Dose, CID, is given to compensate for the difference of 
high blood glucose from the desired value (target) and is calculated as: 
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CID=(Current BG-Target BG)/CF                  (5.6) 
where BG refers to blood glucose and equals to CH in the model (3.5). The correction factor 
(CF) is calculated with the 1800 Rule as 1800/TDD.  
The TDD is set for every patient from their physician. Appropriate adjustments, if necessary, 
are also defined by their physician.  
The values of TDD, CF, CR, CID are obtained from the UVa/Padova Simulator for each 
patient. Hence the administered insulin boluses, calculated as CHO/CR, are: 
Table 4.9: Insulin bolus to compensate for 50 g of CHO 
Patient
1 
Patient
2 
Patient
3 
Patient
4 
Patient
5 
Patient
6 
Patient
7 
Patient
8 
Patient
9 
Patient1
0 
5.57U 3.165U 5U 6.27U 10U 5.02U 2.27U 3.87U 10U 10U 
 
The optimisation results are presented in Figure 4.15 for 8 patients. The grey line shows the 
optimised glucose profile while the black line shows the simulated profile when the bolus is 
given simultaneously with meal; the light dotted grey line is the optimised glucose profile 
when the T1DMS model is used instead of the proposed model in the optimisation, for 
comparison. The optimal timing of insulin administration for every patient is summarised in 
Table 4.10. When the bolus is given at the optimal time the glucose profile is improved in 
terms of maintenance of the concentration within the normal range for all the patients. In 
Table 4.10 the area between the upper glucose bound and the glucose profile is calculated.  
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Simultanously 
 with meal T1DMS 
 
Optimised glucose 
profile with T1DMS 
 Optimised glucose 
profile with proposed 
model 
 Upper 
glucose 
 limit     
      
Figure 4.15: Optimisation of bolus timing; light grey: optimised glucose profile using the T1DMS, 
grey: optimised glucose profile using the proposed model and black line: glucose profile when bolus 
given simultaneously with food using the T1DMS.  
 
Table 4.10:Area under the curve (outside the normal range) 
 
Glucose 
curve 
Optimised 
Glucose curve 
(T1DMS) 
Optimised  
Glucose curve 
(proposed model) 
Optimal  
bolus time  
(T1DMS) 
Optimal bolus 
time 
(proposed model) 
Pat1 8.330e+03 5.126e+03 4.751e+03 140min 110min 
Pat2  2.191e+03 1.321e+03 1.8536e+03 36min 16min 
Pat 3  5.174e+03 4.482e+03 4.527e+03 32min 32min 
Pat4 6.708e+04 5.892e+03 1.195e+04 66min 84min 
Pati5  4.064e+03 1.718e+03 2.355e+03 62min 64min 
Pati6  2.096e+05 3.945e+03 2.420e+03 62min 48min 
Pat7 2.083e+05 2.785e+02 3.266e+02 52min 44min 
Pat8 5.972e+04 1.209e+03 1.075e+03 100min 140min 
Pat 9 1.165e+04 8.913e+03 3.537e+03 74min 68min 
Pat10 1.493e+04 1.262e+04 1.672+04 72min 72min 
 
As illustrated in Figure 4.15 improved glycaemic control can be achieved for both the 
examined models when the time to provide the insulin dose is optimised. This result is 
confirmed with Table 4.10, which shows that the area under the curve for the optimised 
curves is smaller than the simulated curves indicating that the time glucose is spent above the 
upper glucose bound is less. Additionally, hypoglycemic events are not observed for any of 
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the patients, despite the considerable difference of the bolus timing between them. This is 
related to the sensitivity of the patient to insulin as mentioned before and for the specific 
optimal dose the patient would not reach the lower glucose bound. 
If we either compare the graphs or the results in Table 4.10, we can notice that the solution of 
the optimisation problem using the proposed model or the T1DMS may be different. For 
some of the patients the optimisation results are similar, indicating a good fit of the 
parameters, but for other patients (such as patient 4 or patient 2) the optimal time to 
administer the dose differs from 20 to 40min. This demonstrates that additional experimental 
data, apart from glucose and insulin profiles are required to capture entirely the dynamics of 
each patient. However, the trend of the glucose profiles as well as the approximately same 
timing range confirms that the reliability of the proposed model is acceptable and that it can 
predict individual patient dynamics.  
4.9 Alternative insulin infusion 
An alternative to bolus dosing is considered as a piecewise constant infusion rate that holds a 
constant value over 5 min time intervals. The profile is calculated with optimising criterion 
the minimum range of glucose outside the normal bounds. The results are demonstrated for 
two adults, adult 3 and adult 5 for illustrative purposes. Figure 4.17, for patient 3 includes the 
optimised glucose profile when the bolus is given at the time calculated with the previous 
optimisation problem (a), the glucose profile when a piecewise approach is considered (d) 
with time frame of 32 min (Table 4.10) and both are compared with the glucose profile when 
bolus is given simultaneously with meal (b). The two approaches produce the same effect on 
glucose, indicating that a stepwise infusion could be considered as a possible mechanism 
since it provides flexibility and can be better adjusted in an automated delivery system. In 
Figure 4.17, for patient 5, in order to avoid a big time frame (64 min) which can be restricting 
from a control point of view and to overcome the issues related to pre-bolusing (risk of 
hypoglycaemia)  a time frame of 30 min is considered. The glucose profiles are compared and 
additionally the profile when bolus is given 30min in advance (c) is included. The stepwise 
approach (d) and the 30 min bolus in advance (c) produce comparatively the same results. 
This case of adult 5 although it is not the optimal, can still be regarded as a considerable 
alternative for control design. 
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Figure 4.16: Optimal glucose profiles when insulin is given as a bolus and as a piecewise constant 
infusion (adult 3) 
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Figure 4.17: Optimal glucose profiles when insulin is given as a bolus and as a piecewise constant 
infusion (adult 5) 
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The two figures indicate that the alternative to bolus dosing insulin infusion can produce the 
exact same effect on blood glucose concentration. Therefore, the stepwise insulin infusion is a 
potential delivery mechanism that will be considered in the closed loop insulin delivery. The 
MINLP problem is simplified to NLP reducing the complexity introduced by the binary 
variables.     
Key Points 
 Delayed insulin effect on blood glucose (after effect) 
 Inter-patient and intra-patient variability of insulin effect 
 MINLP solution to identify the optimal time to administer an insulin bolus dose 
 Tight glycaemic control when the time lag is considered 
 Alternative insulin infusion to be used in the closed loop insulin delivery system  
 
4.10 Concluding Remarks 
In this Chapter, the model presented in Chapter 3 is analysed in terms of structure, parameter 
correlations and identifiability and physiological relevance. GSA was used to determine the 
most influential model parameters that were estimated from glucose and insulin concentration 
profiles for each patient. The simulation studies demonstrated that the model is reliable in 
terms of flexibility and predictive ability. The inherent time lags due to delayed insulin 
absorption and action have been quantified for the 10 patients and it has been shown that for 
the same insulin dose the delayed effect on glucose is patient dependent. Therefore, patient-
specific optimisation studies were performed to find the optimal timing to give the bolus 
dose. An alternative, stepwise insulin regimen has been considered and the optimisation 
results indicate that it can be an attractive alternative for closed loop applications.  
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5. Closed Loop Control in T1DM- An Overview 
5.1 Introduction 
In this Chapter an overview of the existing methodologies for closed loop insulin delivery in 
T1DM is presented. The concept of the artificial pancreas (AP) has been widely considered as 
the potential treatment of T1DM and many research groups have been extensively working 
towards this direction. The state-of-the art on the topics related to the AP technology can be 
found in: (Kovatchev et al., 2010), (Dassau et al., 2013), (Thabit and Hovorka, 2013), (Soru 
et al., 2012), (Cobelli et al., 2012), (Breton et al., 2012),(Herrero et al., 2013). The Chapter 
continues with a brief introduction to the theoretical background of Model Predictive Control 
(MPC) and finally the control oriented model for the application of MPC for insulin delivery 
is presented.  
5.2 Literature review 
In the past decades a great effort has been made to develop suitable control algorithms which 
calculate the appropriate insulin administration rate to maintain the blood glucose 
concentration within the normal range. Many approaches have been evaluated as can be seen 
in the following reviews: (Lee and Bequette, 2009), (Bequette, 2005), (El Youssef, Castle and 
Ward, 2009), (Takahashi, Xiao and Hu, 2008), (Valletta, Chipperfield and Byrne, 2009), 
(Cobelli et al., 2009), (Doyle, Jovanovic and Seborg, 2007), (Doyle et al., 2014), (Thabit and 
Hovorka, 2014).  
The first clinical approach to automatically regulate blood glucose concentration is the 
Biostator which was developed in the 1970s, was approved by the Food and Drug 
Administration (FDA) and made commercially available by Miles Laboratory. Although it is 
an actual artificial pancreas that reports efficient external glucose control in hospitalised 
patients (Reece, Coustan and Gabbe, 2004), (Cobelli, Renard and Kovatchev, 2011), the 
invasive intravenous route of insulin delivery and glucose sensing as well as its large size 
makes this system inappropriate for everyday use.   
The development of more efficient techniques for blood glucose control is inseparable from: 
the development of fast-acting insulin analogues (e.g. insulin lispro, insulin aspart), which 
have minimized the time to maximum insulin effect; the use of the less invasive subcutaneous 
route instead of the intravenous one, which accelerated the progress in the technology of 
Chapter 5: Closed Loop Model Predictive Control  
 
96 
 
glucose monitoring systems and insulin pumps; and finally the development of computer-
based algorithms, which has enhanced the quality of therapeutic advisory systems.  
Several control methodologies have been suggested in the literature such as Proportional-
Integral-Derivative (PID), Model Predictive Control (MPC), adaptive control, Sliding Model 
Control (SMC), fuzzy logic and neural network, as presented in more detail below: 
PID 
PID control has been widely used as a potential method for blood glucose regulation. The 
PID controllers operate on the error (difference between the measured output and the desired 
glucose concentration) in a feedback system and suggest a control signal (insulin infusion) 
that is applied to the system (patient). The relatively simple implementation has established 
the PID control as an important alternative for blood glucose regulation. Several clinical trials 
have been conducted to evaluate overnight glucose control, the effect of exercise, the addition 
of glucagon, the intraperitoneal infusion etc.     
 
Table 5.1: Clinically Evaluated PID controllers 
Control 
Algorithm 
Control Algorithm 
Reference 
Clinical Trial Summary 
ePID with Insulin 
Feedback (IFB)  
(Steil et al., 2006), 
(Weinzimer et al., 
2008), (Steil et al., 
2011), 
1.(O’Grady et al., 
2012) 
 
2.(Sherr et al., 2013) 
1. In-clinic overnight closed loop 
trial suggests 78% of time glucose 
spent in normal range 
2. Effect of afternoon exercise on 
nocturnal hypoglycaemia: CL better 
than OL 
Fading Memory 
Proportional  
Derivative 
algorithm 
(FMPD) 
(Gopakumaran et al., 
2005), 
(Ward et al., 2008) 
(Castle et al., 2010) 
Insulin plus glucagon: reduced 
frequency of carbohydrate 
treatment 
PID 
Several PID 
algorithms were 
evaluated 
(Dauber et al., 2013) 
In-clinic closed loop control in 
children. Improvements in time 
spent above 300mg/dl and total 
AUC compared to open loop. 
PID (Steil et al., 2006)  (Renard et al., 2010) Intraperitoneal insulin infusion 
ePID (Steil et al., 2006) 
(Weinzimer et al., 
2012) 
Evaluation of the effects of 
pramlintide on CL-delayed time to 
peak BG and reduced magnitude of 
BG peak 
Although it was reported that glucose spends adequate amount of  time in normoglycaemia 
for several experimental conditions with PID controllers (Doyle et al., 2014), it has also been 
reported that there is an increased risk of hypoglycaemia due to inappropriate dosing coming 
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from the integral feature (Bequette, 2005), (Marchetti et al., 2008). Hence, PD controllers are 
considered instead. However, PD controllers require complementary components such as 
fault detection algorithms, pump shut-off or feedforward control to address the issue of 
maintenance of glucose within the upper and the lower level. Another limitation of a PID 
controller is that it cannot include the inherent time delays of the system, which can lead to 
hypoglycaemia.  
MPC 
The limitations of PID control as well as the ability of MPC i) to handle constraints ii) of 
straightforward applicability iii) to handle time delays and complex nonlinear systems and iv) 
to calculate the control action in anticipation of the future output, have motivated its wide use 
for blood glucose regulation. In Parker et al. (1999) a linear MPC for optimal insulin dosing 
is designed based on the Sorensen model (Sorensen, 1978) which incorporates a state 
estimator. Additionally, a nonlinear quadratic dynamic matrix control with state estimation is 
evaluated that takes advantage of the information coming from the nonlinear model.  
Magni et al. (2007) evaluated an unconstrained MPC with the internal predictive model being 
a linearised reduced state space of (Dalla Man, Rizza and Cobelli, 2006) with linear 
representation of kempt (A.10). Three clinical studies were based on this MPC control design. 
The first study was conducted in 2008-2009 (n=20 adults, length=14.5h). The study resulted 
in reduced hypoglycaemic events with closed loop compared to open loop and better 
glycaemic maintenance in the target range. The second clinical study evaluated a fully 
integrated artificial pancreas (Breton et al., 2012), (n=11 adolescents and 27 adults, length = 
22h). This trial involved the testing of two modular closed-loop control designs, the standard 
control to range and the enhanced control to range. Both designs are based on combining a 
range correction module (RCM) and a safety supervision module (SSM). The RCM involves 
an unconstrained linear MPC algorithm as described in Magni et al. (2009) that calculates the 
correction insulin infusion of a predetermined nominal open-loop profile. The SSM aims to 
prevent hypoglycaemia, therefore it involves features such as risk analysis of blood glucose 
data (Kovatchev et al., 2000) and IOB (Insulin On Board) constraints (Ellingsen et al., 2009). 
The clinical study resulted in an ived glycaemic control with enhanced CTR achieving a 97% 
near normoglycaemia. Finally, a clinical study (B. Kovatchev et al., 2013) was conducted 
using an integrated modular control,  as explained in Patek et al. (2012),  to evaluate the 
performance of the integrated artificial pancreas in outpatient settings. The system consists of 
a continuous safety module, a control module and an interface module. The safety module is 
Chapter 5: Closed Loop Model Predictive Control  
 
98 
 
similar to the one considered in the previous study (Breton et al., 2012), whereas the control 
module involves the same principles of range correction module as in (L. Magni, Forgione, et 
al., 2009) and (Magni et al., 2007), as described above, but the control design is 
individualised in terms of individual cost function. The results indicated no significant 
difference of the control performance between inpatient and outpatient settings.  
In Hovorka et al. (2004) a nonlinear MPC is designed that estimates on line the model 
parameters which vary with time using Bayesian techniques. A series of clinical studies were 
conducted using an adaptive algorithm based on MPC as described in Bequette (2005) to 
evaluate mainly the closed loop performance during the night. In Hovorka et al. (2010) an 
overnight closed loop study is described which concluded that the applied MPC strategy can 
reduce the time spent in hypoglycaemia compared to standard open-loop therapy. In (Elleri et 
al., 2011), (Elleri et al., 2012), (Elleri et al., 2013) overnight studies in children and 
adolescents are performed using a fully automated closed-loop strategy to investigate the 
influence of initiation timing after regular meals and exercise. The results indicated that 
earlier time of closed-loop initiation can achieve tighter glucose control; nonetheless the 
impact of exercise remains a challenge for the closed loop system.  
In Soru et al., (Soru et al., 2012) a model derived by linearising  the original (Dalla Man, 
Rizza and Cobelli, 2007) model around the basal conditions was used. Two MPC approaches 
were designed to individualise the closed loop system. The first involves the tuning of the 
cost function and the second the derivation of individual approximate models from system 
identification and optimal tuning of cost function from real life experiments, such as 
reference input-output, signals and weights of cost function. An adaptive MPC algorithm 
including an IOB feature using an ARMAX internal model has been clinically evaluated 
(Turksoy et al., 2013), (n=3, length (h)=32 or 60h).  The study indicated that 62% of the 
observations were spent in the near normoglycemic range.  
Multi-parametric MPC for blood glucose concentration was evaluated in (Dua, Doyle and 
Pistikopoulos, 2006), (Dua, Doyle and Pistikopoulos, 2009). In mpMPC the online 
optimisation problem is solved off line via parametric programming  (Bemporad et al., 2002) 
and the objective function as well as the future control actions are obtained as a function of 
the measured output or states, i.e. the parameters,  and the regions in the state or output space 
were the parameters are valid; hence all the  possible control trajectories are calculated in 
advance, minimising the required computational effort of online MPC. A clinical trial (n=17, 
length =6.3h) was conducted to evaluate the performance of a personalised artificial pancreas 
(Dassau et al., 2013) based on linear multi-parametric MPC including an IOB feature 
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(Ellingsen et al., 2009).  The internal linear model (Percival et al., 2010) used in the control 
design is identified from individual patient data of 3days of open loop studies while the 
control algorithm is described in (Dua, Doyle and Pistikopoulos, 2006), (Dua, Doyle and 
Pistikopoulos, 2009), (Dua et al., 2008), (Bemporad et al., 2002). The study resulted in an 
average of 70% of the trial time in near normoglycemia ensuring the ability of the control 
design to be further investigated.  
A control approach based on zone-MPC was clinically evaluated (Harvey et al., 2014). 
Details about the “control-to-range” algorithm are described in (Grosman et al., 2010). The 
internal control-relevant model is individually tuned using a priori clinical information (van 
Heusden et al., 2012). A supportive health monitoring system (Harvey et al., 2012) was used 
in addition to zone-MPC to prevent hypoglycaemia episodes and to increase the safety of the 
system. The study (length=24h) involved unannounced meals and exercise as well as an 
overnight period which resulted in an average of 80% of the trial time near normoglycaemia. 
Table 5.2 describes a selection of MPC designs evaluated in clinical trials.  
Table 5.2: MPC control Algorithms evaluated in clinical trials 
Clinical Studies Reference Summary 
(Hovorka et al., 2014), (Elleri et al., 
2012), 
(Elleri et al., 2013),  
(Elleri et al., 2011), (Hovorka et al., 
2010) 
The MPC design of this study is based on (Bequette, 
2005) using internal model (Hovorka et al., 2002).  
(Kovatchev et al., 2010),  
(B. Kovatchev et al., 2013) 
The linear MPC design is described in (Magni et al., 
2007). The model used for validation is found in (Dalla 
Man, Rizza and Cobelli, 2007) but modified adequately 
for T1DM. This model is linearised at average 
population basal conditions. The MPC specifications are 
tailored to each patient. An interface and safety module 
are included in (Patek et al., 2012).  
(Russell et al., 2012) 
Bihormonal closed loop system (El-Khatib et al., 2010) 
insulin administration with MPC control and glucagon 
with PD. The internal model is ARMAX with identified 
model parameters.  
(Dassau et al., 2013) 
The linear mpMPC design is described in (Percival et 
al., 2010), the model used is a transfer function with 
patient-specific parameters. More details on the explicit 
MPC can be found in (Dua, Doyle and Pistikopoulos, 
2006) 
(Harvey et al., 2014) Zone-MPC as described in (Grosman et al., 2010) in 
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parallel with health monitoring system (Harvey et al., 
2012) 
(Breton et al., 2012) 
(B. Kovatchev et al., 2009) range correction module and 
safety supervision module  
Although the applied MPC theory for glucose regulation has reduced the occurrence of 
hypoglycaemic episodes in most clinical studies (Doyle et al., 2014), the challenge remains 
when the patient is examined in free living conditions (Bequette, 2012), subjected to 
unannounced disturbances such as a meal. This involves the risk of direct prandial 
hyperglycaemia that leads to aggressive insulin action and possible postprandial 
hypoglycaemia. Another important issue is the high intra and inter-patient variability that 
dominates the system. To address this problem patient specific approximations of the original 
system (L. Magni, Raimondo, et al., 2009), (van Heusden et al., 2012),  and control 
specifications are considered. Although this approach has minimised the effect of intra-
patient variability on the  prediction ability of the internal model, inter-patient variability 
remains an important source of uncertainty that requires advanced control techniques such as 
robust control (Sakizlis, Dua, et al., 2004), (Pistikopoulos et al., 2009) or complementary 
components (Breton et al., 2012) to incorporate the effect and control its impact on the 
system.  
Other Algorithms 
Fuzzy Logic control has been evaluated as a potential approach for blood glucose regulation. 
Control-to-range and control-to-target modules have been incorporated in the MD-Logic 
Artificial pancreas (Atlas et al., 2010) which was tested in a clinical trial. A series of clinical 
trials  based on MD-Logic AP were conducted (Nimri et al., 2014), (Nimri et al., 2012), 
(Nimri et al., 2013), (Phillip et al., 2013) and the study is still on-going but the results suggest 
that closed-loop can be implemented as standard overnight treatment. A pump shut off 
algorithm is proposed using a Kalman filter for blood glucose value and rate of change 
estimation (Cameron et al., 2012) and evaluated in an in-patient study. A sliding model 
control has also been considered (Abu-Rmileh, Garcia-Gabin and Zambrano, 2010) which 
presents simplicity in the implementation but more robust performance compared to a PID.  
5.3 Challenges of the closed loop design 
The purpose of the artificial pancreas is to ameliorate the living standards of a patient with 
T1DM. This can be translated to the following requirements of a closed loop system: 
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1. Safety of the patient 
2. Flexibility to adapt to changing patient characteristics  
3. Reduced side-effects  
4. Minimally invasive therapeutic devices and minimum patient requirements for 
initialisation and individualisation  
These requirements can be very challenging for the development of a fully automated insulin 
delivery system regardless of the chosen type of control algorithm. The challenges are 
summarised below: 
 Complexity of the system: nonlinearities, time delays, patient specific dynamics, 
which make the development of representative mathematical models relatively 
difficult especially models that capture the dynamics of different patients with 
different characteristics and on top of that the derivation of reliable linear approximate 
models. 
 Delayed insulin absorption due to the subcutaneous route that produces an after effect 
of insulin on glucose that should be taken into consideration. 
 High intra- and inter-patient variability: source of uncertainty that should be taken into 
account in the control strategy. 
 Personalised control design due to high intra and inter-patient variability: there is high 
demand to develop patient-specific therapeutic methods towards a more personalised 
health-care that treats every patient according to their needs. 
 Hard constraints on glucose concentration. Violation of the constraints can have 
serious acute and chronic health complications. 
 The presence of disturbances such as meal, exercise, stress, illness that have a 
significant effect on the insulin-glucose dynamics, factors of everyday life that should 
be taken into account either in the model or the control design. 
  Once insulin is delivered to the body it cannot be removed, which makes the 
development of the automated system very challenging. Glucagon has been suggested 
as a complementary hormone to counteract the insulin effect.  
 The uncertainty of free living conditions that requires a robust control strategy.          
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5.4 Model Predictive Control 
The suggested control strategy for glucose regulation with manipulating insulin infusion, 
refers to model predictive control theory (Dua, Doyle and Pistikopoulos, 2006, 2009). The 
standard approach of all the MPC methodologies is the use of a mathematical representation 
of the controlled system (model) to predict the system’s output/states, for a finite time horizon 
(prediction horizon). The model is used for the formulation of an optimisation problem that 
minimises an appropriately chosen objective function. Decision variables of this problem are 
the predicted values of the manipulated variable (insulin) in a generally smaller future time 
horizon, the control horizon. When the optimal sequence of the future control actions is 
determined, only the first value is applied on the system and the optimisation problem is then 
reformulated and solved at the next time instant, when new information of the system is 
available. The basic concept of MPC is illustrated Figure 5.1.  
 
Figure 5.1: Schematic of Model Predictive Control 
The appropriate current control action is obtained by solving on-line, at each sampling 
instant, the finite horizon open-loop optimal control problem: 
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ut+1 
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yRt-1 
yRt 
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Rt+2 
yRt+N 
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yt 
yt+2 
yt+M yt+N-1 yt+N 
Past Control Input 
Predicted Control Input 
Measured Output 
Predicted Output 
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min
x,y,u
𝐽 = ∑ xk
′ Qkxk
N−1
k=1
+ ∑(yk − y
R)
′
QRk(yk − y
R)
N−1
k=1
+ ∑ uk
′ Rkuk
M−1
k=1
+ ∑ Δuk
′ R1kΔuk
M−1
k=1
 
 
 (5.1) 
s.t.    
xk+1 = Axk + Buk + Edk  
 yk = Cxk  
ymin ≤ yk ≤ ymax  
umin ≤ uk ≤ umax  
 Δumin ≤ uk+1 − uk ≤ 𝛥umax  
The problem is formulated as a quadratic programming problem (APPENDIX B.2) that is 
solved using established functions and tools in MATLAB. 
Table 5.3: definitions of symbols found in ( 5.1) 
Symbol Definition 
A State matrix 
B Input matrix 
C Output matrix 
E Disturbance matrix  
N Prediction Horizon 
M Control Horizon 
Q Weight Matrix for the states 
QR Weight Matrix for the output deviation from the reference point 
(blood glucose concentration) 
R Weight Matrix for the input (insulin infusion rate) 
R1 Weight Matrix for the change in the control input 
y System output (blood glucose concentration) 
y
R
 Reference point 
x System states 
u Control input (insulin infusion rate) 
Δu Step change in control input 
 
The MPC specifications used in the following chapter are presented in detail for each patient 
in Appendix D.  
5.5 Kalman Filter 
System Uncertainty  
There are two main sources of uncertainty in a wide class of systems that cause a limited 
ability to accurately represent the real process with a mathematical model:  
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 Observation uncertainty (measurement “noise”) 
 Process uncertainty (unmodeled disturbances)  
A simple way to describe these two sources of uncertainty is the formulation of a linear state 
space model as a stochastic system (Rawlings and Mayne, 2009): 
1k k k k
k k k
x Ax Bu Gw
y Cx 
   
 
                       with   
0(0)x x                (5.2) 
The random variable 𝑤k ∈ ℝ
ℊ is introduced to describe the process uncertainty while the 
variable  𝜐𝑘 models the noise of the measurement device. Matrix 𝐺 ∈ ℝ
𝑛×ℊ is used to fine 
tune the effect of the process uncertainty on the states.  
Kalman Filter 
The linear Kalman Filter is a widely used method for unconstrained state estimation for the 
system of (5.2) of normally distributed with zero mean process disturbance 𝑤𝑘 and 
measurement noise 𝜐𝑘 :  
 
𝑤(0)~𝑁(0, 𝑄)  and 𝜐(0)~𝛮(0, 𝑅) 
 
The zero mean is chosen for w and υ because the disturbances and the effects with nonzero 
mean are considered to be included in the model.  
The optimal state estimation is calculated using the following algorithm (5.3-5.7) which 
includes a two steps approach (Chui and Chen, 2008). The first step predicts the state and 
covariance estimates using the model equations and previous estimates while the second 
updates the prediction using information from the observations. 
 
1) Time Update / “Prediction” 
State Prediction: 
?̂?𝑘 
− = 𝐴?̂?𝑘−1 + 𝐵𝑢𝑘−1 (5.3) 
Projection of the error covariance: 
𝑃𝑘
− = 𝐴𝑃𝑘−1𝐴
𝑇 + 𝑄𝐾𝐹 (5.4) 
2) Measurement Update/ “Correction” 
Computation of the Kalman gain: 
𝐾𝑘 = 𝑃𝑘
−𝐻𝑇(𝐻𝑃𝑘
−𝐻𝑇 + 𝑅𝐾𝐹)
−1 (5.5) 
State estimate update: 
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?̂?𝑘 = ?̂?𝑘 
− + 𝐾𝑘(𝑧𝑘 − 𝐻?̂?𝑘 
−) 
(5.6) 
Error covariance update: 
𝑃𝑘 = (𝐼 − 𝐾𝑘𝐻)𝑃𝑘
− (5.7) 
The choice of QKF and RKF depends on the examined system. Generally a large QKF is used 
when there is no prior knowledge, and this force the states to be determined by the upcoming 
measurements yK. A large value of RKF is used for a noisy measurement process.  
 
5.6 Model Approximation 
Sources of nonlinearity in the model of glucose-insulin interactions can be found not only in 
non-linear expressions of specific variables (e.g. gastric emptying), but most importantly in 
non-linear dependencies among variables (e.g. insulin dependent peripheral glucose 
absorption). Another challenging inherent source of complexity in this system is the time 
delay from the moment the input is applied to the effect on glucose being observed.  This 
time lag is related to the subcutaneous route of insulin administration, the detection of a 
glucose fluctuation and the patient’s sensitivity to insulin. The difference in the glycaemic 
response produced by the same dose of insulin in different individuals indicates that there is a 
high intra-patient variability involved in glucose-insulin interactions.   
However, the internal model used to predict the future output G(t) depending only on past 
inputs u(k-1),u(k-2),..., is usually considered to be linear because this makes the calculation of 
the optimal insulin infusion relatively simplified in a model predictive control framework. 
Hence, the aforementioned challenges of nonlinearity, time delays and patient variability have 
to be described by a simple linear model. 
The accuracy of the internal model used in MPC is essential since it forecasts the future 
behaviour of the system based on which the controller optimises the control action. Therefore 
the internal model should accurately represent the patient’s specific dynamics. Even if 
feedback can overcome some issues of inaccurate modelling, in order to achieve efficient 
control the internal model should be carefully considered.   
The original model is linearised at basal state, assuming that kempt=(kmax-kmin)/2 and p=pb. The 
16 states model is then reduced to 10 states using the redmod function in MATLAB. Further 
reduction decreases the model’s prediction ability. The discretised, with sampling time 5min, 
reduced linear model is used as the internal model in MPC. Two cases are considered for 
model linearisation, which will be further used in Chapter 6: 
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Case 1: Development of patient-specific approximate model 
It is assumed that the available patient data are informative enough to estimate the original 
model parameters as presented in the parameters estimation section (4.5) and develop an 
approximate model that accurately predicts the patient’s dynamics.  Hence, the individual 
model parameters are considered in the linear state-space model. 
Case 2: Development of an adjusted mean approximate model 
In this case, it is assumed that a priori knowledge of the patient’s dynamics cannot be 
obtained and that only standard clinical tests are available, such as CGMS glucose profiles, 
TDD, patient characteristics and meal information. Then the approximate model with mean 
values of the parameters is used but adjusted accordingly for the specific patient. The 
adjustable parameter is kp1 and is an element of the second column of Bd matrix which 
determines the constant terms of the states that are considered in the linearisation. The 
individual parameters of the control design that are individually tuned when using the mean 
approximate model are the body weight, the total daily dose and the upper insulin constraint, 
the weights of the objective function and the control horizon.       
𝑥 = [𝐶𝐾 𝐶𝐺 𝐶𝑃 𝐶𝐵 𝐶𝐻 𝐶𝐿 𝐶𝑃𝑡 𝑈 𝐼𝑑 𝐼1 𝑆1 𝐼𝑏 𝑆2 𝑄𝑠𝑡𝑜1 𝑄𝑠𝑡𝑜2 𝑄𝑔𝑢𝑡]′ 
𝐴 =
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 ,  C=[0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0] 
𝐷 = [0] 
The accuracy of the patient specific approximate model is presented in Figure 5.2 for patient 
no2. 
 
Figure 5.2: Comparison of original model, linearised model and reduced model when 50 g of 
carbohydrates are consumed and a 5 U bolus is given to patient no2 
A measure to calculate the goodness of the fit between the original, the linearised and the 
reduced model is the normalised mean square error as presented in (5.8). 
𝐹𝑖𝑡 = (1 −
∑ |𝑦𝑖 − 𝑦𝑖|̂
𝑁
𝑖=1
∑ |𝑦𝑖 − 𝑦|̅
𝑁
𝑖=1
) × 100 (5.8) 
  
The fit is of the patient specific linearised approximate model to the original model is 93.6%.  
Therefore, the linearised model accurately approximates the original model. The reduced 
linear model fits at 99.7% the full-states linearised model.   
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5.7 Concluding Remarks 
In this Chapter an overview of the existing methodologies to address the blood glucose 
regulation problem with a closed loop insulin delivery system was presented. Emphasis is 
given on the MPC control designs, because MPC will be further used in this thesis. The 
challenges of an automated system are described of which the uncertainty originated by high 
patient variability and the unknown disturbances are the most crucial. The theoretical 
background of MPC formulation and the Kalman filter is presented and more details can be 
found in Appendix B.2, which will be used in the following Chapter. The proposed model 
described in Chapter 3 is linearised and reduced to be further used in the control design 
presented in the next Chapter.   
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6. Model Predictive Control Studies in T1DM 
6.1 Introduction 
In this chapter the design of a closed loop insulin delivery system for T1DM is presented. The 
aim is to maintain the blood glucose concentration within the normal range (80-140mg/dl) by 
manipulating the control input, the insulin infusion rate. Insulin is given not as the 
conventional basal/bolus pattern but as a piecewise constant infusion rate that holds a value 
for specific time intervals. The performance of the developed control design is evaluated in 
the presence of meal disturbances and other uncertain factors. Apart from the MPC, 
additional components are introduced to meet the specific requirements of blood glucose 
regulation under unknown meal disturbances as explained in the following sections.  
6.2 Control Objective 
The aim of the developed control designs that are presented in the following sections is to 
efficiently regulate the blood glucose concentration. However, the issues that make glucose 
regulation rather challenging are the following: 
 Complexity of the inherent dynamics (Chapter 3 and 4) 
 Time delays (sections 4.7-4.9) 
 Intra -patient variability (section 4.5-4.9) 
The need of a closed loop system to perform efficiently under free living conditions adds up 
the following challenges: 
 Presence of unknown meal disturbances 
 Metabolic uncertainty 
Therefore, with the proposed control designs we aim to: 
 Develop personalised insulin delivery systems 
 Take into account the involved time delays 
 Compensate for the unknown meal disturbances 
 Address the issue of uncertainty 
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6.3 Model Predictive Control Strategy for insulin delivery in T1DM 
Two general strategies for blood glucose regulation are studied. The first is a systematic 
strategy which aims for personalised blood glucose control, whereas the second is an 
“approximation” strategy that can be considered for blood glucose regulation in the absence 
of informative patient data.  
I. Systematic Strategy 
It involves the following steps: 
Step 1: Collection of CGMs data with available inputs (insulin, meal, exercise) and 
plasma insulin concentration profile 
Step 2: Estimation of the original model parameters for each patient (as described in 
section 4.5) 
Step3: Derivation of linearized patient specific models (as described in section 5.6) 
Step 4: Systematic Strategy: Control design 
II. “Approximation” Strategy 
It involves the following two steps: 
Step 1: Mean approximate model (mean values of the parameters of the linearized 
model – section 5.6) 
Step 2: “Approximation” Strategy: Control design 
The control designs for the two strategies are different because the first strategy uses the a 
priori knowledge of the patient dynamics to enhance the closed loop performance in the 
presence of unknown disturbances and variability by solving an open loop optimisation 
problem. On the other hand, the second strategy overcomes the effect of inaccurate modelling 
with feedback by considering an additional controller. The inherent time delays of the system 
are described with the linear approximate model presented in section 5.6. The internal model 
predicts the delayed insulin effect and therefore, the efficacy of glucose regulation depends on 
the controller’s ability to compensate for the after effect. The parameters of the control 
formulation that are individually specified in both cases are the body weight, the total insulin 
daily dose and the upper insulin constraint, the weights of the objective function and the 
prediction horizon.       
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The control designs for each strategy are described in detail in the following sections: 
6.4 Systematic Strategy (I): Control designs 
In Figure 6.1 a general control strategy to regulate blood glucose concentration is presented. 
It consists of four parts that are activated depending on the type of meal disturbances di, as 
defined in Table 6.1; an optimisation problem, an MPC controller, a state estimator and a 
scheduling level. Depending on the type of meal disturbances different combinations of the 
components are activated to efficiently regulate blood glucose concentration.  
 
Figure 6.1: General proposed control strategy that consists of three blocks, MPC, State Estimator and 
optimisation that are activated depending on the nature of the meal disturbances. In the case of 
predefined disturbances (dp) the problem of optimal insulin delivery is an output optimisation 
problem, in the case of announced disturbances (da) the problem is a state feedback MPC involving a 
scheduling feature for upper insulin constraint. For unknown disturbances (du) the entire strategy is 
activated involving an output feedback MPC.     
Table 6.1: Meal disturbance types 
Symbol Disturbance Type 
dp Predefined  
da Announced 
du Unknown 
Hence, the following control designs (CDs), as presented in Table 6.2 are evaluated for 
different types of meal disturbances, di. When the meal plan is predefined and known in 
advance then the regulation problem becomes an open-loop dynamic optimisation problem 
and only the grey block dp is activated (CD1). The optimisation problem is solved and the 
optimal insulin infusion rate that acts to maintain the blood glucose concentration within the 
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normal range is calculated.  CD2 involves a regulation level with a state feedback MPC and a 
scheduling level that enhances the overall control performance. This design is activated when 
the size of meal disturbances becomes known at the moment of meal consumption.  CD3 
combines an optimisation problem for a known reference meal plan and a correction output 
feedback MPC to address the presence of unknown disturbances, which are estimated with a 
state estimator as explained below. And finally, CD4 involves the MPC, the scheduling level 
and the state estimator and is tested in comparison to CD3 for unknown disturbances.  
Table 6.2: Glucose regulation designs  
Control Designs Description  Disturbance type 
CD1 Dynamic Optimisation-Open-loop Control Predefined 
CD2 Online MPC with scheduling level  Announced 
CD3 Optimisation and Correction MPC  Unknown 
CD4 Online MPC with scheduling level  Unknown 
 
Prediction Horizon 
The system involves high input and disturbance delays, as was explained in section 4.7. 
Therefore, in order to predict the after effect of a given input, the prediction horizon should be 
at least equal to the time lag. However, every patient has different glucose-insulin dynamics 
and the time delay factor should be considered as patient-specific. Although the time lag is 
dependent on the insulin dose (section 4.7) for the insulin infusion rates considered in the 
closed loop system an assumption of constant patient specific time delays is reasonable. Table 
6.3 shows the prediction horizon of the 10 patients that is calculated as the average time to 
observe a 1mg/dl change in blood glucose concentration when simulation studies of a step 
change of 0.5U/h insulin dose from 0 to 5U/h were performed. 
Table 6.3: Prediction Horizon (N) for the 10 patients 
Patient N Patient N 
Patient 1 13 ≜ 65min Patient 6 10 ≜ 50min 
Patient 2 11 ≜ 55min Patient 7  8 ≜ 40min 
Patient 3   7 ≜ 35min Patient 8 11 ≜ 55min 
Patient 4 10 ≜ 50min Patient 9 14 ≜ 70min 
Patient 5 13 ≜ 65min Patient 10 13 ≜ 65min 
 
6.4.1 (CD1) Dynamic Optimisation: Predefined Disturbances (dp) 
When a patient follows an exact meal plan, meaning that the exact amount and the time of the 
meal is known in advance, then this information is introduced in the general regulation design 
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as predefined meal plan and the optimisation block in Figure 6.1 is activated.  Hence, if the 
only uncertainty in the system is caused by the meal disturbances, then in the case of 
predefined meal plan the feedback control and the open loop control are equivalent (Rawlings 
and Mayne, 2009). The following optimisation problem is solved: 
min
𝑢𝑖
∫ (𝑤1 + 𝑤2)𝑑𝑡
𝑡𝑓
0
 (6.1) 
 
s.t      𝐺 = 𝑓( 𝑥(𝑡),̇ 𝑥(𝑡), 𝑦(𝑡), 𝑢(𝑡))  
(6.2) 
∑𝑢2𝑖 = 𝑇𝐷𝐷
𝑁
𝑖=1
 
(6.3) 
𝑤1 ≥ 0, 𝑤1 ≥ 𝐺 − 𝐺𝑚𝑎𝑥    𝑎𝑛𝑑    𝑤2 ≥ 0,     𝑤2 ≥ 𝐺𝑚𝑖𝑛 − 𝐺 (6.4) 
where tf is the 24h time horizon, G is the blood glucose concentration described by the 
nonlinear process model (6.2) for every patient (3.1-3.15); Gmax (140 mg/dl) and Gmin 
(80mg/dl) are the maximum and minimum glucose concentration bounds. The optimal insulin 
infusion, u2, appropriate to compensate for the forthcoming glucose increase due to the meal 
intake can change every 5min, therefore the time intervals are N= 288. The TDD is the total 
daily insulin dose for every patient.  The optimisation studies were formed and solved in 
gPROMS (PSE, 2011c).  
The advantages and disadvantages of CD1 are summarised as follows: 
  Personalised insulin delivery  
 Feed forward insulin action to account for delayed insulin effect 
 No compensation for unknown disturbances 
 Metabolic uncertainty is not considered 
 
6.4.2 (CD2) Online MPC with Scheduling Level: Announced Disturbances 
(da) 
When information concerning the amount of meal is made available only at the time it is 
given, then the disturbance is considered as “announced” and the control strategy involves a 
scheduling and a regulation level to enhance the performance of the controller, Figure 6.2. 
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The day is divided in 4 periods, and in each period the maximum insulin delivery is different. 
It is assumed that the meal plan follows a specific trend in terms of carbohydrates 
consumption and for this case it is considered that the maximum amount of carbohydrates is 
consumed during lunch according to Figure 6.2. 
 
Figure 6.2: Control design CD2 
For each period (sleeping, breakfast, lunch, dinner), the upper insulin limit is changed and 
therefore a different optimisation problem is solved. The amount of the maximum delivered 
insulin as determined in the scheduling level can be tailored to every patient according to 
their lifestyle. This information aims to facilitate the prediction beyond the considered 
horizon and hence to improve glucose regulation. A fine tuning of the control specifications 
for every patient R, R1, QR ensures the maintenance of glucose concentration within the 
normal range, the total insulin delivery to be less than the specified dose and prevent 
hypoglycaemia in the case of a skipped meal. 
The advantages and disadvantages of CD2 are summarised as follows: 
 Personalised insulin delivery (patient-specific approximate model, scheduling level 
tailored to patient’s diet) 
 Prevention of hypoglycaemia 
 Cannot prevent immediate prandial hyperglycaemia due to delayed insulin effect 
 No compensation for unknown disturbances 
 Metabolic uncertainty is not considered 
6.4.3 (CD3) Optimisation and Correction MPC: Unknown Disturbances (du) 
In the case of unmeasured meal disturbances, there is no information concerning the amount 
and the time of the meal. In this case, a nominal controller reacts aggressively to regulate the 
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glucose deviation from the reference point, which means increased insulin infusion as long as 
glucose violates the constraints. But this control action involves the risk of postprandial 
hypoglycaemia due to insulin after effect and also immediate prandial hyperglycaemia. 
Therefore, a different control design is proposed to compensate for unmeasured disturbances 
as illustrated in Figure 6.3. It consists of the patient model, an optimizer acting as a reference 
regulator, an MPC controller acting as the correction control, and a state estimator.  
 
Figure 6.3: Control design CD3 
The proposed control design regulates the glucose concentration when a reference meal plan 
is considered and additionally responds appropriately to compensate for the deviation from 
the reference meal when a different size meal is consumed. A similar approach which 
involves a feedforward and a feedback part has been reposted in (Boiroux et al., 2010). But in 
our work this approach is used for unknown meal disturbances and the feedforward part is 
used to enhance the response of the controller due to the delayed insulin absorption.  The 
CGM error is simulated with white Gaussian noise using a signal-to-noise ratio equal to 30. 
Optimizer: Reference Regulator 
The desired glucose value Gref is set for every patient. A predefined reference meal plan is 
considered to trigger the control action. Feedback about the current state is obtained by the 
approximate model output yopt, . yopt is calculated when the optimisation problem for the 
original non- linear model is solved for the predefined meal plan (described in section 6.4.1) 
and the optimal insulin infusion is applied to the approximate model.   
MPC:  Correction Control 
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MPC aims to find the optimal insulin infusion rate to regulate the difference of glucose as a 
real measurement coming from the patient, G, and glucose as calculated when solving the 
reference optimisation problem, yopt. This difference can be regarded as an unknown 
disturbance of the system that leads to an offset in the set point, Gref,2=0. So the correction 
control is described as a disturbance rejection problem. In order to remove the offset and the 
nonzero disturbances the original system is augmented with a disturbance model, as presented 
in (6.6). The output feedback of the patient is obtained as the difference of the actual 
measurement and the reference control output (G-yopt), from which the state and the 
integrating disturbance are estimated using a state estimator.  
[
𝑥𝑘+1
𝑑𝑘+1
] = [
𝐴 𝐵𝑑
0 𝐼
] [
𝑥𝑘
𝑑𝑘
] + [
𝐵
0
] 𝑢𝑘 + 𝑤𝑘 
  (6.6) 
𝑦𝑘 = [𝐶 𝐶𝑑] [
𝑥𝑘
𝑑𝑘
] + 𝜐𝑘 
where dk is the integrating disturbance. The matrix 𝐵𝑑 ∈ ℝ
𝑛×𝑛𝑑 is chosen to be the second 
column of Bd matrix presented in section 5.6 and matrix 𝐶𝑑 = 𝐼 ∈ ℝ
𝑛𝑑×𝑛𝑑. The variances of 
variables w and υ are adjusted according to the output data (Odelson, Rajamani and Rawlings, 
2006). The new derived augmented linear model (𝑛 = 10, 𝑛𝑑 = 1) is detectable, see (6.7), 
which means that the states will converge to the real states when a Kalman filter is used, 
hence this strategy can be employed: 
𝑟𝑎𝑛𝑘 [
𝐼 − 𝐴 −𝐵𝑑
𝐶 𝐶𝑑
] = 𝑛 + 𝑛𝑑 = 11                                 (6.7) 
The objective function is modified accordingly to include the nonzero disturbance d.  
minx,y,u 𝐽 =∑ (Cxk + Cddk − Gref,2)
′
QR(Cxk + Cddk − Gref,2)
N−1
k=1 + ∑ u1,k
′ Ru1,k
M−1
k=1       (6.8) 
𝑠. 𝑡.   ?̂?𝑘+1 = 𝐴?̂?𝑘 + 𝐵𝑢1,𝑘 + 𝑤𝑘                  (6.9) 
𝑦2,𝑘 = 𝐶?̂?𝑘 + 𝜐𝑘                  (6.10) 
y2,min ≤ y2,k ≤ y2,max                  (6.11) 
umin ≤ uk ≤ umax                   (6.12) 
Where the estimated states are:  
?̂? = [𝑥1 𝑥2 𝑥3 𝑥4 𝑥5 𝑥6 𝑥7 𝑥8 𝑥9 𝑥10 𝑑]′ 
And 𝑦2 = 𝐺 − 𝑦𝑜𝑝𝑡. The control specifications for MPC are presented in Table 6.4 
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Table 6.4: Specifications of MPC and the Kalman Filter 
Variable Value Variable Value Variable Value 
y2,min -10        mg/dl umin 0              U/min 𝑄𝐾𝐹 100 
Y2,max  10        mg/dl umax 0.2TDD   U/min 𝑅𝐾𝐹 5 
 
The advantages and disadvantages of CD3 are summarised as follows: 
 Personalised insulin delivery (patient-specific approximate model, Kalman Filter) 
 Feed forward insulin action to account for delayed insulin effect 
 Compensation for unknown disturbances 
 Account for metabolic uncertainty as unmeasured disturbance 
 A reference meal plan is always considered 
 
6.4.4 (CD4) Online MPC with Scheduling Level: Unknown Disturbances 
(du) 
Control design CD4 applies the same principles of zero-offset design as CD3, but instead of 
the optimizer it includes the scheduling level to enhance the control performance. Therefore, 
the unknown disturbances are estimated using the augmented system in the state estimator, 
but now the output and input used for the estimation is the glucose measurement, G, and u1, 
respectively, presented in Figure 6.4 for clarity. The CGM error is simulated with white 
Gaussian noise using a signal-to-noise ratio equal to 30. 
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Figure 6.4: Control design CD4 
The advantages and disadvantages of CD4 are summarised as follows: 
 Personalised insulin delivery (patient-specific approximate model, Kalman Filter, 
scheduling level tailored to patient’s diet) 
 Compensation for unknown disturbances 
 Account for metabolic uncertainty as unmeasured disturbance 
 No compensation for delayed insulin effect 
 
6.5 Performance analysis of the four control designs CD1-CD4 
The previously presented control designs, presented in Table 6.2 are evaluated for different 
types of meal disturbances, di. In all control designs the performance of the controller is 
evaluated with the results of blood glucose concentration, referred as G. 
6.5.1 Control Design 1 (CD1): Dynamic Optimisation  
A predefined meal plan of 45, 70 and 70 g of carbohydrates for breakfast, lunch and dinner is 
considered given at 420, 720 and 1080 min and the optimisation problem is solved for the 
entire 24h horizon. A piecewise constant infusion rate that holds a constant value for 5min 
time intervals is calculated with optimising criterion the minimum range of glucose outside 
the normal bounds. The TDD is treated as an end-point constraint and is set individually for 
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every patient. The optimisation problem is solved in gPROMS. The results are presented for 
all patients in Figure 6.5.  
 
 
Figure 6.5: Glucose profiles for the 10 adults (upper graph) when optimal insulin infusion 
(lower graph) is delivered 
It can be concluded that very tight glycaemic control is achieved for most of the patients 
when the meals are known in advance and the patient follows the exact predefined plan. In 
more detail, the percentage of the time spent outside the euglycaemic range is presented in 
Table 6.5 for all adults. As confirmed by Figure 6.5, it is difficult to maintain the blood 
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glucose levels of adults no 4 and no 10 within the normal range. However, if these results are 
compared to the time spent in normoglycaemia when conventional optimal insulin dosing is 
applied, it can be stated that superior glucose control can be achieved with optimised insulin 
infusion for all patents.   
Table 6.5: Comparison of the time spent outside the normal glucose range when optimisation of 
insulin infusion is performed and conventional optimal insulin dosing is administered 
%Time Ad 1 Ad 2 Ad 3 Ad 4 Ad 5 Ad 6 Ad 7 Ad 8 Ad 9 Ad10 Mean 
 Optimised Insulin Infusion  
G <70 0 0 0 0 0 0 0 0 0 0 0 
G <80 0.9 0 0 15.9 0 0 0 0 0 0.9 1.8 
80<G<140 99.0 100 96.1 53.5 76.2 90.1 99 90.1 95 48.5 84.7 
140<G<180 0 0 3.9 29.8 23.7 9.9 0.99 9.9 4.9 50.5 13.3 
180<G<250 0 0 0 2.9 0 0 0 0 0 0 0.29 
G >250 0 0 0 0 0 0 0 0 0 0 0 
Gmin 79 80 87 71 112 89 90 90 80 79 86 
Gmax 139 137 147 192 145 146 140 146 144 153 149 
 Conventional Optimal Insulin Dosing  
G <70 0 0 0 0 0 0 0 0 0 0 0 
G <80 0 0 0 0 0 0 0 0 0 0 0 
80<G<140 52.2 73.7 42.7 48.9 49.9 52.8 75.8 50.7 26.7 30.9 50.43 
140<G<180 40.9 26.2 57.2 41.6 50.1 42.7 24.1 49.2 62.6 58.4 45.3 
180<G<250 6.8 0 0 9.5 0 4.4 0 0 10.6 10.6 4.19 
G >250 0 0 0 0 0 0 0 0 0 0 0 
Gmin 100 95 102 99 99 103 102 88 93 96 97.7 
Gmax 201 157 175 204 169 186 162 166 216 196 183.2 
In more detail, no event of hypoglycaemia occurs for either the optimised insulin infusion or 
the conventional optimal insulin dosing. The time period during which glucose is above 
140mg/dl is 36% longer with the conventional insulin dosing than with the optimised insulin 
infusion, while the time spent above 150mg/dl is 24% larger with the conventional insulin 
dosing. Hence, when the exact meal plan is known in advance, then the administration of 
insulin as calculated by the solution of the optimisation problem is a reliable way to tightly 
maintain the blood glucose concentration within the normal range. However, CD1 assumes 
that not only the meal plan is known in advance (something which is not always easy to 
achieve in practice), but also that there is no model mismatch in terms of patient individual 
dynamics and that there is no intra-patient variability. However, free living conditions deviate 
significantly from the ideal simulated conditions. These assumptions are reconsidered and 
examined in the following sections.  
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6.5.2 Control Design 2 (CD2): Online MPC with Scheduling Level 
In this section the control design CD2 for announced disturbances is evaluated for the 10 
patients. The patient models are developed in gPROMS, while the control design in 
MATLAB, gO:MATLAB is used to exchange data between the two environments. The 
design is validated against:  
A. The proposed model 
B. The UVa/Padova Simulator 
The considered meal plan is 45, 70 and 60 g of carbohydrates for breakfast, lunch and dinner 
and the meals are given at 420, 720 and 1080 min as previously.  
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A. Against the Proposed Model 
  
B. Against UVa/Padova Simulator 
  
Figure 6.6: MPC control for 10 adults in the presence of announced disturbances.; Upper graphs 
blood glucose concentration (mg/dl) profiles; lower graphs control action, insulin (U/min). The black 
lines show the results when CD2 is validated against the proposed model while the grey lines the 
results against the UVa/Padova Simulator.  
The purpose of Figure 6.6 is first to compare the results produced by CD2 when evaluated 
against the proposed model and the UVa/Padova Simulator and second to examine the 
reliability of CD2. The results of A and B are very similar, which implies that the proposed 
model could be generally viewed as a reliable equivalent to the UVa/Padova Simulator. The 
approximate model used as the internal MPC model can predict the current states for both 
models and the controller suggests a similar control action for all patients. The observed 
differences could be due to inaccuracies in the parameter estimation of the proposed model 
due to the lack of informative data of different meal sizes and insulin infusions. As far as the 
efficiency of CD2 is concerned, the results suggest that this strategy is not flexible enough to 
handle the fluctuations of glucose concentration. The controller suggests the maximum 
insulin infusion at the announcement of the disturbance, which cannot prevent the prandial 
hyperglycaemia. The control specifications are fine tuned to ensure the avoidance of 
hypoglycaemia.  
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6.5.2.1 Case Study: Skipped Meal 
CD2 is evaluated in the case of a skipped meal. As it can be verified from Figure 6.7 the 
controller reacts accordingly when the breakfast or the lunch are skipped at 420 and 720 min 
respectively.  
  
Figure 6.7: Skipped breakfast and skipped lunch for adult 5 
 
6.5.3 Control Design 3 (CD3): Optimisation and Correction MPC  
In this section the CD3 control design as explained before is evaluated.  The ability of the 
controller to maintain the blood glucose concentration in the normal range is tested for large 
meal sizes of 75, 100 and 90 g and for normal meal sizes of 45, 75 and 60 g of carbohydrates 
given for breakfast at 420 min, lunch at 720 min and dinner at 1080 min respectively, as 
shown in Table 6.6. The reference meal plan is 20, 30 and 25 g respectively. The total insulin 
amount does not exceed the TDD for each patient plus approximately 6 U to compensate for 
the large meal sizes. The results from CD3 are compared to the CD4 for the same meal sizes 
and presented in Table 6.7 and Table 6.8.  
Table 6.6: Evaluation of CD3 with two meal scenarios 
 Scenario 1 Scenario 2 
Breakfast 75 g 45 g 
Lunch 100 g 75 g 
Dinner 90g 60 g 
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Table 6.7: CD3 predefined reference meal plan (Scenario 1) 
 % time 
<70 
% time 
<80 
% time 
80<G <140 
% time 
140<G <180 
% time 
180<G <250 
% time 
>250 
Gmin 
(mg/dl) 
Gmax 
(mg/dl) 
Adult1 0 1.3 72.9 18.3 8.6 0 89 203 
Adult2 0 0 71.5 22.9 5.5 0 81 190 
Adult3 0 2.3 65.0 20.5 12.0 0 70 228 
Adult4 0 0.3 25.0 56.9 17.8 0 76 247 
Adult5 0 0 55.5 29.2 14.9 0 79 239 
Adult6 0 3.1 60.4 14.6 21.9 0 71 226 
Adult7 0 0 67.0 20.1 12.8 0 82 205 
Adult8 0 4.9 68.4 19.5 7.0 0 77 194 
Adult9 0 1.4 59.2 23.4 13.1 2.8 72 265 
Adult10 0 2.4 50.3 23.4 24.8 2.4 76 259 
Mean 0 1.6 59.5 24.9 13.8 0.52 77 226 
SD 0 1.6 14.1 11.9 6.2 1.1 5.7 26.9 
 
Table 6.8:CD4 unknown disturbances (Scenario 1) 
 % time 
<70 
% time 
<80 
% time 
80<G <140 
% time 
140<G <180 
% time 
180<G <250 
% time 
>250 
Gmin 
(mg/dl) 
Gmax 
(mg/dl) 
Adult1 1.4 4.5 53.8 22.2 19.4 0 62 238 
Adult2 4.5 7.9 54.9 25.3 11.8 0 63 202 
Adult3 4.1 5.5 45.8 37.1 11.4 0 46 249 
Adult4 5.2 12.8 52.7 12.5 7.6 14.2 62 326 
Adult5 0 0 43.1 29.8 27.1 0 85 246 
Adult6 6.3 12.7 52.4 9.9 20.9 3.9 54 270 
Adult7 6.6 12.8 52.8 9.1 16.1 8.6 58 288 
Adult8 5.2 9.3 51.7 29.5 9.4 0 65 199 
Adult9 0 0 39.2 33.7 20.5 6.5 90 303 
Adult10 0 2.1 36.1 27.1 29.5 5.2 72 281 
Mean 3.4 6.8 48.3 23.6 17.4 3.8 66 260 
SD 2.6 5.1 6.7 10.0 7.4 4.9 13.4 41.4 
Table 6.7 shows that with CD3, on average 59.5% of the time is spent within the normal 
glucose range, while with CD4 the percentage of the time spent in the normal range is 48.3%. 
With CD3 there is no event of hypoglycaemia and the minimum observed glucose value is 
71mg/dl for adult 6, in contrast to CD4 where an average 3.4% of the time is spent in 
hypoglycaemia with a minimum observed glucose value of 46 mg/dl. Additionally, the time 
spent in hyperglycaemia ( >180mg/dl ) is much higher for CD4 with a 21.2% of the time, 
while for CD3 the respective percentage is 14.3%. The 10 adults respond, as expected, 
relatively different from each other, but as it can be observed from Table 6.7 there is no event 
of hypoglycaemia in all the studied adults and only adult 9 and adult 10 spend time above 250 
mg/dl. However, for CD4 the results are significantly different with the glucose values being 
distributed towards the extremes for most of the adults. A Mann-Whitney test was performed 
to compare CD3 and CD4. The p-value is calculated for each glucose range and for the ranges 
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G<70 (p-value= 0.002), G<80 (p-value=0.036), 80<G<140 (p-value= 0.013), it was indicated 
that the null hypothesis for equal medians is rejected at 5% significance level.  Therefore CD3 
can be regarded as a potential strategy to compensate for unknown meal disturbances in terms 
of minimizing hypoglycaemia and maintaining glucose levels within the safe range. The 
glucose profile and the control action with both CD3 and CD4 are presented in Figure 6.8 for 
adult 1 for illustrative purposes.    
 
Figure 6.8: Comparison of glucose regulation with CD3 and CD4 for adult 1. The meals are given 
420, 720 and 1080 and contain 75, 100 and 90 g of carbohydrates respectively (Scenario 1) 
 
 
The control designs CD3 and CD4 are evaluated for different meal sizes and presented for 
adult 1 in Figure 6.9. 
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Figure 6.9: Comparison of glucose regulation with CD3 and CD4 for adult 1. The meals are given 420, 
720 and 1080 and contain 45, 75 and 60 g of carbohydrates respectively (Scenario 2) 
 
Figure 6.8 and Figure 6.9 confirm that tighter glycaemic control can be achieved when CD3 is 
used and a feed forward reference action is applied to enhance the control performance in the 
presence of unknown disturbances.  
Key Results for the Systematic Strategy Control Designs 
 Control Design 1: Tight glycaemic control  
 Control Design 2: Not flexible enough, but no event of hypoglycaemia for the study data 
 Control Design 3: Good glycaemic control; 85% of the time spent near normoglycaemia 
for Scenario 1; no event of hypoglycaemia for the study data 
 Control Design 4: Not efficient glycaemic control; 72% of the time spent near 
normoglycaemia for Scenario 1, with 3.4% in hypoglycaemia 
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6.6  “Approximation” Strategy (II): Control Designs 
In this section the “approximation” strategy is evaluated and compared with the systematic 
strategy. The general control design applied in this approach is presented in Figure 6.10. This 
design differs from Figure 6.1 in the grey box that now instead of an optimisation problem a 
second MPC is considered. Additionally, the yopt becomes yref, as calculated when the 
reference tracking problem with known meal disturbance is solved and the optimal insulin 
infusion is applied. Finally, CD2 and CD4 are the same as presented previously.  
 
Figure 6.10: General control design for “Approximation” Strategy 
Effect of Mean Approximate model 
In order to illustrate the effect of using the mean approximate model instead of the patient-
specific approximate model, we consider the control design CD3 of section 6.4.3 but 
assuming that the internal control model is now the mean approximate model. This 
assumption in the context of Strategy I is not correct since, if there is no information of the 
exact patient dynamics, the optimisation problem will not calculate the optimal insulin 
infusion for each patient. However, for analysis purposes, assuming that u2 is available and 
can be applied, we investigate the effect of using mean approximate internal models rather 
than exact in the control design. Figure 6.11 is a control variability grid analysis (CVGA) plot 
(Magni et al., 2008) which has been established as a very useful tool to evaluate the 
performance of different control strategies in a population of patients. The area is divided in 
zones, each one representing the level of euglycaemic maintenance. For each patient a dot is 
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plotted that shows the extreme glucose excursions for a given control strategy applied for a 
specific period. The performed closed loop experiment involves the consumption of 45, 75 
and 60 g at 420, 720 and 1080 for all patients (Scenario 2). The black dots represent the CD3 
closed loop performance with a patient specific internal model while the white dots represent 
the same closed loop experiment but for the mean approximate model. We can see that the 
white dots are more distributed, with patients found in zone upper B and lower D in contrast 
to the black dots which are mostly found in zone A and lower B. Figure 6.12 shows the 
cumulative distribution of the data for both cases. It can be seen that the data coming from the 
patient-specific model produce a sharper profile indicating that the patients are within tight 
glycaemic control for most of the time. The light grey area which represents the profiles from 
the mean model is wider confirming the distributed results presented in Figure 6.11.  
 
Figure 6.11: CVGA of CD3 for patient specific approximate model (black dots) versus mean 
approximate model (white dots) 
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Figure 6.12: Cumulative distribution of blood glucose concentration. The light grey area shows the 
range of closed loop glucose distribution when the mean approximate model is used for the ten 
patients; whereas the dark grey area shows the range of closed loop glucose distribution when the 
exact patient model is used (Strategy I). The dashed line is the mean cumulative glucose distribution 
of the light grey area while the dash-dot line the mean of the dark grey area.  
6.6.1 Comparison of CD3: Strategy I and Strategy II 
The performance of CD3 for Strategy I and Strategy II is compared in Figure 6.13 for 
Scenario 2 for all patients. It can be noticed that the results of Strategy II are undoubtedly 
satisfactory since all patients are in zones A and B. When compared to the results from CD3 
of Strategy I with mean model (as explained above) we can see that the additional MPC acts 
efficiently to compensate for the effects of poor model and tighter glycaemic control can be 
achieved. Figure 6.14 shows the cumulative distribution of CD3 for Strategy I and II. We can 
observe that both areas are very sharp and tight indicating that most of the time glucose is 
maintained tightly within the normal range.  
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Figure 6.13: CVGA of CD3 for patient specific approximate model (black dots), Strategy I, versus 
mean approximate model (white dots) and versus CD3 Strategy II (white circles)  
 
Figure 6.14: Cumulative distribution of blood glucose concentration. The light grey area shows the 
range of closed loop glucose distribution of Strategy II for the ten patients; whereas the dark grey area 
shows the range of closed loop glucose distribution for Strategy I. The dashed line is the mean 
cumulative glucose distribution of the light grey area while the dash-dot line the mean of the dark grey 
area.  
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Figure 6.15 confirms the results found in Figure 6.14 for Scenario 2, now for Scenario 1. It 
can be observed that Strategy I and II present similar behaviour even for larger meal sizes and 
optimal control is achieved for both cases.  
 
Figure 6.15: Comparison of glucose regulation with CD3 for both Strategy I and Strategy II applied 
on adult 1. The meals are given 420, 720 and 1080 and contain 75, 100 and 90 g of carbohydrates 
respectively (Scenario 1) 
Key Results for the “Approximation” Strategy Control Designs 
 Compensation for model mismatch with feedback coming from an additional 
controller 
 Control Design 3: Good glycaemic control  
6.7 Case Study: Skipped Meal 
In this section the case of a skipped meal is evaluated for both the Systematic Strategy and the 
“Approximation” Strategy, as shown in Figure 6.16 This graph shows the advantage of 
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Strategy I over Strategy II. We can see that optimisation of the insulin delivery over the entire 
horizon is much more efficient than the optimisation over the prediction horizon in such an 
unstable system with long time delays. The insulin action proposed by the solution of the 
optimisation problem is adequate for each sampling period since the reference meal 
disturbance is known in advance and insulin is delivered smoothly long before the occurrence 
of glucose fluctuation. Therefore in the case of a skipped meal the drop of glucose profile is 
not as severe as in the “Approximation” Strategy because the compensation for a meal 
disturbance starts early having a smooth effect on glucose. On the other hand, in the 
“Approximation” Strategy the reference meal announcement is obtained within the 
framework of the prediction horizon and the action of the controller although it is produced 
earlier than the meal disturbance, it is sharper than in Strategy I, causing a big drop on blood 
glucose concentration.  
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Figure 6.16: Skipped lunch for adult 1 and Scenario 2 
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Figure 6.17: Skipped lunch for adult 1 and Scenario 1  
 
The same conclusions are supported with Figure 6.17 for Scenario 1. The drop in glucose 
concentration is greater since the considered meal disturbances are bigger which means more 
insulin is required to compensate for the glucose increase. Therefore, the reference meal plan 
can be adequately adjusted according to the patient’s meal habits in case of normal 
consumption of larger meals.  
6.8 Case Study: Variable Meal Time 
Figure 6.18 shows the glucose profile for adult 1 for the Systematic Strategy when a meal of 
50 g is given 30min before or 30min after, or simultaneously with the predefined 30 g 
reference meal. It can be noticed that good glycaemic control is achieved even at the case 
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when a meal is consumed 30min before the considered reference meal which triggers the 
control action and no event of hypoglycaemia is occurring.  
 
Figure 6.18: Evaluation of CD3 with Systematic Strategy (I) when a meal of 50 g is given 30 min in 
advance, 30 min after and simultaneously with the reference meal of 30 g  
The results of Figure 6.18 are compared with Figure 6.19 for the exact conditions, but for the 
“Approximation” Strategy. Once more, we can see that good glycaemic control is achieved 
and no event of hypoglycaemia is occurring. Additionally, the advantage of considering the 
Systematic Strategy is confirmed since it can maintain glucose tightly within the range, 
although the increased postprandial glucose values observed in the “Approximation” Strategy 
do not raise a potential issue for the patient’s safety.  
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Figure 6.19: Evaluation of CD3 with “Approximation” Strategy (II) when a meal of 50 g is given 
30min in advance, 30 min after and simultaneous with the reference meal of 30 g  
The results of Figure 6.18 and Figure 6.19 are confirmed in Figure 6.20 and Figure 6.21 for a 
different meal size. Good glycaemic control is achieved, i.e. no event of hypoglycaemia is 
occurring, when a meal of 80 g of carbohydrates is consumed 30 min in advance, 30 min after 
or simultaneously with the time of the considered predefined meal of 30 g.  
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Figure 6.20: Evaluation of CD3 with Systematic Strategy (I) when a meal of 80 g is given 30 min 
in advance, 30 min after and simultaneous with the reference meal of 30 g 
 
Figure 6.21: Evaluation of CD3 with “Approximation” Strategy (II) when a meal of 80 g is given 30 
min in advance, 30 min after and simultaneous with the reference meal of 30 g 
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The main assumption of CD3 is that all the predefined meals will be consumed. Nonetheless, 
the reference meal plan can be determined individually depending on the patient’s lifestyle.  
6.9 Case Study: Intra-patient Variability 
The impact of intra-patient variability on glucose regulation is evaluated by imposing a 
circadian sinusoidal variation on the parameter k1 (3.24). This is related to insulin dependent 
glucose absorption and is very influential according to the sensitivity analysis presented in 
Chapter 4. The choice of the parameter as well as the imposed variation is in good agreement 
with the literature (Fabietti et al., 2006). The amplitude of the wave is 30% of the nominal 
value of k1, according to (6.13): 
𝑘1 = 𝑘1,𝑚𝑒𝑎𝑛 (1 − 0.3𝑠𝑖𝑛 (
2𝜋
24
)) , 0 ≤ 𝑡 ≤ 24               (6.13) 
The complete circadian cycle of parameter k1 is presented in Figure 6.22 for adult1.  
 
Figure 6.22: Complete circadian cycle of k1 with a 30% change in magnitude  
The impact of parameter k1 variation on glucose concentration is shown in Figure  6.23. The 
light grey line shows the glucose concentration profile when CD1 is applied with no intra-
patient variability considered. This profile is compared to the darker grey line that shows the 
influence of intra-patient variation on glucose profile, when no further control action is 
applied, but only CD1. It can be noticed that the profile changes according to the sinusoidal 
variation with increased values of glucose concentration when the value of k1 decreases and 
low values of glucose concentration with the increase of k1.  
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Figure  6.23: glucose profile when CD1 is applied with no considered variability and CD1 in 
the presence of variability for Scenario 2 adult 1. 
To address this fluctuation in the case of unknown meal plan, CD3 is applied for both 
Systematic and “Approximation” strategies. The results are presented in Figure 6.24.  
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Figure 6.24: CD3 performance in the presence of intra-parient variability for Strategy I and 
Strategy II, comparison of  glucose profile when CD1 is applied in the presence of variability 
for Scenario 2 adult 1.  
 
It can be observed that both control strategies respond accordingly to decrease the glucose 
concentration when it tends to increase due to the imposed variability. Additionally, when 
glucose tends to decrease, both control designs achieve to maintain the concentrations above 
the hypoglycaemic level. This graph also shows the flexibility of “Approximation” Strategy 
when glucose concentration tends to decrease due to the imposed variability. The two 
considered controllers respond adequately so as not to deliver more insulin than required, 
whereas in the “Systematic” Strategy the reference insulin delivery is pre-calculated and 
administered anyway. Therefore, in this strategy the controller cannot act to prevent the 
impact of the variability, however in the presence of unknown disturbances and imposed 
variability the controller maintains glucose concentration within the normal range.  
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6.10 Conclusions 
The key actions taken to address the control objectives presented in Section 6.2 are 
summarised as follows for the control designs of the Systematic Strategy and the 
“Approximation” Strategy: 
Actions 
Systematic 
Strategy 
“Approximation” 
Strategy 
 Develop personalised insulin delivery systems 
- Development of patient-specific approximate models   
- Specify individually the parameters: BW,TDD,umax, 
QR,R,R1 
  
- Scheduling level tailored to patient’s diet   
- Solution of patient-specific optimisation problem   
- Patient-specific prediction horizon   
- Flexibility to determine the reference meal plan 
according to patient’s diet 
  
 Take into account the involved time delays 
- Describe the inherent time delays in the linear 
approximate models 
  
- Include the time lag in the prediction horizon   
- Enhance the feed forward action of the controller   
 Compensate for the unknown meal disturbances 
- Consider an augmented state space system to describe 
the unknown disturbance as extra state using a Kalman 
filter 
  
 Address the issue of uncertainty 
- Metabolic uncertainty as unmeasured disturbance   
- Evaluation of performance robustness in several 
conditions 
  
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6.11 Concluding Remarks 
Two general strategies of glucose regulation are presented. The Systematic Strategy involves 
the steps towards a patient-specific closed loop insulin delivery that takes advantage of the a 
priori knowledge of the system dynamics. The “Approximation” Strategy compensates for the 
effect of poor knowledge of the patient’s dynamics with the inclusion of an additional 
controller.  
The complications of the system such as the occurrence of disturbances that have a major 
effect on the system’s dynamics, the large time delays and the patient variability make the use 
of a simple controller for the solution of the closed loop inappropriate as this can lead to poor 
control performance. Therefore, the proposed frameworks involve an MPC, a state estimator, 
an optimizer/MPCref and a scheduling feature.  
In the case that the disturbances are known in advance, the results indicate that good control 
can be achieved. In particular, glucose can be maintained within or close to the normal range 
despite intra- patient variability, differences in meal sizes and/or timing and skipped meals. 
The proposed methodology of Optimisation and Correction MPC (Control Design 3) 
considers that a reference meal is given and thus it is assumed that the patient always 
consumes a breakfast, a lunch and a dinner. In the case of skipping one of these meals it was 
shown that efficient glycaemic control cannot be achieved, especially by the 
“Approximation” Strategy. On the contrary, when the meal is announced at the time it is 
given then the controller responds adequately in the case of a skipped meal. The proposed 
methodology can be formulated according to the patient’s needs and the issue of skipping a 
meal can be addressed either by manually providing this information or by compensating for 
the after effect.     
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7. Concluding Remarks & Future Directions 
 
7.1 Project summary 
The proposed mathematical model of glucose-insulin interactions in T1DM is a 
physiologically based compartmental model that describes glucose metabolism in actual 
anatomical compartments, inspired by the work of  (Sorensen, 1978).  Glucose is distributed 
in six organs (heart, brain, liver, kidney, gut, and periphery) via blood circulation and it is 
absorbed by the tissue cells to provide them with energy. Insulin, through the subcutaneous 
route, is distributed via the blood circulation to enhance glucose uptake by the periphery 
(adipose tissue and muscle cells) and to signal the liver to suppress the endogenous glucose 
production and therefore, maintain the blood glucose concentration within the normal range. 
The pharmacokinetic parameters and variables of glucose metabolism (distribution volumes, 
blood flows, and cardiac output) are expressed as functions of age, weight, gender and height 
to account for the individual patient characteristics. The rate of glucose appearance in the 
blood after meal consumption, the endogenous glucose production and the glucose excretion 
from the kidneys are described with models obtained by the literature that have been 
clinically validated and are embedded in the proposed model structure. Regarding the insulin 
kinetics, four potential models are presented, and a series of evaluation tests have indicated 
the most suitable model to describe experimental data obtained by the literature (Boden, 
Cheung and Homko, 2003). Additionally, the model used for endogenous glucose production 
was evaluated with clinical data, obtained again by the literature (Boden, Cheung and 
Homko, 2003). A global sensitivity analysis was performed to determine which model 
parameters have a significant influence on the measured output. The GSA specified that the 
most influential parameters are those related to insulin effect on glucose. Particularly the 
parameters k1 and k2, linked to insulin sensitivity, have the most significant effect on blood 
glucose concentration.  
The model of UVa/Padova simulator (Dalla Man, Rizza and Cobelli, 2006) was implemented 
and simulated in gPROMS. The commercial version of the T1DMS was used to obtain the 
patient-specific glucose-insulin profiles. These profiles, for 10 examined adult patients, were 
treated as experimental data to estimate the parameters of the proposed model and obtain 
individualised dynamic glucose and insulin profiles. The estimated parameters were the most 
influential ones as identified using GSA. The parameters of the Ra and EGP sub models were 
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also estimated. The remaining,  non-influential parameters were kept at their mean values. 
The simulated results indicated that the proposed model can accurately predict individualised 
glucose profiles and that the model parameters are well adjusted for all patients.  
Therefore, this model is used as a virtual patient for closed loop studies, and after 
simplification, as a predictive tool in the context of model based control, according to the 
framework presented in Figure 7.1:  
 
Figure 7.1: Framework of closed loop validation studies in the context of model predictive control  
The meal disturbances in the system have a significant effect on glucose dynamics and trigger 
the system away from the steady state. Depending on the nature of the meal disturbances 
different control designs are developed. In the presence of known disturbances the problem 
becomes an open loop optimisation problem over the entire examined time horizon. When the 
disturbance is announced at the time it occurs then the control design involves an MPC 
controller and a scheduling level which specifies several time periods according to the daily 
meal plan of the patient during which the upper insulin bound is different; a different 
optimisation problem is solved in each time period. Finally, in the case of unknown 
disturbances it became obvious that a nominal state feedback MPC controller is inadequate to 
efficiently regulate the blood glucose concentration, and hence a different control design is 
proposed. The feed forward ability of MPC that acts in anticipation of the future fluctuations 
due to disturbances is enhanced when considering a reference meal plan of specific size and 
time that is always given to the patient. This is inspired by the function of the healthy 
pancreas that provides the system with already stored insulin when receiving a signal of 
increased blood glucose and then it produces new insulin to compensate for the rest of the 
increased glucose. Therefore, in the case of the artificial pancreas, the system is ready to 
provide the optimal insulin infusion to compensate for a small reference meal, in order to 
overcome the effect of long time delays and to prevent the prandial hyperglycaemia induced 
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by a large meal. An open loop optimisation problem is solved for the considered meal plan 
and the solution is incorporated into the control action. Then an MPC controller acts on the 
difference of glucose concentration, resulting from the unknown meal disturbance, and the 
expected glucose, resulting from the reference meal plan when the optimal insulin infusion is 
given. The performance of this control design presents a significant improvement over the 
nominal state feedback MPC for unknown disturbances. Cases of imposed variability in the 
meal time, variability in the parameters related to insulin sensitivity and skipped meals are 
tested to evaluate the reliability of the proposed control design.  
In the case of limited patient information of the glucose-insulin dynamics a mean 
approximate model with adjusted parameters related to obvious patient characteristics is 
considered. The performance of this control strategy is evaluated for all the aforementioned 
disturbance types and cases. Necessary modifications in the general control design are 
considered. It was evident that even though the patient-specific control design outperforms 
the approximate control design, the approximate strategy shows a general applicability 
towards the development of closed loop artificial pancreas.     
7.2 Key contributions of this thesis 
The key contributions of this work are summarised: 
Modelling & Model Analysis (Chapters 3 and 4) 
 Development of a novel physiologically based compartmental model of glucose-
insulin interactions in T1DM that combines actual anatomical compartments and 
functions that have already been validated in the literature. 
 Description of fundamental pharmacokinetic properties with individual patient 
characteristics. 
 Original insights of the insulin kinetics model, in terms of model identifiability, 
parameter estimation and correlation. The model structure was developed by 
comparison of alternative models with experimental data and a series of model 
analysis tests. 
 Determination of the model parameters with the most influential effect on the 
measured output through global sensitivity analysis. The results confirmed that the 
influence of pharmacodynamic parameters is more significant than the influence of 
pharmacokinetic parameters.  
Chapter 7: Concluding Remarks & Future Directions 
 
146 
 
 Estimation of the patient parameters for 10 adult patients using data obtained from the 
UVa/Padova T1DMS treated as clinical data. Ten individual glucose-insulin dynamic 
systems that describe precisely the glucose-insulin interactions are developed. 
 Investigation of time delays on the system was investigated with open loop 
optimisation studies. Solution of an MINLP problem to find the optimal timing to 
administer a bolus insulin dose. A continuous insulin infusion as an alternative to the 
conventional basal- bolus insulin treatment was considered and the optimisation 
results showed that it can be applied in closed loop studies.  
Closed loop control for optimal insulin delivery (Chapters 5-6, Appendix A, C) 
 Development of two general control strategies: a systematic strategy that aims towards 
a personalised insulin delivery system and an “approximation” strategy that 
compensates for lack of patient information.  
 Inclusion of features such as a scheduling level which is modifiable for each patient, 
the personalised reference optimisation problem, the patient specific MPC controller, 
to develop individual closed loop insulin delivery systems. 
 Consideration of the known disturbance rejection problem as a personalised open loop 
optimisation problem. 
 Assessment of unknown disturbances as disturbance rejection with zero offset towards 
a robust MPC design. 
 Investigation of the effect of uncertain factors such as variability in the meal time and 
size, skipped meal and variability in insulin sensitivity on the system in the closed 
loop formulation. The control design presents feasible performance under the imposed 
uncertainty which encourages its further consideration.  
 Evaluation of the performance of the control strategies by triggering the system with 
large meal sizes.  
 Preliminary results using explicit Model Predictive Control for closed loop insulin 
delivery.   
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7.3 On-going and Future Directions 
Model Validation 
The proposed model describes accurately individual glucose-insulin profiles. However, 
validation with clinical data is required to increase the level of confidence for further 
consideration.  The validation of the model with simulated data as experimental data indicates 
the applicability of the model to represent patient-specific dynamics. Further all model 
parameters can be estimated precisely using data that are collectable during clinical practice. 
Nonetheless the ideal simulation environment deviates significantly from the real system 
which is dominated by high intra- and inter-patient variability.  Therefore, the performance of 
the model needs to be evaluated with real patient data.  
Model Extension 
There are many conditions of everyday life that influence the hormone levels leading to 
disruption of the homeostasis and consequently to variations in glucose metabolism. 
Conditions such as stress, illness, exercise have a significant effect on glucose distribution 
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and absorption from the involved organs. In the case of T1DM, the complications increase 
because glucose regulation with exogenous insulin under these conditions can be very 
challenging. In order to achieve tight glycaemic control with exogenous insulin, the patient 
needs to fully understand the underlying phenomena of alterations in insulin sensitivity 
during exercise, the different metabolic effect during mild and vigorous exercise, the role of 
epinephrine that triggers the release of stored glucose in the blood stream under stressful 
conditions or illness. The determination of indicators for such conditions has been proposed 
in the literature in order to enhance the prediction of blood glucose concentration under free 
living conditions. A multivariable model including the galvanic skin response and the energy 
expenditure as additional inputs was proposed by Turksoy et al. (Turksoy et al., 2013) for the 
closed loop system. Towards this direction an extended version of the proposed model 
including the representation of glucose dynamics during exercise could decrease the 
uncertainty of glucose predictability. Stress and illness, which do not constitute a 
deterministic condition, can be regarded as model uncertainty that should be addressed in the 
closed-loop system. 
Robust closed loop insulin delivery  
One of the key challenging issues of closed loop insulin delivery is the high intra- and inter-
patient variability. Even though there has been an effort towards patient-specific glucose 
dynamics predictions with the introduction of patient-specific variables and parameters, as 
well as personalised glucose regulation with the determination of time horizons, TDD, 
scheduling feature and weights of the cost function tailored for each patient, the glycaemic 
variability remains an unpredictable quantity. The factors that influence the ability to predict 
the blood glucose concentration are summarised in Kildegaard et al. (2009) and involve the 
metabolic variability, meal variability, insulin and glucose monitoring variability and lifestyle 
variability. All these factors can significantly affect the blood glucose predictability and make 
the system very challenging to control. In the context of MPC there is a need towards robust 
control designs for insulin delivery systems. Robust control concerns the systems that are 
uncertain in the sense that the actual behaviour of the system cannot be described with 
predictions based on the nominal system (Rawlings and Mayne, 2009). Therefore, in the 
presence of uncertain predictions, robust control ensures that the control actions do not 
violate the constraints and that the optimisation solution always exists (Richards, 2005). The 
uncertainty of the system can be due to unknown additive disturbances, model mismatch and 
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simplifications (Rawlings and Mayne, 2009). The system can be expressed as the LTI system 
with unmeasured disturbance (Bemporad and Morari, 1999): 
𝑥𝑡+1 = 𝐴𝑥𝑡 + 𝐵𝑢𝑡 + 𝐻𝑤𝑡,    𝑥(0) = 𝑥0                                       (7.1) 
𝑦𝑡 = 𝐶𝑥𝑡 + 𝐾𝑤𝑡   
With 𝑤(𝑡) ∈ 𝑊 and W is a bounded set.  
Another way to include the uncertainty in the system is with parametric uncertainty: 
𝑥𝑡+1 = 𝐴(𝜃)𝑥𝑡 + 𝐵(𝜃)𝑢𝑡                   (7.2) 
𝛩 = {𝜃𝑙𝑏 ≤ 𝜃𝑘 ≤ 𝜃𝑢𝑏; ∀𝜃 ∈ ℝ
𝑞} 
[𝐴(𝜃), 𝛣(𝜃)] ∈ 𝛺, where Ω is a pre-specified polytope. 
These types of uncertainties (7.1-7.2) can occur in the same application. The problem 
traditionally is approached by minimising the worst-case scenario (maximum w) based on 
open loop predictions but this can lead to over-conservative control performance (Sakizlis, 
M.P. Kakalis, et al., 2004), (Bemporad and Morari, 1999). Many different proposals of 
feedback Robust MPC have been proposed and can be found in the literature (Rawlings and 
Mayne, 2009), (Langson et al., 2004), (Maciejowski, 2002). 
On-line parameter estimation 
A complementary approach to decrease the system uncertainty is to estimate on-line the 
model parameters which contribute significantly to the system dynamics. This method aims to 
address the uncertainty originated from the metabolic variability such as alterations in insulin 
sensitivity. A Bayesian approach was used by (Hovorka et al., 2004) to update the values of 
certain parameters. An on-line parameter estimation formulated as a least-squares problem is 
evaluated in (Krieger and Pistikopoulos, 2014) for the case of anaesthesia. The relevance of 
the underlying physiology to the model parameters that need to be updated provides useful 
directions for the problem simplification.    
Model reduction techniques  
In the considered insulin-delivery system the internal model used for the control design is a 
large linear model. Combined with the involved large time horizons the development of the 
optimal control design (offline; development of mpMPC) can be indeed very challenging due 
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to the increased computational complexity. Model reduction techniques can be used as an 
alternative to overcome the limitations of large or inaccurate models by deriving simple but 
precise models to describe the dynamics of non-linear, complex systems. In this case, the 
development of explicit multi-parametric MPC could be feasible.   
Explicit Model Predictive Control / Robust mp-MPC 
In order to overcome the significant online computations involved in the closed-loop optimal 
control implementation an alternative solution of the on-line optimisation problem has been 
proposed (Pistikopoulos et al., 2002), (Pistikopoulos, Georgiadis and Dua, 2007a), 
(Pistikopoulos, Georgiadis and Dua, 2007b), which relies on a parametric optimisation-based 
approach. In essence, the online solution of the optimisation problem is replaced by the off 
line derivation of the explicit mapping of the optimal decisions in the space of the plant 
uncertainty. The ability to solve off-line the MPC optimisation problem makes the mp-MPC 
technology ideal for implementation on a simple hardware like a chip, “MPC-on-a-chip”, for 
portable or embedded devices (Pistikopoulos, 2012). For the closed loop insulin delivery 
system, although there has been tremendous progress in the involved device technology 
(insulin pump, smartphones, CGMS) and their interconnectivity a controller solved offline 
through simple function evaluation and implemented on a chip can enhance the reliability of 
the entire system. In Dassau et al. (2013) the performance of mp-MPC has been clinically 
evaluated for the closed loop delivery of insulin resulting in very encouraging outcomes using 
this technology. Appendix C focuses with the development of mpMPC controllers in the 
context of the proposed control designs presented in section 6.4.3. Further in-silico validation 
studies are required to gain confidence in the mpMPC control formulation. The derivation of 
robust mp-MPC has gained vast consideration in the literature. The combination of the two 
involved theories has been examined in (Bemporad, Borrelli and Morari, 2003), 
(Manthanwar, Sakizlis and Pistikopoulos, 2005), (Sakizlis, M.P. Kakalis, et al., 2004), 
(Kouramas, Sakizlis and Pistikopoulos, 2009), and can be a promising potential for the 
challenging system of insulin delivery.  
Further Developments towards the Artificial Pancreas 
Towards the development of an artificial pancreas the validation of the proposed closed loop 
strategy in a real experimental set-up is required. This implies firstly the validation of the 
proposed model and secondly the derived control strategy. The use of the UVa/Padova 
Simulator for the derivation of the approximate model as well as the virtual patient has 
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presented efficient glucose regulation in the closed loop system (Appendix A.2). 
Additionally, the testing of the derived control strategy on the UVa/Padova Simulator as the 
virtual patient in many cases has shown good control performance. Further in-silico 
validation can increase the level of confidence for the proposed closed loop design. The 
substitution of online MPC in the presented control designs with mpMPC will improve the 
reliability of the automated closed loop insulin delivery system. Towards this direction 
Appendix C explains the formulation of the system but further simulation studies are required 
to define efficiently the system’s specifications to achieve tight glycaemic control.  
Additionally, incorporation of complementary components such as Insulin-on-Board and 
hypoglycaemia alarms could improve the closed loop control performance especially in the 
case of skipped meals.    
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APPENDIX A 
 
  A.1 Model of UVa/Padova Simulator  
Glucose Metabolism: A two compartment model is used to model the glucose subsystem 
with Gp and Gt representing the plasma and tissue glucose mass (mg/kg) respectively.  
𝑑𝐺𝑝
𝑑𝑡
= 𝐸𝐺𝑃 + 𝑅𝑎 − 𝑈𝑖𝑖 − 𝐸 − 𝑘1𝐺𝑝 + 𝑘2𝐺𝑡    Gp(0)=Gpb            (A.1) 
𝑑𝐺𝑡
𝑑𝑡
= 𝑘1𝐺𝑝 − 𝑘2𝐺𝑡 − 𝑈𝑖𝑑      Gt(0)=Gtb            (A.2) 
𝐺 =
𝐺𝑝
𝑉𝑔
        G(0)=Gb                 (A.3) 
The EGP (mg/kg/min) is the endogenous glucose production, the Ra (mg/kg/min)the rate of 
glucose appearance in the bloodstream after meal consumption, Uii and Uid (mg/kg/min) are 
the insulin independent and insulin dependent glucose utilisation, E(mg/kg/min) is the renal 
glucose excretion,  k1,k2 (min
-1
) are rate parameters of glucose kinetics and Vg(dl) is the 
glucose distribution volume.  
Rate of glucose appearance (Ra) from meal 
𝑑𝑄𝑠𝑡𝑜1
𝑑𝑡
= −𝑘𝑘𝑔𝑟𝑖𝑄𝑠𝑡𝑜1 +𝐷𝛿(𝑡) Qsto1(0)=0 (A.4) 
𝑑𝑄𝑠𝑡𝑜2
𝑑𝑡
= −𝑘𝑒𝑚𝑝𝑡𝑄𝑠𝑡𝑜2 + 𝑘𝑔𝑟𝑖𝑄𝑠𝑡𝑜1 Qsto2(0)=0 (A.6) 
𝑑𝑄𝑔𝑢𝑡
𝑑𝑡
= −𝑘𝑎𝑏𝑠𝑄𝑔𝑢𝑡 + 𝑘𝑒𝑚𝑝𝑡𝑄𝑠𝑡𝑜2 Qgut(0)=0 (A.7) 
𝑄𝑠𝑡𝑜 = 𝑄𝑠𝑡𝑜1 + 𝑄𝑠𝑡𝑜2 Qsto(0)=0 (A.8) 
𝑅𝑎 =
𝑓𝑘𝑎𝑏𝑠𝑄𝑔𝑢𝑡 (𝑡)
𝐵𝑊
 Ra(0)=0 (A.9) 
𝑘𝑒𝑚𝑝𝑡 = 𝑘𝑚𝑖𝑛 +
𝑘𝑚𝑎𝑥−𝑘𝑚𝑖𝑛
2
{tanh (𝑎1(𝑄𝑠𝑡𝑜 − 𝑏 ∙ 𝐷(𝑡))) − tanh (𝑏1(𝑄𝑠𝑡𝑜 − 𝑑 ∙ 𝐷(𝑡))) + 2}   
(A.10) 
a1 =
5
2∙𝐷∙(1−𝑏)
                   (A.11) 
b1 =
5
2∙𝐷∙𝑑
                              (A.12) 
With Qsto1, Qsto2 (mg) the glucose mass in solid and liquid phase, Qsto (mg) the overall glucose 
mass in the stomach, Qgut (mg) is the glucose mass in the small intestine, kempt (min
-1
) is the 
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rate of gastric emptying, a1 and b1 are model parameters, kmax, kmin (min
-1
)are the max and 
min gastric emptying, kabs (min
-1
) is the rate constant of intestinal absorption, kgri is the rate 
constant of grinding, f (dimensionless) is the fraction of intestinal absorption, b and d are 
percentages of the dose and D (mg)  is the amount of ingested meal. 
Endogenous Glucose Production (EGP)  
𝐸𝐺𝑃 = 𝑘𝑝1 − 𝑘𝑝2𝐺𝑝 − 𝑘𝑝3𝐼𝑑𝑒𝑙2   EGP(0)=EGPb                      (A.13) 
𝑑𝐼𝑑𝑒𝑙1
𝑑𝑡
= −𝑘𝑖(𝐼𝑑𝑒𝑙1 − 𝐼𝑝)    I1(0)=Ipb           (A.14) 
𝑑𝐼𝑑𝑒𝑙2
𝑑𝑡
= −𝑘𝑖(𝐼𝑑𝑒𝑙2 − 𝐼𝑑𝑒𝑙1)    Id(0)=Ipb           (A.15) 
With Idel2 (pmol/l) the delayed insulin signal (chain of two compartments), kp1 (mg/kg/min) 
the extrapolated EGP at zero glucose and insulin, kp2 (min-1) the liver glucose effectiveness, 
kp3 (mg/kg/min per pmol/l) the insulin action on the liver and ki (min
-1
) the rate parameter for 
the delay between insulin signal and action 
Insulin dependent glucose utilization  
𝑈𝑖𝑑 =
𝑉𝑚𝐺𝑡
𝑘𝑚0+𝐺𝑡
      Uid(0)=Uidb           (A.16) 
𝑉𝑚 = 𝑉𝑚0 + 𝑉𝑚𝑥𝑋𝑑𝑖𝑠𝑝     Vm(0)=Vm0            (A.17) 
𝑑𝑋𝑑𝑖𝑠𝑝
𝑑𝑡
= −𝑝2𝑢𝑋𝑑𝑖𝑠𝑝 + 𝑝2𝑢(𝐼𝑝 − 𝐼𝐵𝐴𝑆𝐴𝐿)  Xdisp(0)=0           (A.18) 
𝑈𝑡𝑜𝑡 = 𝑈𝑖𝑖 + 𝑈𝑖𝑑                            (A.19)
   
With Xdisp (pmol/L) insulin in the interstitial fluid, Vm0 (mg/kg/min) and km0 (mg/kg) the 
Michaelis–Menten related parameters, Vmx (mg/kg/min per pmol/liter) the disposal of insulin 
sensitivity and p2u (min-
1
) the rate constant of insulin action on peripheral glucose utilization. 
Glucose Renal Excretion  
𝐸 = {
𝑘𝑒1(𝐺𝑝 − 𝑘𝑒2)
0
  
𝑖𝑓 𝐺𝑝 > 𝑘𝑒2
𝑖𝑓 𝐺𝑝 ≤ 𝑘𝑒2
         E(0)=0            (A.20) 
With ke1 (min
-1
) the glomelural filtration rate and ke2(mg/kg) the glucose renal threshold 
 
Insulin Kinetics  
𝑑𝐼𝑠𝑐1
𝑑𝑡
= −(𝑘𝑑 + 𝑘𝑎1) ∙ 𝐼𝑠𝑐1 + 𝑢(𝑡)    Isc1(0)=Isc1ss                      (A.21) 
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𝑑𝐼𝑠𝑐2
𝑑𝑡
= 𝑘𝑑𝐼𝑠𝑐1 − 𝑘𝑎2𝐼𝑠𝑐2     Isc2(0)=Isc2ss                          (A.22) 
𝑑𝐼𝑙
𝑑𝑡
= −(𝑚1 +𝑚3)𝐼𝑙 +𝑚2𝐼𝑝   Il(0)=Ilb           (A.23) 
𝑑𝐼𝑝
𝑑𝑡
= −(𝑚2 +𝑚4)𝐼𝑝 +𝑚1𝐼𝑙 + 𝑘𝑎1𝐼𝑠𝑐1 + 𝑘𝑎2𝐼𝑠𝑐2  Ip(0)=Ipb                      (A.24) 
𝐼 =
𝐼𝑝
𝑉𝑖
        I(0)=Ib             (A.25) 
𝑚3 =
𝐻𝐸𝑏𝑚1
1−𝐻𝐸𝑏
                   (A.26) 
With Il (pmol/kg)the insulin mass in liver, Ip (pmol/kg) insulin mass in the plasma, I (pmol/l) 
the plasma insulin concentration, Isc1(pmol/kg) the amount of non-monomeric insulin in the 
subcutaneous space, Isc2 (pmol/kg) the amount of monomeric insulin in the subcutaneous 
space, u(t) (pmol/kg/min) the exogenous insulin infusion rate, m1,m2,m3,m4 (min
-1
) the rate 
parameters of insulin kinetics, VI (L/kg) the insulin distribution volume, kd (min
-1
) the rate 
constant of insulin dissociation, ka1 (min
-1
) the rate constant of non- monomeric insulin 
absorption and ka2 (min
-1
) the rate constant of monomeric insulin absorption.  
A.2 Model Predictive Control Framework 
The general framework used for the control design to regulate the BG concentration is 
presented in Figure A.2.1, as also showed in Chapter 7. It involves the development of a high 
fidelity model that accurately predicts the glucose-insulin dynamics in T1DM, the 
simplification of the original model with system identification or model order reduction 
techniques to derive a reliable approximation of the system dynamics and finally the design 
of the appropriate control strategy. In the MPC formulation one of the key components is the 
approximate model that needs to be relatively simple to facilitate the computational 
complexity, but also very informative to include the entire system dynamics. In this section, 
the involved steps of closed loop insulin delivery are presented while emphasis is given on 
the importance of developing a reliable, patient-specific approximate model for MPC. 
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Figure A.2.1: Framework for MPC controllers design  
 
1.  “High Fidelity” Model 
The mathematical model used in this study as a virtual patient for closed loop control 
validation studies as well as to derive approximate models necessary for model based control 
is the model developed by the Cobelli group (Dalla Man, Rizza and Cobelli, 2007), (Dalla 
Man et al., 2007), and presented in section A.1. The model is simulated in gPROMS using 
individual patient parameters obtained from the commercial UVa/Padova Simulator for 10 
adults.  
2. The Approximate Model 
Two methods are employed to derive an accurate linear approximate model suitable for 
control purposes. The first presented method is system identification and the second model 
linearisation and reduction. 
System Identification 
The linear model describing the dynamics of the glucose-insulin interactions was determined 
using the System Identification Toolbox of MATLAB. Due to the complexity caused by the 
inherent nonlinearities of the system the linear model was built by identifying two separate 
transfer functions describing the insulin-glucose and food-glucose interactions. The two 
models are then combined by taking into account the involved time delays for each 
component and then it is converted in a state space formulation.  
z
delayU
p1 p2 p3
delayF
p1 p2 p3
p
z
p
(1+T )s
G(s) = k exp(-T s)×Insulin(s)
(1+T s)(1+T s)(1+T s)
(1+T )s
G(s) = k exp(-T s)×Food(s)
(1+T s)(1+T s)(1+T s)
  
               (A.27) 
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The time delays are replaced with a second order Padé approximation: 
exp(−𝜃𝑠) ≈
1 − 𝑘1𝑠 − 𝑘2𝑠
2
1 + 𝑘1𝑠 + 𝑘2𝑠2 
(A.28) 
The applied methodology is presented for patient no2. Input/ Output data obtained from 
simulating the original model are used to identify the process model. The identified values of 
the model parameters of (A.27) are shown in Table A.2.1 
Table A.2.1: Identified parameters of transfer function models 
Effect of Insulin Effect of Meal 
Symbol Value Symbol Value 
kp 4.271e-07 kp 1.933 
Tz -13.931 Tz 1.917e+05 
Tp1 51.953 Tp1 1.214e+07 
Tp2 5.912 e+02 Tp2 1.295e+02 
Tp3 1.184e+10 Tp3 1.297e+02 
Tdelay 50 Tdelay 16.8 
The accuracy of the identified transfer functions is shown in Figure A.2.2 for the effect of a 
meal containing 90 g of carbohydrates on BG concentration and in Figure A.2.3 for the effect 
of 10U of insulin. The approximation error is 11.79% and 6.8% respectively. 
 
Figure A.2.2: Comparison of original model and TF for meal effect on glucose when 90 g of 
carbohydrates are consumed 
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Figure A.2.3: Comparison of original model and TF for insulin effect on glucose when a bolus of 10U 
is given 
The involved time delays are included in the converted state space model as additional states. 
The resulting continuous state space model is discretised with sampling time ts = 5 min that 
represents the time to receive a BG reading with a continuous blood glucose monitoring 
system. 
The glucose profile when 45 g of carbohydrates and 6U of insulin are given is shown in 
Figure A.2.4 for the original model and the identified state space model. 
 
Figure A.2.4: Comparison of original model and state space model 
The fit of the model to the original data is calculated with (5.8) and is: Fit=84.5% 
The identified model as seen in Figure A.2.4 represents accurately the system dynamics in the 
presence of meal disturbances. Hence, it can be regarded as a reliable prediction tool for 
closed loop studies. 
The advantage of this model is that it distinguishes the time delay factors coming from insulin 
and from food; hence it can be used straightforwardly in time delay control approaches. The 
disadvantage is that the resulting state space model is large (10 states) and that the states are 
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artificial in terms of not describing the physiological states and therefore the information 
inside the system is limited.  
Linearisation 
The model of UVa/Padova Simulator is linearised. The linear model involves 12 states: 
𝑥 = [𝐺𝑝 𝐺𝑡 𝑋𝑑𝑖𝑠𝑝 𝑄𝑠𝑡𝑜1 𝑄𝑠𝑡𝑜2 𝑄𝑔𝑢𝑡 𝐼𝑑𝑒𝑙1 𝐼𝑑𝑒𝑙2 𝐼𝑠𝑐1 𝐼𝑠𝑐2 𝐼𝑙 𝐼𝑝]′ 
When the model is linearised at the steady state, an approximation of constant physiological 
conditions, the glucose concentration does not coincide with the profile of the original model 
in the presence of meal disturbances and insulin boluses, resulting in large off-set. To 
overcome the difficulty to find stable equilibrium points during meal consumption and insulin 
absorption, that trigger the system away from the steady state, and to capture the dynamics of 
the system during fasting, prandial and postprandial conditions of different meal size and 
insulin boluses, a series of parameter estimation studies are performed to estimate the values 
of specific parameters of the linear model related to meal and insulin absorption that are 
described with nonlinear equations. The parameter estimation studies are performed in 
gPROMS and involve the design of patient specific in silico experiments of different meal 
plans and insulin regimens that take into consideration: 
1) Effect of one meal on BG concentration- no bolus is considered (Experiment A) 
2) Effect of one bolus on BG concentration –no meal is considered (Experiment B) 
3) Effect of one meal and bolus given simultaneously (Experiment C) 
4) Steady state –no bolus and meal are considered (Experiment D) 
5) Day simulation with different meal sizes and bolus doses (Experiment E) 
The values of the estimated parameters are presented in Table A.2 for the 10 adults.  
Physiologically based Model Reduction 
In order to reduce the computational complexity in a control application caused by the 
relatively large size of the previously presented 12 states linear physiological model, 
physiologically based model order reduction is used to mathematically transform the model 
equations such that to provide the same dynamical behaviour but in a smaller size system. 
The involved time delays of the system both in glucose absorption from food and in insulin 
absorption through the subcutaneous tissue does not allow the lumping of many 
compartments and further simplification of the model.  The equations to be reduced are the 
states [Isc1 Isc2 Il Ip]′. The compartments Isc1 and Ip are forced to be left unmodified since 
they are used in other equations in the model.  
APPENDIX A 
 
160 
 
 
The linear equations are described with the general formulation:  
dy
𝑑𝑡
= 𝐾𝑦                  (A.29) 
where y= 1 2[    ]
T
sc sc l pI I I I  and K=
0 0 01
0 02
0 0 ( )1 3 2
( )1 2 1 2 4
k kad
k kad
m m m
k k m m ma a


 
 
 
 
 
  
 
 
The new system is described by (A.31) where K̂ is the new set of parameters with rank n = 2. 
The new parameters are found by solving a maximum likelihood parameter estimation 
problem in gPROMS that determines the values of the new set of parameters that maximise 
the probability that the new mathematical equations will predict the dynamics of the original 
model that is used to specify suitable experiments obtained from the experiments. 
𝑑?̂?
𝑑𝑡
= ?̂?𝑦  (A.30)
 
The set of the reduced equations is defined as: 
𝑑
𝑑𝑡
⌊
𝐼𝑠𝑐1
𝐼𝑝
⌋ = ⌊
𝐴(9,9) 𝐴(9,10)
𝐴(10,9) 𝐴(10,10)
⌋ ⌊
𝐼𝑠𝑐1
𝐼𝑝
⌋       
The values of the parameters are presented in Table A.2 for the 10 patients.  
Hence, the states of the reduced model are: 
𝑥𝑟𝑒𝑑 = [𝐺𝑝 𝐺𝑡 𝑋𝑑𝑖𝑠𝑝 𝑄𝑠𝑡𝑜1 𝑄𝑠𝑡𝑜2 𝑄𝑔𝑢𝑡 𝐼𝑑𝑒𝑙1 𝐼𝑑𝑒𝑙2 𝐼𝑠𝑐1 𝐼𝑝]′ 
Further reduction of the model states lead to loss of the system dynamics. The model is 
discretised with ts=5 min. Figure A.5 compares the dynamic model with the state space 
reduced order model and Figure A.6 shows the accuracy of the linearised model. 
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Figure A.2.5: Comparison of full state and reduced linearised model for patient no2.  
 
Figure A.2.6: Comparison of original model and linearised model when 50 g of carbohydrates are 
consumed and a 5 U bolus is given to patient no 2 
The model accuracy is calculated using (5.8) for patient no 2 is 81%. Although the 
performance error for both models is similar, the linearised model is used for the rest of this 
study, since it enfolds information of the states of the original model, and the patient specific 
parameters can by identified with a systematic approach. 
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Table A.2.2: Estimated parameters of linearised model for10 adults 
 Experim. Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
A(2,2) C,D,E -0.10475 -0.12086 -0.30005 -0.1493 -0.21861 
A(2,3) C,D,E -0.01763 -0.01307 -0.01682 -0.065476 -0.00679 
A(5,5) A -0.00516 -0.01893 -0.00897 -0.018062 -0.00361 
A(6,4) A  0.01314 0.00157 0.00314 0.0098701 0.01552 
Bd(2,1) C,D,E 1.627 0.17399 2.2616 3.9858 0.50847 
 Reduced Model 
A(9,9) B,E -0.043407 -0.018901 -0.020299 -0.018992 -0.025647 
A(9,10) B,E 2.8998E-5 0.0 -1.073E-6 -6.346E-6 2.2079E-5 
A(10,9) B,E 0.003991 0.001407 0.0010587 0.0024120 0.004241 
A(10,10) B,E -0.026149 -0.021764 -0.01929 -0.021041 -0.04864 
  Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 
A(2,2) C,D,E -0.07788 -0.13319 -0.08963 -0.17237 -0.21344 
A(2,3) C,D,E -0.024081 -0.049294 -0.01747 -0.00375 -0.01069 
A(5,5) A -0.015856 -0.014347 -0.00743 -0.02216 -0.01217 
A(6,4) A -0.000119 6.3868E-4  0.00442 -3.458E-7 -1.407E-5 
Bd(2,1) C,D,E 3.516 1.5165 1.4351 0.72648 2.1189 
 Reduced Model 
A(9,9) B,E -0.012480 -0.020122 -0.025168 -0.018841 -0.017661 
A(9,10) B,E -4.983E-8 -1.460E-8 -2.548E-8 -1.053E-7 -3.308E-8 
A(10,9) B,E 8.2755E-4 0.001284 0.0018019 0.001677 0.001356 
A(10,10) B,E -0.018837 -0.013686 -0.014726 -0.030188 -0.022085 
 
The advantage of the linearised model over the previously presented model is that the states 
represent the states of the original model and therefore the deep knowledge of the system’s 
behaviour facilitates the design of control studies. Yet again, this model is large which makes 
the design of explicit MPC relatively difficult.    
The matrices of the linear state space model are presented below. The matrix Bd accounts for 
the basal level of the states.  
A=   
( ) 0 0 0 / 0 0 0 0 02 1 2 3
( , , ) ( , , ) 0 0 0 0 0 0 0 0 01 2 0 0
0 0 0 0 0 0 0 0 0 0 /2 2
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 /
0 0 0 0 0 0 0 0 1
k k k k f BW kp abs p
k k f V k G f V k Gm km t mx km t
p p Vu u i
k gri
k kgri empt
k k kest empt abs
k ki i
k k Vi i i
k kd a
  
  






 0 0 0
0 0 0 0 0 0 0 0 0 02
0 0 0 0 0 0 0 0 0 0 1 3 2
0 0 0 0 0 0 0 0 1 2 1 2 4
k kd a
m m m
k k m m ma a



 
 
 
 
 
 
 
 
 
 
 
 
 
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B=
0 0
0 0
0 0
1
0
0 0
0 0
6000
0
0 0
0 0
0 0
D
BW
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
,  Bd=
1
1
*
2
0
0
0
0
0
0
0
0
0
k U
p ii
kest
p I
u BASAL


 
 
 
 
 
 
 
 
 
 
 
 
  
,  C=
1
0 0 0 0 0 0 0 0 0 0 0
Vg
 
 
  
, D=  0 0  
 
3. Control Design 
The proposed control design regulates the glucose concentration when a reference meal plan 
is considered and additionally responds appropriately to compensate for the deviation from 
the reference meal when a different size meal is consumed. 
 
Figure A.2.7: Proposed control strategy to compensate for unknown meal disturbances consisting of 
two controllers, the reference control that regulates glucose for a reference meal plan and the 
correction control that regulates the difference of the glucose due to real and reference meal plan.    
MPC 1: Reference Control 
The desired glucose value Gref1 is set by the endocrinologist for every patient. A predefined 
reference meal plan is considered to trigger the control action. Feedback about the current 
state is obtained by the model output yref   as calculated when the reference tracking problem 
with announced disturbance is solved and the optimal insulin infusion is applied.   
MPC 2:  Correction Control 
MPC 2 aims to find the optimal insulin infusion rate to regulate the difference of glucose as a 
real measurement coming from the patient, G and glucose as calculated when solving the 
MPC 1 
Patient 
u1 
G 
Gref1 
d 
 ,  ̂ 
MPC 2 
State 
Estimator u2 
Gref2 
Reference Control 
Correction Control 
yref 
G-yref 
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reference control problem, yref. This difference can be regarded as an unmeasured disturbance 
of the system, that leads to an offset in the set point, Gref,2=0. So the correction control is 
described as a disturbance rejection problem. In order to remove the offset and the nonzero 
disturbances the original system is augmented with a disturbance model, as presented in 
Chapter 8. In order to reduce the computational effort the states describing the meal 
absorption [Qsto1 Qsto2 Qgut]′ are removed from the state space model. The output 
feedback of the patient is obtained as the difference of the actual measurement and the 
reference control output (G-yref) and the state feedback is obtained by a state estimator that 
provides information about the current state of the patient and the additional disturbance.  
The matrix 𝐵𝑑 ∈ ℝ
𝑛×𝑛𝑑  is chosen to be the Bd matrix of Section A.3 and matrix𝐶𝑑 =
𝐼 ∈ ℝ𝑛𝑑×𝑛𝑑. The new derived augmented linear model (𝑛 = 7, 𝑛𝑑 = 1) is detectable, see 
(A.31), which means that the states will converge to the real states when a Kalman filter is 
used, hence this strategy can be employed: 
𝑟𝑎𝑛𝑘 [
𝐼 − 𝐴 −𝐵𝑑
𝐶 𝐶𝑑
] = 𝑛 + 𝑛𝑑 = 8                 (A.31) 
The estimated states are:  
?̂? = [𝐺𝑝 𝐺𝑡 𝑋𝑑𝑖𝑠𝑝 𝐼𝑑𝑒𝑙1 𝐼𝑑𝑒𝑙2 𝐼𝑠𝑐1 𝐼𝑝 𝑑]′ 
And 𝑦2 = 𝐺 − 𝑦𝑟𝑒𝑓. The control specifications for MPC 2 are presented in Table A.2.3:  
Table A.2.3: Specifications of MPC 2 and the Kalman Filter 
Variable Value Variable Value Variable Value 
y2,min -10        mg/dl umin 0         U/min ?̂? 100 
Y2,max  10        mg/dl umax 0.02    U/min ?̂? 5 
 
4. Simulation Results 
In this section the control designs are evaluated for predefined, announced and unknown 
disturbances for 10 adults with T1DM, provided by the Simulator. The model is developed in 
gPROMS, while the control designs in MATLAB and gO:MATLAB to exchange data 
between the two environments.   The control designs are denoted as follows: 
CD1 Online MPC, with predefined disturbance 
CD2 Online MPC with scheduling level for announced disturbance 
CD3 Reference and Correction MPC for unmeasured disturbance 
CD4 Online MPC, with unmeasured disturbance 
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A. Predefined and Announced Disturbances 
The results are illustrated in Figure A.2.8. Meal of 45 70 and 60 g of carbohydrates is 
consumed at 420, 720 and 1080 min.    
  
  
  
 
Figure A.2.8: MPC control for 10 adults of UVa/Padova Simulator for measured and announced meal 
disturbances; Upper graphs blood glucose concentration (mg/dl) profiles; lower graphs control action, 
insulin (U/min) 
It can be noticed that tight glycaemic control can be achieved in the presence of predefined or 
announced disturbances. 
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B. Unknown Disturbance rejection 
In this section the CD3 control design as explained before is evaluated.  The ability of the 
controller to maintain the blood glucose concentration in the normal range is tested for large 
meal sizes of 75, 100 and 90 g of carbohydrates given for breakfast at 7:00 am, lunch at 13:00 
pm and dinner at 18:00pm respectively. The reference meal plan is 20, 30 and 25 g 
respectively.  The results are compared to the CD4 for the same meal sizes and presented in 
Table A.2.4 and Table A.2.5.  
Table A.2.4: CD3 (predefined meal plan) 
 % time 
<70 
% time 
<80 
% time 
80<G <140 
% time 
140<G <180 
% time 
180<G <250 
% time 
>250 
Gmin 
(mg/dl) 
Gmax 
(mg/dl) 
Adult1 0 1.7 44.4 38.9 14.9 0 72 247 
Adult2 0 0 68.4 28.4 3.1 0 83 187 
Adult3 0 5.9 36.4 49.3 8.3 0 76 233 
Adult4 0 0 52.8 44.8 2.4 0 87 181 
Adult5 0 1.7 59.7 18.4 20.1 0 76 228 
Adult6 0 5.5 56.6 14.9 22.9 0 76 226 
Adult7 0 0 67.0 20.1 12.8 0 82 205 
Adult8 0 6.2 57.6 28.8 7.3 0 75 226 
Adult9 0 2 57.6 27 12.5 0 71 250 
Adult10 0 2.1 45.5 24.0 21.9 6.5 76 276 
Mean 0 2.5 54.6 29.46 12.62 0.65 77.4 225.9 
SD 0 2.4 10.1 11.4 7.4 2.0 5.0 28.9 
 
Table A.2.5:CD4 (unmeasured) 
 % time 
<70 
% time 
<80 
% time 
80<G <140 
% time 
140<G <180 
% time 
180<G <250 
% time 
>250 
Gmin 
(mg/dl) 
Gmax 
(mg/dl) 
Adult1 0.3 2.4 54.5 15.3 24.3 3.5 69 269 
Adult2 0 2.1 54.5 25.7 17.7 0 74 205 
Adult3 4.5 5.9 44.4 38.2 10.1 1.4 43 256 
Adult4 7.6 10.7 20.5 46.2 22.6 0 59 249 
Adult5 0 0 49.6 23.6 26.7 0 83 237 
Adult6 4.8 6.2 48.2 11.4 31.5 2.4 53 252 
Adult7 6.6 12.8 52.8 9.1 16.1 8.6 58 288 
Adult8 7.6 9.7 50.3 32.3 6.9 0 59 208 
Adult9 0 0 44.7 35 14.2 5.9 85 283 
Adult10 0 2.8 31.0 30.0 30.2 6.2 73 295 
Mean 3.1 5.3 45.0 26.7 20.0 2.8 65.6 254.2 
SD 3.4 4.6 11.0 12.0 8.4 3.1 13.4 31.2 
 
Table A.2.4 shows that with CD3, on average the 54% of the time is spent within the normal 
glucose values, while with CD4 the percentage of the time spent in the normal rage in 45%. 
With CD3 there is no event of hypoglycaemia and the minimum observed glucose value is 
71mg/dl for adult 9, in opposition to CD4 that an average 3.1% of the time is spent in 
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hypoglycaemia with a minimum observed glucose value of 43mg/dl. Additionally, the time 
spent in hyperglycaemia ( >180mg/dl) is much higher for CD4 with a 22.8% of the time, 
while for CD3 the respective percentage is 13.3%. The glucose profile and the control action 
with both CD3 and CD4 are presented in Figure A.2.9 for adult 6 for illustrative purposes. 
    
Figure A.2.9: Comparison of glucose regulation with control design 3 and 4 for adult 6. The meals 
are given at 420, 720and 1080 min and contain 75, 100 and 90 gof carbohydrates respectively.  
 
Variable Meal Time  
Figure A.2.10 shows the glucose profile for adult 6 when a meal of 50 g is given 30min 
before, 30min after and simultaneously with the predefined 30 g reference meal. It can be 
noticed that good glycaemic control is achieved in all cases with no occurring event of 
hypoglycaemia. When the meal is consumed 30min before the predetermined meal time 
prandial hyperglycaemia is occurring since insulin is not acting yet.  
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Figure A.2.10: Evaluation of CD3 when a meal of 50 g is given 30min in advance, 30 min after and 
simultaneous with the reference meal of 30 g 
 
C. Concluding Remarks 
The closed loop control validation studies show that the proposed control design CD3 can 
efficiently regulate the blood glucose concentration when tested for large meal sizes. There is 
no reported event of hypoglycaemia while the mean maximum glucose value being 226 
mg/dl. When this control design is compared with CD4 it becomes obvious that superior 
control can be achieved when the feed forward action of the MPC controller is enhanced in 
the presence of unknown meal disturbances. Further closed loop validation studies are 
required to verify the reliability of the proposed control performance. Hence, the proposed 
control strategy can be regarded as a potential strategy to compensate for the unknown meal 
disturbances since the validation studies performed for the UVa/Padova Simulation model as 
well as the proposed model, shown in Chapter 6, indicate promising closed loop glucose 
regulation. 
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APPENDIX B 
B.1 Parameter Estimation 
The estimated parameters for each patient are presented in detail in the following tables. The 
reported confidence interval for each value is a measure of the estimated precision, indicating 
that the smaller the interval the more reliable the estimated value is.  
 
 
Table B.1: The optimal estimated values for each parameter for the 10 patients and the corresponding (95%) 
confidence interval that indicates that there is 0.95 probability the value of the parameter to be within the 
interval   
Patient k1 k2 kelim ksub Vdist ru,L 
 Estimate 6.29E-05 1.17E-02 8.96E-01 1.21E-02 2.24E-02  0.15 
1 SD 1.18E-06 4.37E-04 1.44E-01 3.08E-05 3.58E-03 3.74E-02 
 CI (±2.32E-06) (±8.57E-04) (±2.81E-01) (±6.04E-05) (±7.03E-03) (±0.073) 
 Estimate 1.09E-04 1.42E-02 1.35E+00 2.04E-02 1.00E-02  0.22 
2 SD 1.59E-06 2.45E-04 1.14E-01 2.75E-05 8.51E-04 0.036 
 CI (±3.12E-06) (±4.79E-04) (±2.24E-01) (±5.40E-05) (±1.67E-03) (±0.051) 
 Estimate 2.67E-04 4.53E-02 3.00E-01 1.88E-02 5.16E-02  0.12 
3 SD 6.03E-06 1.06E-03 2.83E-03 1.17E-05 4.88E-04 1.20E-02 
 CI (±1.188E-05) (±2.09E-03) (±5.56E-03) (±2.31E-05) (±9.61E-04) (±0.002) 
 Estimate 2.74E-04 2.22E-02 1.97E+00 1.97E-02 1.00E-02  0.11 
4 SD 2.20E-05 2.05E-03 8.32E-02 8.71E-06 4.23E-04 4.70E-03 
 CI (±4.33E-05) (±4.03E-03) (±1.63E-01) (±1.71E-05) (±8.30E-04) (±0.009) 
 Estimate 4.59E-05 1.63E-02 1.34E+00 1.94E-02 1.01E-02 0.17 
5 SD 1.98E-06 1.62E-03 1.10E-01 2.47E-05 8.31E-04 1.20E+02 
 CI (±3.88E-06) (±3.17E-03) (±2.15E-01) (±4.85E-05) (±1.63E-03) (±0.042) 
 Estimate 1.79E-04 3.40E-02 2.14E+00 1.51E-02 1.03E-02 0.06 
6 SD 8.44E-06 1.62E-03 1.06E-01 5.79E-06 5.10E-04 4.70E+00 
 CI (±1.68E-05) (±3.18E-03) (±2.09E-01) (±1.14E-05) (±1.00E-03) (±0.001) 
 Estimate 3.83E-04 2.94E-02 1.47E+00 1.66E-02 1.00E-02 0.19 
7 SD 2.19E-05 1.69E-03 7.83E-02 1.05E-05 5.32E-04 2.90E-02 
 CI (±4.29E-05) (±3.32E-03) (±1.54E-01) (±2.06E-05) (±1.04E-03) (±0.057) 
 Estimate 1.56E-04 2.07E-02 1.21E+00 1.96E-02 1.00E-02 0.19  
8 SD 2.80E-05 3.29E-03 5.61E-02 1.52E-05 4.64E-04 6.84E-03 
 CI (±5.51E-05) (±6.45E-03) (±1.10E-01) (±2.98E-05) (±9.10E-04) (±0.13) 
 Estimate 2.11E-05 1.66E-02 1.13E+00 2.46E-02 1.00E-02  0.07 
9 SD 2.79E-06 2.34E-03 1.85E-02 9.23E-06 1.64E-04 5.43E-03 
 CI (±5.47E-06) (±4.59E-03) (±3.62E-02) (±1.81E-05) (±3.22E-04) (±0.001) 
 Estimate 7.86E-05 2.44E-02 1.76E+00 1.98E-02 1.00E-02  0.17 
10 SD 1.37E-05 3.89E-03 1.12E-01 1.53E-05 6.35E-04 3.24E-02 
 CI (±2.69E-05) (±7.63E-03) (±2.19E-01) (±2.99E-05) (±1.25E-03) (±0.063) 
Mean ± SD 
1.58E-04 
±1.18E-04 
2.35E-02 
±1.03E-02 
1.36E+00 
±7.26E-01 
1.86E-02 
±4.48E-03 
1.54E-02 
±1.80E-02 
1.7E-1 
±0.07 
APPENDIX B 
 
170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table B.2: The optimal estimated values for sub model EGP for the 10 patients, the 
standard deviation and the confidence interval 
 ki kp1 kp2 kp3 
 Estimate 3.58E-03 6.52E+00 6.12E-03 2.08E-02 
1 SD 6.34E-05 2.28E-02 1.34E-04 1.42E-04 
 CI (±1.24E-04) (±4.46E-02) (±2.63E-04) (±2.79E-04) 
 Estimate 2.94E-03* 5.03E+00 6.13E-03 1.13E-02 
2 SD   2.17E-02 1.03E-04 1.03E-04 
 CI   (±4.25E-02) (±2.02E-04) (±2.01E-04) 
 Estimate 1.30E-02 5.26E+00 2.44E-03* 1.08E-02 
3 SD 7.81E-05 6.52E-03  2.48E-05 
 CI (±1.53E-04) (±1.28E-02)  (±4.86E-05) 
 Estimate 1.34E-02 7.19E+00 2.44E-03* 2.39E-02* 
4 SD 3.66E-04 4.93E-02   
 CI (±7.17E-04) (±9.67E-02)   
 Estimate 8.18E-03 4.00E+00 7.72E-03 6.64E-03 
5 SD 2.15E-04 6.49E-02 3.78E-04 2.69E-04 
 CI (±4.21E-04) (±1.27E-01) (±7.40E-04) (±5.27E-04) 
 Estimate 1.19E-02 6.53E+00 2.44E-03 1.70E-02 
6 SD 1.07E-04 1.37E-02  5.76E-05 
 CI (±2.11E-04) (±2.69E-02)  (±1.13E-04) 
 Estimate 1.24E-02 7.20E+00* 2.44E-03* 2.39E-02* 
7 SD 1.69E-04    
 CI (±3.31E-04)    
 Estimate 4.44E-03 6.42E+00 6.01E-03 2.17E-02 
8 SD 2.56E-04 7.99E-01 3.10E-03 2.46E-03 
 CI (±5.02E-04) (±1.57E+00) (±6.08E-03) (±4.82E-03) 
 Estimate 4.32E-03 3.97E+00 6.63E-03 7.62E-03 
9 SD 9.26E-05 5.63E-02 2.50E-04 1.19E-04 
 CI (±1.82E-04) (±1.10E-01) (±4.89E-04) (±2.33E-04) 
 Estimate 7.29E-03 4.35E+00 4.99E-03 5.51E-03 
10 SD 9.23E-04 4.93E-01 1.55E-03 5.79E-04 
 CI (±1.81E-03) (±9.66E-01) (±3.03E-03) (±1.13E-03) 
Mean ± SD 
8.15E-03 
±4.23E-03 
5.65E+00 
±1.28E+00 
4.73E-03 
±2.09E-03 
1.49E-02 
±7.35E-03 
*Optimal value at bound 
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*Optimal value at bound 
 
 
 
 
 
 
 
Table B.3: The optimal estimated values for sub model Ra for the 10 patients, the standard 
deviation and the confidence interval 
 b D kabs kmax kmin 
 Estimate 8.80E-01 2.93E-01 5.82E-01* 2.19E-02* 4.55E-03 
1 SD 9.91E-04 7.88E-04   2.01E-05 
 CI (±1.94E-03) (±1.55E-03)   (±3.93E-05) 
 Estimate 7.47E-01 2.00E-01 2.14E-02* 3.04E-02 1.04E-02 
2 SD 8.79E-03 4.84E-03  4.83E-04 1.53E-04 
 CI (±1.72E-02) (±9.49E-03)   (±9.46E-04) (±2.99E-04) 
 Estimate 8.50E-01 1.88E-01 3.25E-02 5.82E-02* 5.72E-03 
3 SD 3.08E-03 9.28E-04 6.79E-04  3.48E-05 
 CI (±6.04E-03) (±1.82E-03) (±1.33E-03)  (±6.82E-05) 
 Estimate 7.36E-01 1.75E-01 5.31E-01 2.51E-02 8.93E-03 
4 SD 7.62E-03 6.59E-03 1.43E-01 4.72E-04 2.21E-04 
 CI (±1.49E-02) (±1.29E-02) (±2.80E-01) (±9.26E-04) (±4.34E-04) 
 Estimate 7.71E-01 2.01E-01 2.21E-02 4.47E-02 5.03E-03 
5 SD 8.71E-03 4.47E-03 1.45E-03 2.62E-03 1.58E-04 
 CI (±1.71E-02) (±8.76E-03) (±2.85E-03) (±5.14E-03) (±3.11E-04) 
 Estimate 8.15E-01 1.09E-01 2.14E-02* 4.32E-02 1.16E-02 
6 SD 1.39E-02 3.72E-03  2.16E-03 1.27E-04 
 CI (±2.72E-02) (±7.28E-03)  (±4.23E-03) (±2.49E-04) 
 Estimate 9.29E-01 1.73E-01 2.14E-02* 2.19E-02* 9.63E-03 
7 SD 1.83E-03 2.84E-03   9.72E-05 
 CI (±3.59E-03) (±5.57E-03)   (±1.91E-04) 
 Estimate 8.60E-01 1.38E-01 4.71E-02 2.81E-02 5.73E-03 
8 SD 1.28E-02 8.56E-03 5.53E-03 2.14E-03 2.42E-04 
 CI (±2.51E-02) (±1.68E-02) (±1.09E-02) (±4.20E-03) (±4.75E-04) 
 Estimate 8.25E-01 3.32E-01 8.34E-02 2.36E-02 3.73E-03 
9 SD 8.16E-03 1.23E-02 7.21E-03 8.05E-04 1.41E-04 
 CI (±1.60E-02) (±2.41E-02) (±1.41E-02) (±1.58E-03) (±2.76E-04) 
 Estimate 8.54E-01 9.82E-02 4.40E-02 5.61E-02 1.09E-02 
10 SD 1.59E-02 7.87E-03 9.05E-03 8.30E-03 3.70E-04 
 CI (±3.12E-02) (±1.54E-02) (±1.77E-02) (±1.63E-02) (±7.26E-04) 
Mean ± SD 
8.27E-01 
±6.10E-02 
1.91E-01 
±7.40E-02 
1.41E-01 
±2.20E-01 
3.53E-02 
±1.41E-02 
7.62E-03 
±2.95E-03 
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B.2 MPC to QP 
The MPC problem, as presented in section 5.4, is formulated in: 
 
min
x,y,u
𝐽 = ∑ xk
′ Qkxk
N−1
k=1
+ ∑(yk − yk
R)
′
QRk(yk − yk
R)
N−1
k=1
+ ∑ uk
′ Rkuk
M−1
k=1
+ ∑ Δuk
′ R1kΔuk
M−1
k=1
 
            s.t 
  xk+1 = Axk + Buk + Edk A.4.1 
yk = Cxk A.4.2 
The prediction of y is obtained by the iteration of the model A.4.1-A.4.2 that can be written in 
matrix –vector form: 
[
 
 
 
 
𝑥1
𝑥2
𝑥3
⋮
𝑥𝑁]
 
 
 
 
=
[
 
 
 
 
𝐴
𝐴2
𝐴3
⋮
𝐴𝑁]
 
 
 
 
𝑥0 +
[
 
 
 
 
𝐵 0 … 0 0
𝐴𝐵 𝐵 … 0 0
𝐴2𝐵 𝐴𝐵 … 0 0
⋮ ⋮ … … …
𝐴𝑁−1𝐵 𝐴𝑁−2𝐵 … 𝐴𝐵 𝐵]
 
 
 
 
[
 
 
 
 
𝑢0
𝑢1
𝑢2
⋮
𝑢𝑁−1]
 
 
 
 
 
+
[
 
 
 
 
𝐸 0 … 0 0
𝐴𝐸 𝐸 … 0 0
𝐴2𝐸 𝐴𝐸 … 0 0
⋮ ⋮ … … …
𝐴𝑁−1𝐸 𝐴𝑁−2𝐸 … 𝐴𝐸 𝐸]
 
 
 
 
[
 
 
 
 
𝑑0
𝑑1
𝑑3
⋮
𝑑𝑁−1]
 
 
 
 
 
The predictions of y are obtained by:  
[
 
 
 
 
𝑦1
𝑦2
𝑦3
⋮
𝑦𝑁]
 
 
 
 
= [
𝐶 0 … 0
0 𝐶 … 0
⋮ ⋮ ⋱ ⋮
0 0 … 𝐶
]
[
 
 
 
 
𝑥1
𝑥2
𝑥3
⋮
𝑥𝑁]
 
 
 
 
 
Hence, in a general form:  
Y=Φx0+ΓU+ΓdD         A.4.4 
Where: 
?̅? ∈ ℝ𝑁𝑛𝑥×𝑛𝑥0   
 
?̅? ∈ ℝ𝑁𝑛𝑥×𝑁𝑛𝑑  𝐷 
A.4.3 
?̅? ∈ ℝ𝑁𝑛𝑥×𝑁𝑛𝑢   
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Φ=
[
 
 
 
 
𝐶𝐴
𝐶𝐴2
𝐶𝐴3
⋮
𝐶𝐴𝑁]
 
 
 
 
 ∈ ℝ𝑁𝑛𝑥×1, Γ=
[
 
 
 
 
𝐶𝐵 0 … 0 0
𝐶𝐴𝐵 𝐶𝐵 … 0 0
𝐶𝐴2𝐵 𝐶𝐴𝐵 … 0 0
⋮ ⋮ … … …
𝐶𝐴𝑁−1𝐵 𝐶𝐴𝑁−2𝐵 … 𝐶𝐴𝐵 𝐶𝐵]
 
 
 
 
∈ ℝ𝑁𝑛𝑥×𝑁𝑛𝑦,   and  
Γd=
[
 
 
 
 
𝐶𝐸 0 … 0 0
𝐶𝐴𝐸 𝐶𝐸 … 0 0
𝐶𝐴2𝐸 𝐶𝐴𝐸 … 0 0
⋮ ⋮ … … …
𝐴𝐶𝑁−1𝐸 𝐶𝐴𝑁−2𝐸 … 𝐶𝐴𝐸 𝐶𝐸]
 
 
 
 
∈ ℝ𝑁𝑛𝑑×𝑁𝑛𝑦 
R is introduced to include the setpoints: 
R=
[
 
 
 
 
 
𝑦1
𝑅
𝑦2
𝑅
𝑦3
𝑅
⋮
𝑦𝑁
𝑅]
 
 
 
 
 
 
The weighing matrices Q, R, QR and R1 are given by: 
?̅? = 𝑑𝑖𝑎𝑔(𝑄,… , 𝑄, 𝑃)  ∈ ℝ𝑁𝑛𝑥×𝑁𝑛𝑥 
?̅? = 𝑑𝑖𝑎𝑔(𝑅,… , 𝑅) ∈ ℝ𝑀𝑛𝑢×𝑀𝑛𝑢  
𝑄𝑅̅̅ ̅̅ = 𝑑𝑖𝑎𝑔(𝑄𝑅,… , 𝑄𝑅) ∈ ℝ𝑁𝑛𝑦×𝑁𝑛𝑦 
𝑅1̅̅ ̅ = 𝑑𝑖𝑎𝑔(𝑅1, … , 𝑅1) ∈ ℝ
𝑀𝑛𝑢×𝑀𝑛𝑢 
The objective function is written as: 
min
x,y,u
𝐽 = 𝜑𝑥 + 𝜑𝑦 + 𝜑𝑢 + 𝜑𝛥𝑢 
Where: 
 𝜑𝑥 = X
′Q̅X 
𝜑𝑦 = (Y − R)
′QR̅̅ ̅̅ (Y − R) 
𝜑𝑢 = U
′R̅U 
𝜑𝛥𝑢 = 𝛥𝑈
′𝑅1̅̅ ̅𝛥𝑈 
Hence, the problem is formulated as a QP problem, (Rawlings and Mayne, 2009), 
(Maciejowski, 2002):  
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States 
𝜑𝑥 = (?̅?𝑥0 + ?̅?𝑈 + ?̅?𝐷)
′?̅?(?̅?𝑥0 + ?̅?𝑈 + ?̅?𝐷) 
      = (?̅?𝑈 + 𝑏)′?̅?(?̅?𝑈 + 𝑏)                                                              With 𝑏 = ?̅?𝑥0 + ?̅?𝐷 
      = (𝑈′?̅?′ + 𝑏′)?̅?(?̅?𝑈 + 𝑏) = 𝑈′𝐵′̅̅ ̅?̅??̅?𝑈 + 𝑏′?̅??̅?𝑈 + 𝑈′?̅?′?̅?𝑏 + 𝑏′?̅?𝑏 
      = 𝑈′?̅?′?̅??̅?𝑈 + 2(𝑏′?̅??̅?)𝑈 + 𝑏′?̅?𝑏 = 𝑈′[?̅?′?̅??̅?]𝑈 + [2𝑏′?̅??̅?]𝑈 + 𝑏′?̅?𝑏 
𝐻𝑥 = ?̅?′?̅??̅? 
𝐺𝑥 = 2𝑏
′?̅??̅? = 2(?̅?𝑥0 + ?̅?𝐷)
′?̅??̅? = 𝑁𝑥𝑥0 + 𝑁𝑑𝐷 
With 𝑁𝑥 = 2?̅?′?̅??̅? and 𝑁𝑑 = 2(?̅?)′?̅??̅? 
Output tracking error 
𝜑𝑦 = (𝑌 − 𝑅)
′𝑄𝑅̅̅ ̅̅ (𝑌 − 𝑅) = (𝛷𝑥0 + 𝛤𝑈 + 𝛤𝑑𝐷 − 𝑅)′𝑄𝑅̅̅ ̅̅ (𝛷𝑥0 + 𝛤𝑈 + 𝛤𝑑𝐷 − 𝑅) 
     = (𝛤𝑈 − (𝑅 − 𝛷𝑥0 − 𝛤𝑑𝐷))′𝑄𝑅̅̅ ̅̅ ((𝛤𝑈 − (𝑅 − 𝛷𝑥0 − 𝛤𝑑𝐷))      With 𝑏𝑦 = 𝑅 −𝛷𝑥0 −
𝛤𝑑𝐷 
    = (𝑈′𝛤′ − 𝑏𝑦
′ )𝑄𝑅̅̅ ̅̅ (𝛤𝑈 − 𝑏𝑦) 
     = 𝑈′𝛤′𝑄𝑅̅̅ ̅̅ 𝛤𝑈 − 𝑏𝑦
′𝑄𝑅̅̅ ̅̅ 𝛤𝑈 − 𝑈′𝛤′𝑄𝑅̅̅ ̅̅ 𝑏𝑦 + 𝑏𝑦
′𝑄𝑅̅̅ ̅̅ 𝑏𝑦 = 𝑈
′[𝛤′𝑄𝑅̅̅ ̅̅ 𝛤]𝑈 − [2𝑏𝑦
′𝑄𝑅̅̅ ̅̅ 𝛤]𝑈 +
         𝑏𝑦
′𝑄𝑅̅̅ ̅̅ 𝑏𝑦 
𝐻𝑦 = 𝛤′𝑄𝑅̅̅ ̅̅ 𝛤 
𝐺𝑦 = 2𝑏𝑦
′𝑄𝑅̅̅ ̅̅ 𝛤 = 2(𝑅 − 𝛷𝑥0 − 𝛤𝑑𝐷)
′𝑄𝑅̅̅ ̅̅ 𝛤 = 𝛭𝜒𝜒0 +𝑀𝑑𝐷 
With 𝑀𝑥 = −2𝛷′𝑄𝑅̅̅ ̅̅ 𝛤 and 𝛭𝑑 = −2𝛤𝑑′𝑄𝑅̅̅ ̅̅ 𝛤 
Input 
𝜑𝑢 = U
′R̅U 
𝐻𝑢 = ?̅? 
Input step change 
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𝛥𝑈 = [𝛥𝑢0 𝛥𝑈1…𝛥𝑢𝑀−1]′ 
Δu0 is defined as u-1-u0 
𝛥𝑈 =
[
 
 
 
 
1 0 0 … 0 0
−1 1 0 ⋯ 0 0
0 −1 1 … 0 0
⋮ ⋮ ⋮ ⋱ 0 ⋮
0 0 0 ⋯ −1 1]
 
 
 
 
𝑈 +
[
 
 
 
 
−1
0
0
⋮
0 ]
 
 
 
 
𝑢−1 
 
𝐻𝛥𝑢 = 𝐻𝑅1′𝑅1𝐻𝑅1 
𝐺𝛥𝑢 = 𝐺𝑅1′𝑅1𝐺𝑅1 
Hence the MPC problem is reformulated in the general QP problem:  
min𝑈 𝐽 =
1
2
𝑈′𝐻𝑈 + 𝐺𝑄𝑃
′ 𝑈 + 𝑐       A.4.4 
With 
𝐻 = 𝐻𝑥 + 𝐻𝑢 +𝐻𝑦 + 𝐻𝛥𝑢 
𝐺𝑄𝑃 = 𝐺𝑥 + 𝐺𝑢 + 𝐺𝑦 + 𝐺𝛥𝑢 
Constraints 
Constraints are imposed on the input, u, the output y, and the input step change Δu. In the QP 
formulation they are expressed as: 
𝐺𝑈 ≤ 𝑊          A.4.5 
Constraints on the states 
𝑋𝑚𝑖𝑛 ≤ 𝑥1, 𝑥2. . 𝑥𝑁 ≤ 𝑋𝑚𝑎𝑥 
With 𝑋𝑚𝑖𝑛 = [
𝑥𝑚𝑖𝑛
𝑥𝑚𝑖𝑛
⋮
𝑥𝑚𝑖𝑛
], 𝑋𝑚𝑎𝑥 = [
𝑥𝑚𝑎𝑥
𝑥𝑚𝑎𝑥
⋮
𝑥𝑚𝑎𝑥
] 
But using A.4.3, it becomes: 
𝐻𝑅1 
 
𝐺𝑅1 
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[ ?̅?
−?̅?
]𝑈 ≤ [
𝑋𝑚𝑎𝑥
−𝑋𝑚𝑖𝑛
] + [−?̅?
𝐴
] 𝑥0 + [
−?̅?
?̅?
] 𝐷 
Constraints on the outputs 
𝑌𝑚𝑖𝑛 ≤ 𝑦1, 𝑦2. . 𝑦𝑁 ≤ 𝑌𝑚𝑎𝑥 
With 𝑌𝑚𝑖𝑛 = [
𝑦𝑚𝑖𝑛
𝑦𝑚𝑖𝑛
⋮
𝑦𝑚𝑖𝑛
], 𝑌𝑚𝑎𝑥 = [
𝑦𝑚𝑎𝑥
𝑦𝑚𝑎𝑥
⋮
𝑦𝑚𝑎𝑥
] 
Using A.4.4, we have: 
[ 𝛤
−𝛤
]𝑈 ≤ [
𝛶𝑚𝑎𝑥
−𝛶𝑚𝑖𝑛
] + [
−𝛷
𝛷
] 𝑥0 + [
−𝛤𝑑
𝛤𝑑
] 𝐷 
Constraints on the inputs 
𝑈𝑚𝑖𝑛 ≤ 𝑢0, 𝑢1, . . 𝑢𝑁 ≤ 𝑈𝑚𝑎𝑥 
Which is written as: 
[
𝐼
−𝐼
]𝑈 ≤ [
𝑈𝑚𝑎𝑥
−𝑈𝑚𝑖𝑛
] 
With 𝑈𝑚𝑖𝑛 = [
𝑢𝑚𝑖𝑛
𝑢𝑚𝑖𝑛
⋮
𝑢𝑚𝑖𝑛
], 𝑈𝑚𝑎𝑥 = [
𝑢𝑚𝑎𝑥
𝑢𝑚𝑎𝑥
⋮
𝑢𝑚𝑎𝑥
] 
Constraints on the input step change 
𝛥𝑈𝑚𝑖𝑛 ≤ 𝛥𝑢0, 𝛥𝑢1, . . 𝛥𝑢𝑁 ≤ 𝛥𝑈𝑚𝑎𝑥 
[
𝛨𝑅1
−𝐻𝑅1
] 𝛥𝑈 ≤ [
𝛥𝑈𝑚𝑎𝑥
−𝛥𝑈𝑚𝑖𝑛
] + [
𝐺𝑅1
−𝐺𝑅1
] 𝑢−1 
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APPENDIX C 
 
Multi parametric MPC is an ideal control method for drug delivery applications and in 
particular for the system of automated insulin delivery for T1DM. The ability to obtain the 
control actions, as functions of the patient measurements, on-line via simple function 
evaluations makes the mpMPC suitable for portable applications (Pistikopoulos et al., 2002), 
(Pistikopoulos, Georgiadis and Dua, 2007b), (Pistikopoulos, Georgiadis and Dua, 2007a)  In 
essence, in mpMPC the online solution of the optimisation problem is replaced by the off line 
derivation of the explicit mapping of the optimal decisions in the space of the plant 
uncertainty. mpMPC is applied in the context of Optimisation and Correction MPC (Control 
design 3) presented in Section 6.4.3. The framework is illustrated in Figure.C.1: 
 
Figure C.1: Proposed framework for closed loop insulin delivery (see section 6.4.3) 
 
An example is illustrated for adult 6. The virtual patient is the UVa/Padova Simulator. A 
nominal mp-MPC is designed using the linear state-space model presented in Appendix A.2 
with estimated states: 
?̂? = [𝐺𝑝 𝐺𝑡 𝑋𝑑𝑖𝑠𝑝 𝐼𝑑𝑒𝑙1 𝐼𝑑𝑒𝑙2 𝐼𝑠𝑐1 𝐼𝑝 𝑑]′ 
The exact formulation of section 6.4.3 is applied here.  
The MPC problem is given in equation 6.8. The explicit solution of the quadratic problem 
(QP) (Bemporad et al., 2002) is obtained: 
min𝑈 𝐽(𝜃) =
1
2
𝑈′𝐻𝑈 + 𝜃′𝐹𝑈 +
1
2
𝜃′𝑌𝜃                   (C.1) 
s.t. 𝐺𝑈 ≤ 𝑊 + 𝐸𝜃  
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For the specific example the parameters θ of the mp-QP problem are defined as:  
𝜃 = [𝐺𝑝 𝐺𝑡 𝑋𝑑𝑖𝑠𝑝 𝐼𝑑𝑒𝑙1 𝐼𝑑𝑒𝑙2 𝐼𝑠𝑐1 𝐼𝑝 𝑑   𝐺   𝑦𝑠𝑒𝑡]  
 
The multi-parametric Quadratic Programming (mp-QP) problem and can be solved with 
standard multi-parametric programming techniques  (Pistikopoulos, Georgiadis and Dua, 
2007b).In this study, Parametric Optimization Software was used (Parametric Optimization 
Solutions (ParOS) Ltd, 2003) to obtain the explicit controller description, which is the 
optimal map of the control variables as function of the parameters of the system. This optimal 
map consists of 8 critical regions and the corresponding control laws. Each of the critical 
regions is described by a number of linear inequalities Aix ≤ bi for 𝑖 ∈ {1… , 𝑛𝐶𝑅} , where nCR 
is the number of critical regions and the corresponding control lows are piecewise linear  
functions of the parameters: U = Ki θ + ci, where i is the index of solutions.  
The performance of the controller is illustrated in the following graph:  
 
Figure C.2: Performance of mpMPC controller for adult 6, when 45, 80 and 70 g of 
carbohydrates are consumed at 420, 720 and 1080 min 
Glucose regulation is achieved with 92.7% of the time spent between 80 and 180mg/dl and no 
event of hypoglycaemia occurs.  
Figure C.3 shows the performance of the controller in the case of a skipped meal at 720 min. 
We can see that 12.8% of time is spent in hypoglycaemia with a minimum glucose value of 
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50mg/dl. It is obvious that further improvement of the control specifications is required to 
prevent the deep drop in glucose concentration. 
 
Figure C.3: Skipped meal at 720 min. Breakfast 45 g and lunch 60 g at 420 and 1080 min 
An example of the function to obtain the control law and the description of the CR is 
presented below: 
---------- Feasible region 7 ---------- 
U1 = -7.49397*Gp +6.48152*Gt -0.800111*xdisp -0.597714*Idel1 -0.0377123*Idel2 -0.00655881*Isc1 -
2.9359*Ip +399.73*d +35.048*G -35.048*Gp0 -0.000779129 
U2 = +0.02 
-0.0187475*Gp +0.0162147*Gt -0.00200163*xdisp -0.00149529*Idel1 -9.43444e-05*Idel2 -1.64081e-
05*Isc1 -0.00734469*Ip +1*d +0.0876791*G -0.0876791*Gp0 <= +5.19828e-05 
+0.0187475*Gp -0.0162147*Gt +0.00200163*xdisp +0.00149529*Idel1 +9.43444e-05*Idel2 +1.64081e-
05*Isc1 +0.00734469*Ip -1*d -0.0876791*G +0.0876791*Gp0 <= -1.94914e-06 
+0.00487771*Gp -0.00437426*Gt +0.00024091*xdisp +0.000336128*Idel1 +9.02606e-06*Idel2 
+7.02158e-08*Isc1 +0.00030467*Ip -0.199185*d -0.0350229*G +1*Gp0 <= +48.2489 
+0.0241355*Gp -0.0216076*Gt +0.00125817*xdisp +0.0016757*Idel1 +4.83288e-05*Idel2 +1.33944e-
06*Isc1 +0.00188703*Ip -1*d -0.170413*G -0.00718897*Gp <= +0.888008 
-0.0244884*Gp +0.0219608*Gt -0.00120948*xdisp -0.00168752*Idel1 -4.5315e-05*Idel2 -3.52516e-
07*Isc1 -0.00152959*Ip +1*d +0.175831*G -0.175831*Gp0 <= -0.000168087 
-1*Gp <= +50 
+1*Gp <= +250 
-1*Gt <= +50 
+1*Gt <= +300 
-1*xdisp <= +700 
+1*xdisp <= +100 
-1*Idel1 <= +50 
+1*Idel1 <= +100 
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-1*Idel2 <= +50 
+1*Idel2 <= +100 
-1*Isc1 <= +50 
+1*Isc1 <= +150 
-1*Ip <= +50 
+1*Ip <= +80 
-1*G <= +10 
+1*G <= +10 
 
Concluding Remarks 
The advantages of using mpMPC control method in drug delivery systems are summarised: 
 Suitable for portable applications 
 Testing off-line of different scenarios to ensure the patient’s safety  
 Advantages of MPC over other control designs 
Further in-silico validation is required to improve the mpMPC performance in the context of 
the proposed framework.  
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APPENDIX D 
 
Table D.1: MPC tuning parameters and specifications for CD2 CD3 and CD4 
 Adult1 Adult2 Adult3 Adult4 Adult5 Adult6 Adult7 Adult8 Adult9 Adult10 
ts (min) 5 5 5 5 5 5 5 5 5 5 
N (min) 65 55 35 50 65 50 40 55 70 65 
M(min) 60 40 30 40 40 45 35 50 40 40 
 CD3 
QR 100000 100000 10000 100000 100000 1000 10000 100000 100000 1000000 
R 1 0.01 0.001 1 0.01 0.001 1 1 0.001 0.01 
R1 1 0.01 1 1 0.01 0.01 1 1 0.001 1 
umax 
(U/min) 
0.2TDD 0.2TDD 0.2TDD 0.2TDD 0.2TDD 0.2TDD 0.2TDD 0.2TDD 0.2TDD 0.2TDD 
umin 
(U/min) 
0 0 0 0 0 0 0 0 0 0 
ymax 
(mg/dl) 
10 10 10 10 10 10 10 10 10 10 
ymin 
(mg/dl) 
-10 -10 -10 -10 -10 -10 -10 -10 -10 -10 
 CD2 - CD4 
QR 100000 10000 10000 1000 100000 1000 100000 100000 1000 100000 
R 0.1 0.001 0.001 0.0001 0.01 0.001 0.001 0.01 0.001 0.001 
R1 0.05 0.001 0.001 0.0001 0.01 0.001 0.0 0.01 0.01 0.001 
Δumax 
(U/min) 
0.01 0.01 0.01 0.008 0.01 0.01 0.008 0.008 0.008 0.008 
Δumin 
(U/min) 
-0.01 -0.01 -0.01 -0.005 -0.01 -0.01 -0.005 -0.005 -0.005 -0.005 
umax-CD2 
(U/min) 
0.1 0.15 0.1 0.05 0.15 0.1 0.08 0.1 0.1 0.12 
umax CD4 
(U/min) 
- - - - - - - - - - 
umin 
(U/min) 
0 0 0 0 0 0 0 0 0 0 
ymax 
(mg/dl) 
140 140 140 140 140 140 140 140 140 140 
ymin 
(mg/dl) 
80 80 80 80 80 80 80 80 80 80 
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